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Summary
SUMMARY
In this study, the topical delivery and anti-psoriatic properies of the major 
anti-inflammatory constituent of fish (eicosapentaenoic acid, EPA) were 
studied, in combination with other anti-psoriatic agents with a view to the 
development of a new therapeutic regimen. In in vitro models of skin 
permeation EPA was delivered successfully and presence of fish oil also 
enhanced the delivery of betamethasone dipropionate (BD) to the lower 
basal layers of the epidermis. The same enhancement was not seen with 
salicylic acid and aspirin. Investigations on the anti-inflammatory action 
properties of fish oil were also successfully carried out. Fish oil alone 
inhibited the expression of key inflammatory enzymes in the skin, 
cyclooxygenase-2 (COX-2) and 5-lipooxygenase (5-LOX) along with a major 
eicosanoid, prostaglandin E2, comparable to that of BD. In HaCaT keratinocyte 
cell culture, the anti-psoriatic properties of fish oil were further 
demonstrated by both growth inhibitory effects and the induction of pro- 
apoptotic markers. The final part of the study investigated in vivo a potential 
new model of psoriasis: the defolliculated mouse. The model responded well 
to formulations containing BD, denoted by a reduction in the epidermal 
thickness associated with the mutation. This suggests a role in screening of 
new therapeutic compound. Treatment with fish oil, however, caused a 
thickening of the epidermis, contradictory to the initial hypothesis. This was 
further confirmed when expression of growth markers Ki67 and K17 were 
found to be increased. Concurrently, Optical Coherence Tomography was 
utilized successfully in the in vivo studies, providing a rapid, non-invasive 
technique of live measurement of skin modulation without the need of 
sacrificing the animals for individual observations. In summary, despite 
unexpected outcome with the in vivo studies, the study provided ample 
evidence to support the incorporation of fish oil in the treatment of 
inflammatory skin diseases such as psoriasis.
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General introduction
Chapter 1
1. Overview
Millions of people in the UK, and around the world, are affected by skin 
diseases, such as eczema and psoriasis. Along with the discovery of newer 
and better pharmacological interventions, a substantial number of patients 
also turn to naturally-derived products to improve their symptoms and as 
supplement to existing therapies. Currently, one of the most popular natural 
products is fish oil, which is rich in polyunsaturated fatty acids. With a wealth 
of evidence supporting its anti-psoriatic and anti-inflammatory activity 
(Calder 2007; Dewsbury et al. 1989; Wolters 2005), this study investigated 
the feasibility of topically applied fish oil and probed on the mechanisms 
involved in its reported anti-psoriatic properties.
1.1 Psoriasis
Psoriasis is a chronic inflammatory disease affecting several sites of the body. 
Though commonly associated with the skin, psoriasis can also affect the nails, 
mucous membranes and the joints. It is clinically defined by the formation of 
sharply demarcated erythematous, scaly and sometimes pustular lesions, 
varying in extent and with a symmetrical distribution on the skin. Often the 
disease manifests itself in periodic flares which may necessitate additional 
therapeutic control (Bos and De Rie 1999)
It has a worldwide prevalence of approximately 2% (Mayser et al. 2002; 
Wolters 2005), although a higher number of cases are found in Caucasians 
compared to other racial types. The prevalence varies throughout the world, 
ranging from 4.6% in the United States, 1.5% of central Europe to 0.4% in 
Chinese population (Wolters 2005).
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Historically, psoriasis was considered to be a variant of leprosy until Robert 
Willan, a British dermatologist, distinguished it as a separate clinical entity in 
the early 19th century (Griffiths and Barker 2007); the term 'psoriasis' is 
derived from the Greek word psora or 'to itch' (Glickman 1986). Its primary 
cause has been attributed to de novo hyperproliferation of the keratinocytes 
and abnormal epidermal differentiation; although the exact reason for this 
deviation from the normal skin physiology was not determined until the 
discovery of gene involvement in predisposing an individual to psoriasis. 
Several theories have been proposed to shed light on the increased 
proliferation of cells:
A. Cyclic nucleotides - Cells are blocked in the Gi phase by high levels of 
cAMP (adenosine 3c, 5c cyclic monophosphate). Any increase in cAMP or 
decrease in cGMP (cyclic guanosine 3c,5c-monophosphate) would increase 
the number of proliferating cells (Voorhees et al. 1976)
B. Arachidonic acid metabolism - Diversion of the arachidonic acid (AA) 
metabolism pathway to the lipooxygenase pathway and release of 
inflammatory mediators, such as 12-hydroxyeicosatetraenoic acid (12-HETE), 
leukotriene B4, and prostaglandins, stimulate cell multiplication (Kragballe 
and Voorhees 1983)
C. Polyamines - Putrescine, spermidine, and spermine are increased. These 
polyamines are important in cellular proliferation. Ornithine decarboxylase is 
the rate-limiting enzyme which increases in the early stages of hyperplasia 
(McDonald 1983)
D. Protease-antiprotease system - Plasminogen activator (a l antitrypsin) and 
cathepsin 1 have a role in epidermal proliferation and differentiation. 
Protease activity increases in psoriasis. Cell surface proteases can be 
activated at the local level (Galadari et al. 2005)
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It has also been suggested that the hyperproliferation is partly due to the 
reduction of cell-cycle time in psoriatic epidermis. In normal skin, cell cycle 
turnover time is estimated to take 457 hours, compared to 37 hours in 
psoriatic skin. Moreover, the transit time between the basal and the granular 
layer is reduced to 2 days instead of the normal 13. There is a mixture of 
resting and cycling cells in the basal layer of the epidermis, and the 
abnormality observed in psoriasis has been determined to be due to 
increased recruitment of cycling cells from the resting fraction.
It is now accepted that the immune system, mediated by primed T- 
lymphocytes and chemical mediators of inflammation or cytokines, e.g. 
interleukin (IL) 1, IL-2, IL-6, IL-8, TNF-a, IFN-c, epidermal growth factor-like, 
fibroblast growth factor (FGF)-like, and platelet-derived growth factors, 
stimulates the proliferation of keratinocytes in focal skin regions. In other 
words, it is an inflammatory process. In psoriasis, there is a prolonged 
stimulation of keratinocytes by T-cells, probably triggered by antigens such as 
bacteria, viruses, or even autoreactivity to proteins of the keratinocyte 
themselves.
The hypothesis that psoriasis is mediated by T-cells is based upon several 
observations. Normal skin from a psoriasis-susceptible patient began to 
express a psoriasis-like condition after being grafted on an immunodeficient 
mouse (Nickoloff 2000). It had also been observed that graft or transplant 
patients who were also suffering from psoriasis showed an improvement 
after being treated with cyclosporine, which has an inhibitory effects towards 
T-cells (Galadari et al. 2005). The same improvements were also observed in 
patients treated with psoralen and UVA, which also acts on T-cells. 
Furthermore, by using Denileukin diftitox, a toxin towards T-cells, reduction 
of psoriatic plaques was apparent (Bagel et al. 1998). Reciprocally, a marked 
aggravation of the disease was observed in patients treated with pro- 
inflammatory agents, such as interferons.
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The disease causes significant m orbidity and ranges in severity from  mild to 
severe. Apart from  its obvious physiological effects (intense itching, pain), 
patients have also been known to  suffer psychologically from  the effects of 
psoriasis (Stein 2005), w ith  significant deterioration in the quality o f life of 
patients, as the severity o f the disease increases (Krueger et al. 2001).
1.1.2 Histological features of psoriasis
Histological examination o f the psoriatic skin reveals significant changes to 
the overall structure and organization o f tissues w ith in the skin. Figure 1.1 is 
a representative haematoxylin and eosin (H&E) stained tissue obtained from  
involved psoriatic skin.
• Acanthosis
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Figure 1.1: H&E staining of involved psoriatic skin
Parakeratosis is the presence o f nuclei w ith in the stratum corneum (SC) 
(indicated by purple dots in the above figure). In normal skin, as the 
keratinocytes (primary skin cells) migrate upwards from the basal layer, 
differentiation o f cells occurs and the cell loses its nucleus as keratinisation
 ( * ) ---------------------------------------------------------
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progresses. The presence of nuclei in the SC indicates an incomplete ('para') 
differentiation and keratinisation process. There is a notable increase in the 
length of epidermal projections or psoriaform hyperplasia and the epidermal 
is generally thickened due to hyperproliferation of keratinocytes (acanthosis). 
Immunostaining reveals infiltration of polymorphonuclear leucocytes, and 
CD4+ and CD8+ lymphocytes in the epidermis and dermis, respectively.
1.1.3 Classification of psoriasis
Psoriasis can be classified by 2 methods. Association with human leucocyte 
antigen (HLA), age of onset and the course of the disease divides psoriasis 
into 2 types:
Type I normally occurs in young adults, with 80% of the patients expressing 
HLA-Cw6. There is a strong familial inheritance and often the manifestations 
of this type of psoriasis are more severe in nature. The course of the disease 
also tends to be more irregular. Incidence of the milder, more localized Type 
II psoriasis peaks between the ages of 50-60 years. HLA-Cw6 expression 
occurs in only 20% of the patients, and a positive family history is rare 
(Swanbeck et al. 1995). The second method of classification is based on the 
clinical presentation. Using this approach, several variants of the disease have 
been identified.
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Figure 1.2 : Psoriasis vulgaris /  plaque psoriasis (Hossain 2008). It is identified by 
the formation of plaques covered in silvery, white scales.
An estimated 80-90% of all psoriatic patients exhibit psoriasis vulgaris or 
plaque psoriasis (Figure 1.2), named as such due to the formation of clearly 
defined papulosquamous plaques which are red in colour and covered in 
silvery, white scales. The plaques occur most commonly on the scalp, elbows 
and knees, the lumbosacral region and the umbilicus with a symmetrical 
distribution. This variant is further characterized by the Koebner 
phenomenon, where developments of new lesions occur at sites of trauma 
(Crissey et al. 2002; Weiss et al. 2002).
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Figure 1.3 : Inverse psoriasis of the buttocks, appearing as smooth patches with 
the absence of scales (Janjua 2004)
Inverse or flexural psoriasis (Figure 1.3) appears as smooth patches on the 
skin of the intertriginous areas, commonly on the genitals, armpits and under 
the breasts. The 'inverse' in this condition refers to the absence of scales as 
opposed to the most common feature found in psoriasis vulgaris (Lebwohl
2003).
Figure 1.4 : Guttate psoriasis, which manifests itself as numerous teardrop shaped 
spots often preceded by an infection (Cohen 2007)
 1 » ) ---------------------------------------------------------
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Numerous teardrop-shaped spots over a large area of the body appear in 
what is known as guttate psoriasis (from gutta, latin for droplet) (Figure 1.4). 
These less than 1cm2 papules are often preceded by infection with (3- 
haemolytic streptococcus or a virus (Mallon et al. 2000). Resolution occurs 
within 3-4 months of onset and appears to be self-limiting.
Figure 1.5 : Pustular psoriasis (Khazal 2009)
Pustular psoriasis (Figure 1.5) manifests itself by formation of small pustules, 
which can either be localized to the hands and feet (palmoplantar plastulosis) 
or taking a more generalized and widespread form (von Zumbusch psoriasis). 
Patients with the generalized form often develop the condition after sudden 
withdrawal of systemic or ultra potent topical corticosteroids, and also 
intercurrent infections. Palmoplantar plastulosis is unique in the sense that it 
affects mostly women, current or previous smokers, and occurs late in life, 
often in the 4th or 5th decades of life. Research also suggests that it has 
different cause to psoriasis vulgaris, and thus being described as a co­
morbidity instead of a variant of psoriasis (Lebwohl 2003).
As the name suggests, psoriatic nail disease or nail psoriasis affects the nails, 
which undergo changes such as discolouration of the nail plate, pitting, 
onycholysis or nail plate separation, formation of 'oil-drop sign', thickening of
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the skin under the nails and crumbling of the nails itself. The condition occurs 
in about 50% of psoriatic patients (Menter et al. 2004).
Figure 1.6 : Erythrodermic psoriasis (Cohen 2002)
Erythrodermic psoriasis (Figure 1.6) involves widespread inflammation across 
the area of the body and subsequent exfoliation of the areas affected. This is 
often a result of exacerbation of uncontrolled plaque psoriasis, which could 
occur with sudden withdrawal of systemic therapies. The reduced ability of 
the skin to provide barrier functions and thermoregulation leads to 
hypothermia, hypoalbuminaemia, cardiac failure and, on a number of 
occasions, death (Griffiths and Barker 2007).
Opinions are still divided whether psoriatic arthritis is a form of psoriasis or a 
co-morbidity affecting psoriatic patients. Approximately 25% of all psoriatic 
patients have been reported to present with a certain degree of joint 
involvement, most commonly in the fingers and toes. Gladman (1988) 
reported a prevalence of between 5-40%. Rheumatoid factors are typically 
absent, enabling the clinician to rule out other forms of rheumatism, such as 
rheumatoid arthritis and osteoarthritis.
{ io )
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1.1.4 Co-morbidities and risk factors in psoriasis
Aside from the joint involvement, long-term sufferers of severe psoriasis are 
linked with several other morbidities, both cutaneous and non-cutaneous 
(Henseler and Christophers 1995). A higher incidence of cardiovascular 
problems and mortality have been reported by several studies (Kaye et al. 
2008; Kremers et al. 2007; Ludwig et al. 2007), with some suggesting that the 
cardiovascular problems, such as atherosclerosis, are in fact a systemic 
manifestation of psoriasis (Alexandroff et al. 2009).
Psoriasis is also associated with several conditions of metabolic origin; 
collectively, they are identified as the metabolic syndrome. According to the 
Adult Treatment Panel III, metabolic syndrome is defined as the presence of 
at least three of the following conditions: abdominal obesity, elevated serum 
triglycerides, low HDL cholesterol, elevated blood pressure and an elevated 
fasting glucose (Azfar and Gelfand 2008).
There is a high prevalence of psoriasis in obese individuals and a direct 
correlation with the body mass index (BMI) (Henseler and Christophers 1995; 
Naldi et al. 2005; Wolkenstein et al. 2009), with one study reporting a higher 
incidence of severe psoriasis (>20% body area affected) in their cohort of 
obese patients (Herron et al. 2005).
The estimated risk of developing psoriasis is also significantly higher with 
current and ex-smokers (Menter et al. 2004; Nancy and Yehuda 2009; 
Wolkenstein et al. 2009), stress (Arnetz et al. 1985), and alcohol consumption 
(Dediol et al. 2009; Kirby et al. 2008). With a concurrent association with 
smoking and metabolic syndrome, the prevalence of chronic obstructive 
pulmonary disease has been proven in a case-controlled study to be 
increased in patients with underlying psoriasis (Dreiher et al. 2008).
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Dermatological conditions which concurrently affect psoriasis patients 
include Candida infections, dermatophyte infections, acne, condylomata 
acuminate, erysipelas, zoster, allergic contact dermatitis, impetigo 
contagiosa, urticaria, eczema herpeticatum, atopic dermatitis. In the study 
carried out by Henseler and Christophers (1995) all these conditions were 
significantly associated (p < 0.05) with psoriasis.
Psoriasis can also be exacerbated by patients on concurrent medications, 
such as anti-malarials, beta-blockers, lithium, interferons and systemic 
glucocorticoids (Menter et al. 2004). Other anecdotal evidence for 
exacerbation of psoriasis has been reported for ACE-inhibitors, gold salts and 
NSAIDs.
1.1.5 Genetic and immunologic aspects of psoriasis
Though the precise causative factor of psoriasis has yet to be determined, a 
genetic link has been determined through population-wide studies. It has 
been shown to be an inheritable disease, particularly marked if inherited on 
the paternal side (Burden et al. 1998). First and second degree relatives of 
psoriatic patients have a higher incidence rate of presenting the disease 
themselves, with studies suggesting that upward of 30% psoriatic patients 
have the involvement of their first degree relatives. Concurrently, 
monozygotic twins have a 50-60% risk of getting psoriasis compared to 
dizygotic twins.
An array of genes, coupled with external and environmental factors, such as 
infection, stress, smoking, high alcohol intake and certain drugs, are accepted 
to be the general causes which lead to the development and the subsequent 
manifestation of psoriasis. Current genome studies have indicated at least 9
1 2
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chromosomal loci (PSORS1-9). Much of the studies have been focused on the 
300-kb PSORS1 locus near HLA-C on chromosome 6p21.3, which accounts for 
30-50% of the genetic contribution to psoriasis (Trembath et al. 1997). 
Psoriasis has also been linked to 17q24-q25 (PSORS2), 4qter (PSORS3), lq21  
(PSORS4), and 3q21 (PSORS5) in different populations, although these 
linkages are not as reproducible as the one with PSORS1 (Galadari et al.
2005).
A separate study conducted by Luszczek et al (2004) on a Polish population 
also revealed a link to the KIR2DS1 gene, which activates a natural killer (NK) 
cells receptor; a finding confirmed independently by studies conducted on 
Japanese (Suzuki et al 2004) and American populations (Holm et al 2005). In 
the study done by Lesueur et al. (2007), they identified a susceptibility locus 
at chromosome 20pl3 named ADAM33 which has a previous association with 
asthma, suggesting a common link between different diseases which are 
inflammatory in nature.
Initially, psoriasis was viewed as a primary disorder of keratinocytes. Over 
time, evidence began to suggest the immunologic nature of the disease. It is 
observed in developing lesions that infiltration by lymphocytes preceded 
epidermal and other changes. Transplant patients with concurrent psoriasis 
saw an improvement in their lesions as a result of taking cyclosporine, a 
potent inhibitor of T-cells, to prevent rejection of transplanted tissues. 
Further proofs were found in xenograft animal models, whereby uninvolved 
skin from psoriatic patients grafted on to an immune-deficient mouse began 
to show psoriaform lesions upon injection of T-cells (Galadari et al. 2005).
Interestingly, recent studies have resurrected the classic argument of 
keratinocytes as the primary instigators of the disease. Zenz et al. (2005) 
reported the successful creation of an animal model showing both 
psoriasiform lesions and joint manifestations by knocking out the genes 
encoding for the activator protein-1 (AP-1) components Junb and Jun within
13
Chapter 1
basal layer keratinocytes. Apart from the lesions, genes encoding for the 
calcium binding proteins S100A8 and S100A9 were also found to be 
upregulated. In a remarkable resemblance to psoriasis, both these proteins 
are overexpressed, meanwhile the Junb gene in human is localized within the 
psoriasis susceptibility locus PSORS6 (Nickoloff 2006). Furthermore, following 
Jun deletion, the mouse epidermal keratinocytes began to produce 
proinflammatory cytokines, supporting previous proponents of keratinocytes 
as the instigators of psoriasis. It is however noted that certain criteria of 
human psoriasis were not reported in the mouse model, the composition of 
the infiltrated T-cells, for example. As yet, opinions are still divided over 
whether psoriasis is the sole result of an impaired barrier function and 
abnormalities of the keratinocytes or due to dysregulation of immune cells
1.1.6 Biomarkers of psoriasis
Currently, diagnosis of psoriasis is reliant solely on clinical presentations. As 
mentioned earlier, there is a prolonged and sustained immune reaction by T 
cells on keratinocytes; however, the exact antigen that triggers the process 
remains elusive. Experimental and clinical data revealed notable expression 
patterns for certain proteins and markers of oxidative stress (Table 1.1), 
which may provide the basis for biochemical diagnosis of psoriasis and 
potential new targets for treatment (Rashmi et al. 2009).
Apart from the markers listed below, it was also reported that the A3 
adenosine receptor is over-expressed in psoriasis. Similarly, it is 
overexpressed in rheumatoid arthritis and Crohn's disease. This receptor has 
now been identified as a novel target for anti-inflammatory agents (Ochaion 
et al. 2009).
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Proposed marker Expression in 
psoriasis
Source
Oxidative stress
Thiobarbituric acid Blood
M alondialdehyde T* Tissue
'r Superoxide dismutase Blood
'r G lutathione peroxidase Blood
Catalase 'T Blood
Neutrophil function T Blood
V Oxidised LDL Tissue
V Anti-oxidised LDL antibody Blood
Cytokeratins + Tissue
Keratinocyte hyperproliferation
Heat-shock proteins (27, 60) + Tissue
'r Connexins (26, 30) Tissue
'r Bcl-X, Bax, p53, Bak T Tissue
'r Epidermal growth factor Tissue
TGF-a t Tissue
Ornithine decarboxylase 
and MAPK activities
Tissue
A P I, BMP-6 * Tissue
Keratin (6, 16) Tissue
Abnormal keratinocyte differentiation
r ' TGase K Tissue
Keratin 1 /1 0 Tissue
Involucrin t Tissue
SKALP + Tissue
MRP-8 + Tissue
> Filaggrin - Tissue
Inflammation
Anti-calpastatin antibody Blood
A" C-reactive protein T Blood
V Fibrinogen T Blood
V Haptoglobin r Blood
TNF-a, IFN-a, IFN-y, 
interleukins (2, 6, 8, 12, 15, 
17, 22, 23), LIF1
Blood
Interleukins (1, 4, 5, 10) Blood
TGF-P, interleukin-18 t Blood
Neuropeptides
SP, VIP, PACAP-38, CGRP, 
NGF
t Tissue
> Somatostatin I ' Tissue
Table 1.1 : Proposed biomarkers for psoriasis. Adapted from  Rashmi et al (2009). 
+, Presence in psoriatic condition only; - absence in norm al skin; 't'* increased 
expression; ^  decreased expression;* changed expression; + combined 
m easurem ent
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1.2 Treatment options
Although incurable, there is a wide variety of treatments currently available 
to treat or control psoriasis. The mode of treatment is determined primarily 
by the extent and severity of the disease. Mild and localized forms are often 
treated topically; although more severe and widespread forms may 
necessitate systemic therapies. In these cases, topical agents would often still 
be included in the therapeutic regimens to control flares. Other factors for 
the clinician to consider before prescribing any therapeutic agents include 
safety concerns for systemic agents, cosmetic issues (several of the 
commonly used agents are highly staining), cost and economic issues, 
accessibility to treatment centres (for phototherapy), and patient acceptance 
and attitude toward the disease. Any single treatment may be employed 
alone, or in combination (Galadari et al. 2005; Gottlieb 2005a).
1.2.1 Topical agents
1.2.1.1 Corticosteroids
Topical corticosteroids have been the mainstay of topical anti-psoriasis
therapy (Stein 2005). Therapy with this class of drug is generally effective and
well tolerated, relatively rapid, and, compared to most other form of 
therapies, economically feasible. They are one of the most commonly 
prescribed topical agents in the US (Feldman et al. 2000) and their range of 
actions include immunosuppression, anti-inflammation, anti-proliferation 
and vasoconstriction (the degree of which determines the potency of a given 
corticosteroid formulation), which are largely mediated through binding with 
intracellular corticosteroid receptors and regulation of gene transcription, 
including those which code for cytokines (Hughes and Rustin 1997).
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Steroids are broadly classified according to their potencies, ranging from 
Class 1 (superpotent) to Class 7 (least potent), and are used daily to provide 
initial control before switching to a twice-weekly regiment employing a lower 
potency agent or another substitute. Examples of corticosteroids include 
betamethasone dipropionate (Figure 1.7), betamethasone valerate, 
clobetasol propionate, fluticasone propionate and hydrocortisone, among 
others. Though commonly prescribed, corticosteroids are not used in patients 
with more than 20% of their body surface affected to limit systemic 
absorption which can lead to pituitary-adrenal axis suppression and Cushing's 
syndrome (Menter et al. 2004).
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Figure 1.7 : Betamethasone dipropionate
Side effects commonly occurring with steroid use among others include 
atrophy or thickening of the skin, striae, telangiectases, acneform eruption, 
rosacea, contact dermatitis and the aforementioned secondary effects 
resulting from systemic absorption.
1.2.1.2 Vitamin D3 analogues
The biologically active form of vitamin D3, 1-a, 25-dihydroxyvitamin D3 or 
calcitriol was first reported in the 1980s to have an effect on induction of cell 
differentiation and growth, in addition to its major role in calcium and bone 
metabolism. Further findings acknowledged its immunomodulatory activities 
(Mathieu and Adorini 2002). This had a profound effect in generating further
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research on this compound and its analogues for a range of other conditions, 
including psoriasis, secondary hyperthyroidism and osteoporosis (Shimizu et 
al. 2006).
The analogues most commonly used in psoriasis are calcipotriene, tacalcitol 
and maxacalcitol (Yamaguchi et al. 2008), which act via several mechanisms, 
the first of such involves inhibition of keratinocytes proliferation and 
stimulation of keratinocyte differentiation (Takahashi et al. 2003). These are 
achieved by interactions of the analogues with nuclear vitamin D receptors 
(VDR) within the keratinocytes (Gottlieb 2005a).
The analogue-VDR interaction also leads to alterations in vitamin D- 
responsive gene transcription, which includes genes involved in keratinocyte 
differentiation and proliferation, as well as those controlling cell adhesion 
and movement. This alteration could possibly also be achieved by 
antagonizing effects of transcription regulators such as activator protein 1 
(Nagpal et al. 2001). Lu et al.(1996), working with treated psoriatic plaques, 
found that topical application of calcitriol decreases T-cell infiltration and 
keratinocyte intracellular adhesion molecule-1 (ICAM-1).
The effectiveness of these agents, in particular calcipotriene, is significantly 
superior to anthralin; a fact also observed in combination therapy with 
potent corticosteroids (versus calcipotriene monotherapy). Clinical 
effectiveness varies between 6-8 weeks; however, therapeutic response 
could also be observed as early as two weeks after initiation of therapy 
(Witman 2001). Side effects include skin irritation, and, with high doses 
(upwards if 360 g/week), a decrease in serum parathyroid levels and increase 
in serum and urine calcium levels have been reported (Bourke et al. 1997).
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1.2.1.3 Retinoids
Retinoids are a class of compounds which are chemically related to vitamin A. 
They include first generation agents, such as retinol, tretinoin, isotretinoin, 
alitretinoin, and newer generations, such as etritinate, tazarotene and 
bexarotene. Currently, only tazarotene is approved for topical treatment of 
plaque psoriasis (Koo et al. 2003), although oral retinoids have been used, 
albeit limitedly due to its toxicity.
The mechanism of action is believed to involve normalizing epidermal 
differentiation, reducing hyperproliferation and reducing the influx of 
inflammatory cells into the skin (Duvic et al. 1997). These actions are 
achieved by binding to retinoic acid receptors and modulating transcription 
of genes involved in psoriasis. These genes have been identified as TIG 1,2 
and 3 (Gottlieb 2005b). Additionally, tazarotene has been shown to reduce 
cell proliferation and inflammation markers and to normalize markers of 
keratinocyte differentiation (Duvic et al. 1998).
1.2.1.4 Anthralin
Anthralin, more commonly known as dithranol (Figure 1.8), is another drug 
used widely as a topical agent to treat psoriasis. It is an anthracene derivative 
used topically with strengths ranging from 0.1-2%. Its anti-psoriatic action lies 
in its ability to produce free radicals in the cellular mitochondria, interfering 
with the cell's energy supply and, thus, retarding DNA replication and cell 
multiplication (Orojan et al. 2006). It has a slower onset of action compared 
to corticosteroids, although it has the advantage of not causing any rebound 
or withdrawal effects, which are typical with the former.
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Figure 1.8 : Anthralin (Dithranol)
The poor efficacy and safety profile of anthralin compared to other topical 
therapies led to its reduction of use (Callis and Krueger 2003). Apart from 
that, it has undesirable property of leaving a stain and burning sensation 
(Agarwal et al. 2001). In the US, it is still used to treat moderate to severe 
plaque psoriasis in patients not adequately responding to other agents. In the 
UK, it has been in use for more than 80 years, with Dithrocream® and 
Micanol ® as examples of proprietary preparations developed for home use 
(Menter et al. 2004)
1.2.1.5 Coal tar preparations
Coal tar is an effective treatment for chronic stable plaque psoriasis, scalp 
psoriasis, atopic dermatitis, and seborrheic dermatitis. It is perhaps one of 
the oldest preparation used in dermatological diseases, dating back to 
ancient time (Paghdal and Schwartz 2009). Though not properly understood, 
it is believed to exert its action via reduction of cellular proliferation by 
suppressing DNA synthesis (Smith et al. 2000). Its photosensitizing properties 
were utilized in combination therapy with ultraviolet B (UVB) radiation in 
what was called the Goeckerman regimen (Lebwohl 2003). Several concerns 
arising from its use and the development of newer topical agents led to a 
decline in its use. Apart from the staining, it is rather messy to use and has an 
undesirable odour. It can cause folliculitis, photosensitivity, and is a 
carcinogen in animal models, although its association with human cancers 
has not been shown (Gottlieb 2005a).
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1.2.1.6 Other topical treatments
1.2.1.6.1 Salicylic acid
Salicylic acid (Figure 1.9) is a well-known agent employed widely in the 
treatment of dermatological diseases, such as psoriasis, acne, verruca, warts 
and other hyperkeratotic states (Loden 2000; Tsai et al. 1999). This beta- 
hydroxy acid is originally derived from the bark of the willow tree, and often 
used in conjunction with other topical anti-psoriatics, such as dithranol, 
corticosteroids and coal tar.
The reason for this combination is that in psoriasis, the presence of highly 
keratinized plaques/scales hinders the delivery of topical agents which 
necessitates removal of the scales. Salicylic acid is often described as a 
'keratolytic' and it has the property of promoting the softening and lifting of 
the scales by a mechanism not fully understood; although it is believed to be 
related to its ability to affect stratum corneum structure by "dissolving 
intracellular cement and reducing cellular cohesion between keratinocytes" 
(Bashir et al. 2005) and increasing the hydration and softening of the scales 
by reducing the pH of the applied area (Davies and Marks 1976).
It is available in preparations ranging from lotions, shampoos, and is also 
formulated together with other drugs, for example betamethasone 
dipropionate (Diprosalic©, Schering). A study by Krochmal et al (1989) 
showed that delivery of several corticosteroids were increased by 2-fold or 
more when formulated together with salicylic acid and showed no effects on
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Figure 1.9 : Salicylic acid
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the physicochemical stability for up to 2 months. The increased delivery 
resulted in increased efficacy, as proven by Koo et al. (1998), whereby more 
than 75% improvement in skin lesions were seen in 53% of patients 
compared to 36% not treated with salicylic acid. This finding was further 
supported by a separate study by Katz et al (1998). Overall, the increased 
delivery supported the action of SA on the SC.
1.2.1.6.2 Emollients & moisturizers
Diseases such as psoriasis are commonly associated with dry and scaly skin 
conditions resulting from the impaired barrier (Bikowski 2001). Emollients 
and moisturizers are designed to soften the SC and reduce formation of 
scales by increasing hydration in the skin. An adjuvant in the treatment of 
psoriasis, these agents work by producing an occlusive film that limits water 
evaporation. This leads to increased skin hydration. Apart from treating the 
symptoms of dry skin, the use of emollients help to maintain the integrity of 
the skin barrier by supplying the compromised stratum corneum with vital 
lipids and accelerate barrier recovery (Lebwohl and Herrmann 2005). The 
concurrent use of emollients has also been found to increase the delivery of 
corticosteroids, leading to a decrease in steroid dosage and minimizing the 
associated side effects (Fluhr et al. 2008).
1.2.2 Phototherapy
It has been well observed that natural sunlight has the effect of improving 
the condition of psoriatic patients. Since then, these effects have been 
successfully replicated with the use of artificial lamps generating ultraviolet 
light. For decades, the Goeckerman regimen, combining UV lamp and
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application of coal tar under occlusion, has been a mainstay in therapy 
(Zanolli 2003). Although the introduction of newer agents and home UV 
treatment led to its decline, it remained an important treatment modality. 
There have even been cases where successful remission of psoriasis was 
achieved using the regimen in recalcitrant patients who are not responsive to 
the latest biological therapies (Serrao and Davis 2009).
1.2.2.1 UVA and UVB
Natural UV radiation can be divided into 3 distinct types according to the 
wavelength: UVA, UVB and UVC. UVA (320-400nm) penetrates the deeper 
layers of the dermis. It is used in combination with systemic therapy with 
psoralen (Figure 1.10), a photosensitizer, as the radiation is largely ineffective 
on its own. This combination is commonly known as PUVA (Psoralen-UVA) 
and has been classed as 'photochemotherapy'. It is indicated for patients 
presenting with moderate to severe psoriasis not responsive to topical 
therapies. It can also benefits cases of localized disease, in combination with 
retinoids (Gottlieb 2005b).
Figure 1 .10 : Psoralen
As opposed to UVA, UVB works best at the epidermis where absorption is at 
its highest. Two sources of UVB are used in therapy. The broadband UVB 
(270-350nm) is more commonly available than the narrowband UVB (311- 
313). The latter, however, is generally regarded to be safer and more 
effective. UVB is indicated in extensive chronic plaque psoriasis or seborrheic 
psoriasis unresponsive to topical therapy and persistent guttate psoriasis 
(Menter et al. 2004).
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Phototherapy is often used in combination with other forms of treatment. 
After initial remission or clearance is achieved, it is maintained using either 
topical or systemic therapy. Another reason for the combination is also to 
minimize exposure to UV light and reciprocally reduce the dose of 
maintenance drugs. The use of phototherapy requires proper observation 
from trained practitioners to reduce the associated side effects such as 
burns, and the long-term risk of skin malignancies.
1.2.2.2 Excimer laser therapy
Excimer laser (308nm) is produced from a mixture of a noble gas (argon, 
krypton or xenon) and a halogen (typically fluorine or chlorine) induced with 
a high energy current to form an unstable excited dimer or 'excimer' for 
short. As the excited dimers return to the ground state, the emitted energy, 
in the form of laser light, is then delivered to the target by means of an fibre 
optic cable (Baker 2008; Passeron and Ortonne 2005).
The use of excimer lasers for psoriasis began in the late 1990s. It is used to 
selectively target blood vessels within psoriatic lesions and leads to ablation 
of the targeted vessels. The principle behind this form of phototherapy came 
from the findings that showed changes in dermal papillary blood vessels 
during the initial development of lesions. By blocking these vessels, it was 
found that the developmental process can be halted and led to a clearing of 
lesions. The advantages of excimer lasers over conventional phototherapy 
are the overall effectiveness, clearing lesions quicker than UVB and providing 
a longer remission. The high precision also means that uninvolved tissues are 
spared from UV effects, thus reducing long-term risk associated with 
phototherapy (Baker 2008).
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1.2.3 Systemic treatments
Systemic treatments are usually reserved for extensive cases of psoriasis, 
where topical treatments are impractical and the patients are not responsive 
to phototherapy (Menter et al. 2004). Typically, patients with more than 10- 
15% of body area affected by psoriasis are considered as 'severe', although 
the decision to initiate systemic therapy may be influenced by other factors, 
such as debilitation or serious reduction in quality of life, regardless of the 
severity in terms of body area (Feldman et al. 2005).
1.2.3.1 Methotrexate (MTX)
CK .OH
Figure 1 .11 : M ethotrexate
MTX (Figure 1.11) is widely accepted as the 'gold standard' in systemic 
therapy for psoriasis and has been in use for more than 40 years (Menter et 
al. 2004). It is a structural analogue of folic acid (vitamin B3), an important 
trace element required for DNA synthesis and cellular division. MTX acts by 
competitively inhibiting the enzyme responsible for folic acid metabolism, 
dihydrofolate reductase, thus interfering with DNA synthesis and the 
subsequent cellular division (Robert et al. 1982). It is notoriously linked with 
several side effects resulting from folate deficiency (reversible with 
concurrent folic acid supplementation), such as nausea, diarrhoea, stomatitis 
and abdominal distress, and in severe cases can also lead to anaemia and
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neutropenia as a result of bone marrow suppression. Long-term use can be 
toxic and has been associated with increased risk of malignancies and 
hepatotoxicity (Patel et al. 2009; Suzuki et al. 2007).
1.2.3.2 Cyclosporme/ciclosporin
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Figure 1.12: Cyclosporine
Cyclosporine or ciclosporin (Figure 1.12), belongs to a group of drugs called 
the calcineurin inhibitors. It is derived from a fungus found in the soil, 
Tolypocladium inflatum Gams (Warren and Griffiths 2008). The effectiveness 
of cyclosporine (Figure 1.12) on the control of psoriasis symptoms was 
discovered when transplant patients with psoriasis prescribed with 
cyclosporine to prevent organ rejection coincidentally began showing signs of 
improvement on their psoriatic lesions (Galadari et al. 2005). It is a potent 
immunosuppressant, acting by binding on cyclophilin, a protein found in the 
cytoplasm of immunocompetent T-cells, leading to its inhibition. It was 
through cyclosporine use that the association of psoriasis with T-cell activity 
was established.
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As with MTX, the use of cyclosporine is hindered by its dose dependent 
toxicity and associated risk of malignancy with long-term use (Ho 2004)
1.2.3.3 Systemic retinoids
The topical use of retinoids and the metabolite acitretin has been discussed 
in Section 1.2.1.3. It is given systemically, often in combination with UV 
treatment of other systemic agents, such as cyclosporine, to reduce dosage 
of both agents (Menter et al. 2004).
1.2.3.4 Hydroxycarbamide
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Figure 1 .13 : Hydroxycarbamide
Hydroxycarbamide (Figure 1.13), also known as hydroxyurea, is an anti­
metabolite typically used to treat malignancies of the blood. It inhibits the 
production of DNA by interfering with the enzyme ribonucleoside 
diphosphate reductase (Sharma et al. 2004). It is generally regarded as a 
second line therapeutic agent for psoriasis (Bhushan et al. 2001; Sharma et al.
2004) and brings about improvement much slower compared to MTX 
(Menter et al. 2004). Furthermore, its successful use in patients was also 
associated with bone marrow toxicity, with leukopenia or thrombocytopenia 
in 50% of patients (Lebwohl and Ali 2001).
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1.2.3.5 Other systemic agents
Other immune-modifying agents that have been used in the treatments of 
severe psoriasis include azathioprine, 6-mercaptopurine, the cyclosporine- 
like tacrolimus and pimecrolimus, and the fungal derived mycophenolate 
mofetil (Kaaroud et al. 2007; Menter et al. 2004). These agents are normally 
used in cases non-responsive to typical systemic agents.
1.2.4 Immunobiologies
Immunobiologies are molecules or proteins, derived from living organisms or 
recombinant DNA technology, used to treat diseases. It is the latest class of 
therapeutic agents to be introduced as part of the arsenal against psoriasis. 
These agents act on specific immune responses involved with development 
or maintenance of disease (Gottlieb 2005b). The main types of 
immunobiologies are recombinant cytokines or growth factors, monoclonal 
antibodies, and fusion proteins. These agents are administered intravenously, 
and as yet there are no oral or topically applied immunobiologies available. 
The actions of immunobiologies can be classified in 4 different ways; 
elimination of pathogenic T-cells (fusion proteins, e.g alefacept), blockade of 
T-cell activation, stimulation and migration (monoclonal antibodies e.g 
efalizumab), alteration of T-cell proliferative signals/immune deviation 
(monoclonal antibody) and blocking of pro-inflammatory effector cytokines 
(fusion protein, recombinant cytokines and monoclonal antibody) (Menter et 
al. 2004).
The high target specificity of these biological responses provides a modality 
of treatment which allows minimal exposure to uninvolved targets, leading to
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a reduction in toxic or side effects associated with systemic agents (Baker 
2008).
1.3 Role of fatty acids in the treatment of psoriasis
There has been considerable interest in the use of naturally occurring 
products in improving the symptoms of psoriasis, apart from the 
pharmacological interventions listed previously. Anecdotal evidence report 
the successful use of a wide range of natural products, from aloe vera (Syed 
et al. 1996), honey (Al-Waili 2003) and traditional Chinese herbs (Koo and 
Arain 1998). Perhaps one of the most documented and popular natural 
treatment is the use of bioactive fatty acids and lipids from oils derived from 
sources such as fish.
1.3.1 Fatty acids -  an overview
To better understand the use of fatty acids in treatment of psoriasis, it is 
important to understand some facts about fatty acids. Fatty acids are straight 
chain hydrocarbons possessing a carboxyl (COOH) group at one end (a) and a 
methyl group at the other (cj) end. As pictured in Figure 1.14, they can be 
divided into several groups based on their chemical structure. The saturated 
fatty acids, e.g palmitic acid (16:0) and lauric acid (12:0), have no double 
bonds or functional groups along the hydrocarbon chain. They are found 
mostly in animal tissues, as a form of energy store.
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Fatty acids
Omega-6Omega-3
Saturated PolyunsaturatedMonounsaturated
Figure 1.14 : General classification of fatty acids
The monounsaturated and polyunsaturated fatty acids, on the other hand, 
possess either one or several double bonds or functional groups, respectively.
1.3.2 Polyunsaturated fatty acids (PUFA)
PUFAs are fatty acids possessing 2 or more double bonds in their chemical 
structure. The position of the first double bond from the terminal methyl 
group is used to define and classify the classes of PUFAs. The carbon in the 
terminal methyl group is known by the Greek letter Omega (to). Other 
designation may use the letter 'n' instead. Hence, PUFAs can be classified 
into co-3, or n-3 (the double bond 3 carbons away from to carbon) and u)-6 or 
n-6 (6 carbons away from to) (Ziboh 1996).
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1.3.3 Essential fatty acids (EFA)
EFA is the term often used to encompass the closely related n-3 and n-6 fatty 
acids. This term was derived after the discovery that these fatty acids are 
important for a lot of biochemical processes in the body and not just a fuel 
source. The use of the term is further strengthened by the fact that they 
cannot be synthesized in vivo and can only be obtained from dietary sources. 
A third group of PUFAs, the omega-9 FAs, the primary example being oleic 
acid (18:1), is not considered an EFA, as the human body possesses all the 
necessary enzymes required for its production (James et al. 2000).
The main fatty acids for each class of EFAs are linoleic acid, LA (18:2, n-6 ) and 
alpha-linolenic acid, ALA (18:3, n-3). From these 2 precursors, longer fatty 
acids with a higher degree of unsaturation can be synthesized, therefore, 
strictly speaking, only these 2 fatty acids are 'essential'. However, considering 
the role of the resulting long chain FAs, a lot of researchers use the term EFAs 
for all of the physiologically important PUFAs belonging to the 2 omega 
groups. The longer chain fatty acids are as follows:
n-3 fatty acids
❖ Stearidonic acid, SDA (18:4)
❖  AII-C/s 8,11,14,17-Eicosatetraenoic acid, ETA (20:4) -  an intermediary 
between SDA and EPA
❖ Eicosapentaenoic acid, EPA (20:5) (Figure 1.15a)
❖ Docosahexanoic acid, DHA (22:6) (Figure 1.15b)
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Eicosapentaenoic acid, 20:5
Docosahexaenoic acid, 22:6
Figure 1.15 : a) Eicosapentaenoic acid (top) and b) docosahexaenoic acid (bottom) 
n-6 fatty acids
❖ Gamma-linolenic acid, GLA (18:3)
❖  Di-homo Gamma-Linolenic acid, DGLA (20:3)
❖  All-C/'s 5,8,11,14-Eicosatetraenoic acid (Arachidonic acid), AA (20:4)
1.3.4 Sources of EFAs
The EFAs are obtained through the diet, either as the precursor forms (LA and 
ALA) or the longer chain derivatives. Major sources of LA are egg yolk, lard, 
meat, and the oils of corn, peanut, safflower, soy, sunflower and walnut 
(Connor 1999; James et al. 2000), while flaxseed, canola, and green leafy 
vegetables are particularly rich sources for the n-3 counterpart, ALA. y- 
linolenic acid (GLA), the elongation product of LA and the precursor for AA 
and dihomo-y-linolenic acid (DGLA) can be found in substantial amounts in 
evening primrose oil, a popular dietary supplement taken for relieving 
symptoms of pre-menstrual syndrome. Other sources include borage, 
blackcurrant seed and hemp seed oil.
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1.3.5 Fish oil as a rich source of n-3 FAs
Unlike its precursor, ALA, the 2 major n-3 fatty acids EPA and DHA can only be 
obtained from animal sources, apart from perhaps certain species of 
microalgae. Fish oil, particularly fatty or oily fishes, which are typically found 
in colder waters, are the primary source for the 2 FAs. There are at least 50 
different fatty acids, ranging from Ci4to C24 in chain lengths, fatty acids with 
differing degrees of saturation branching, different isomers, and other 
characteristics, with EPA and DHA accounting for 18-36% of total FAs in fish 
oil (Haraldsson and Hjaltason 2001). The fatty acids exist in the form of 
triglycerides or are incorporated in the membrane as phospholipids. In fact, 
the phospholipids in fish are even more enriched in EPA and DHA compared 
to the triacylgycerols, ranging from 40-55%. However, the phospholipids are 
not considered as a viable source of EPA and DHA because of their low 
amount (1-1.5% per body weight) and the difficult extraction processes 
required (Haraldsson and Hjaltason 2001)
The types of fish include salmon, menhaden, herring, mackerel, sardine, 
trout, anchovy, and sprats, among others. The long chain n-3 FAs are 
accumulated in the flesh of these fish as they pass up the food chain resulting 
from consumption of phytoplanktons.
1.3.6 Physiological functions of EFAs
In the body, the fatty acids are important towards a lot of physiological 
processes and functions. They are part of the phospholipids which form the 
cellular membranes. One of the most important roles of the PUFAs is the 
formation of inflammatory mediators or eicosanoids from this membrane
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reservoir in response to noxious stimuli, and will be the main thrust of this 
study and will be elaborated further in the coming section.
The EFAs are also an important component in signalling pathways within the 
body. Formation of endogenous cannabinoids e.g anandamide from 
arachidonic acid, is still an area which is poorly understood. This class of lipid 
messenger is found in most tissues and is at present believed to be involved 
in pain sensation (Pertwee 2001), mood regulation (Martin et al. 2002), 
appetite (Di Marzo et al. 2001; Kirkham and Tucci 2006), memory and 
cognitive learning (Marsicano et al. 2002; Martin et al. 2002)
The EFAs play a significant role in the development and maintenance of the 
nervous system, with DHA perhaps the most important FA of them all. The 
human brain is composed mainly of fat, and 40% of the constituent PUFAs 
are DHA (Singh 2005). 60% of the PUFAs in the human retina are also made 
up of DHA. There is a direct correlation between the levels of DHA in infants 
supplied through breast milk and the level of neurodevelopment and visual 
acuity, as reported by Jensen (2001).
1.3.7 EFAs and inflammation
As mentioned earlier, the EFAs play a major role in the inflammation process 
within the body. They are the precursors of the mediators of the 
inflammation/AA cascade (Figure 1.16) termed the eicosanoids. The n-6 FA, 
arachidonic acid (AA, 20:4) is the primary FA in the phospholipid membrane 
of the cell, and upon hormonal release or physical stimulation, e.g. injury, 
trauma, is liberated from the membrane by the action of phospholipases. 
Depending on the subsequent enzymatic pathways (cyclooxygenases or 
lipooxygenases), it is converted to prostaglandins, leukotrienes and 
thromboxanes (Wada et al. 2007). Despite the beneficial role of protecting
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the body, inflammation, when it becomes out of control, has been implicated 
in the pathogenesis of diseases such as cardiovascular problems, asthma, 
arthritis, diabetes, inflammatory bowel diseases, and skin diseases, including 
psoriasis.
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Figure 1.16 : Inflammation/AA cascade (Davis et al 2002). Arachidonic acid
liberated from diacylglycerol of phospholipids are converted to different classes of 
eicosanoids depending on the enzymatic pathway. The cyclooxygenase pathway 
(A) results in production of prostaglandins (PGs) and thromboxane (TXAs), while 
the lipooxygenases pathway (B) lead to production of leukotrienes (LTs).
It is generally regarded that eicosanoids derived from AA are pro- 
inflammatory and have been reported to be over-expressed in inflammatory 
diseases. High levels of leukotriene B4 (LTB4) is characteristic of arthritis, 
Crohn's disease, ulcerative colitis and lupus erythematosis (Simopoulos 
2002). Along with the oxidation product of AA, 12-hydroxyeicosatetraenoic 
acid (12-HETE), LTB4 has been found in high amounts in psoriatic lesions and 
implicated in the pathogenesis of the disease (Fogh et al. 1989; Iversen et al. 
1997). It is a powerful chemotactic and chemokinetic agent for leucocytes
{ 35 }
Chapter 1
and neutrophils. It has also been shown to induce DNA synthesis and 
promote hyperproliferation in keratinocytes (Fogh and Kragballe 2000).
Prostaglandin E2 (PGE2), another major product of AA metabolism by COX-2, 
plays a major role in tissue oedema, hyperalgesia, and IL-6 production at sites 
of inflammation (Ruzicka et al. 1986). It also has been implicated in psoriasis, 
although its exact role in the pathogenesis was not properly elucidated (Ikai 
1999). In the lesions, up to 5 times increase were seen compared to normal
skin (Reilly et al. 2000), while another study suggested that the increase is as
high as 40% compared to non-involved skin (Ikai 1999).
The modern human diet tends to have an imbalance between the n-6 and n-3 
fatty acids. This is related to the reduction of fish consumption caught from 
its natural habitat, and an increase in consumption of meat and domestically 
raised fish which are fed with high contents of n-6. NHANES III (United States 
Department of Health and Human Services 2004), a database compiling the 
nutrient consumption of Americans, reported a median intake of 0 g for EPA 
and DHA, and less than 1 g of ALA.
1.3.8 n-3 Fatty acids and inflammatory diseases
In his seminal work published in 1987, (Horrobin 1987) reported a low 
incidence of inflammatory diseases such as congestive heart diseases, 
rheumatoid arthritis, asthma and psoriasis among the indigenous Inuits of 
Greenland. This was attributed to their high EPA intake from fatty fishes, 
which is found in abundance in the cold waters surrounding the island. Since 
his findings, much effort has been taken to study the apparently beneficial 
effects of n-3 fatty acids in reduction and treatment of diseases with 
inflammatory components. Most of the studies over the years had focused 
on cardiovascular diseases, the leading killer of man of recent times, and the
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role of n-3 as a cardioprotective agent (Daviglus et al. 1997; Harper and 
Jacobson 2001; Lopez-Garcia et al. 2004; Weber and Leaf 1991). 
Nevertheless, Calder (2001) concluded that the use of high levels of EPA and 
DHA are supported in patients with other forms of chronic inflammatory and 
allergic diseases. A list of inflammatory diseases reported to be responsive to 
supplementation with n-3 is shown in Table 1.2.
The way n-3 FAs affect inflammatory process lie in its interaction with n-6 
FAs. It has been well documented that supplementation of n-3 FAs lead to 
their incorporation into cellular membrane replacing AA as the major fatty 
acid in the phospholipids (DeFilippis and Sperling 2006). As a consequence, 
less n-6 will be available for liberation. Meanwhile, metabolism of n-3 FAs 
yield less potent inflammatory mediators, namely the 5-series LTs and 3- 
series PGs. LTB5, for example is 10 times less potent than LTB4 (Mayser et al.
2002). Another aspect of the relation between n-3 and n-6 apart from the 
altered lipid profile of the cell membrane is the relative affinity of the FAs 
towards enzyme within the inflammation cascade. The n-3 FAs have a higher 
affinity towards the binding site of both COX and LOX, leading to competitive 
inhibition of n-6 metabolism.
! Acute respiratory disease syndrome
I Allergic diseases
Asthma
Atherosclerosis-related cardiovascular diseases 
Inflammatory bowel diseases 
Osteoarthritis 
Psoriasis 
Rheumatoid arthritis 
Traumas of multiple aetiology
___________________ Viral and bacterial pneumonia____________________
Table 1.2 : List of diseases responsive to n-3 supplementation (Gil 2002)
Apart from the n-3s competition with n-6 fatty acids, they are believed to 
assist alleviation of inflammation by the formation of newly identified lipid 
mediators or 'lipoxins' such as resolvins and protectins (Schwab and Serhan
2006). These bioactive compounds play a role in resolving inflammation -
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sort of a braking mechanism which is switched on during the 'resolution 
phase' of inflammation. These lipoxins display potent anti-inflammatory, pro­
resolving, immunoregulatory and neuroprotective properties (Serhan and 
Savill 2005).
1.3.9 n-3 and psoriasis
As mentioned earlier, inflammation plays a central role in the pathogenesis of 
psoriasis. Therefore, psoriatic patients could theoretically benefit from n-3 
supplementation. Previous works by (Mayser et al. 2002) and Kojima et al 
(1991), working with intravenous EPA and highly purified EPA capsule 
supplements respectively, found a marked improvement in patients. This 
concurs with an earlier clinical trial done by (Bittiner et al. 1988) proving the 
benefits of fish oil in alleviating symptoms of psoriasis.
The effects of n-3 on inflammatory enzymes such as COX-2 and 5-LOX had 
also been studied (Thomas et al. 2007a). These two enzymes are the main 
metabolizing enzymes in the skin and the enzymes or the metabolic product 
have been implicated in inflammatory skin conditions such as psoriasis. The 
study employed immunohistochemical methods on freshly excised porcine 
skin treated with fish oil on its own and in combination with other agents 
such as ketoprofen. It was found that a mixture of the two provided the 
highest degree of enzyme inhibition, signified by the reduced intensity of the 
staining. This supported the hypothesis of a combined action of both agents 
in COX-2 inhibition; ketoprofen, a known COX-2 inhibitor and EPA which 
actively competes with arachidonic acid to produce less potent inflammatory 
mediators.
In the skin, EPA is metabolized by epidermal 15-lipoxygenase (15-LOX) to 
monohydroxylated metabolites, 15(S)-hydroxyeicosapentaenoic acid (15-
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HEPE) and 15(S)-hydroxyeicosatrienoic acid (15-HETrE). These metabolites 
share the ability of EPA in competing with arachidonic acid within the 
inflammation cascade to produce less potent inflammatory mediators, with 
Vang & Ziboh (2005) suggesting that the metabolites are even more potent 
than EPA with regards to this process. Depth profile analysis by Thomas and 
Heard (2007) revealed that the greatest conversion of topically applied EPA 
to the more potent 15-HEPE occurred at the metabolically active basal layer 
of the skin. It is postulated that this is of particular benefit in treatment of 
psoriasis, as this layer is in a state of hyperproliferation (thus, higher 
metabolic activity) in psoriatic skin.
1.4 Models of psoriasis
The use of animals in scientific procedures and experimentations hark back to 
the time of the Greeks, where references of animal experimentation were 
recorded as early as the 3rd century BC (Cohen and Loew 1984). The 
contribution of animal studies is immense, especially with recent advances in 
development of humanized and transgenic animal models exhibiting genes 
implicated in the pathogenesis of human diseases (Laboratory Primate 
Advocacy Group 2005).
In the study of psoriasis, there have been numerous models, particularly 
murine, utilized in research over the years. Due to the complex nature of the 
disease, these models understandably have certain limitations in the 
reproduction of psoriasis and psoriatic arthritis characteristics, exhibiting 
different parts of the numerous pathogenic mechanism involved. 
Nevertheless, collectively these models have improved the understanding of 
how psoriasis develops and crucially, providing the next step in finding a 
potential cure. In recent times, there have also been claims of the discovery
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of a 'true' animal model of psoriasis which exhibits switchable triggers for 
both psoriasis and psoriatic arthritis (Zenz et al. 2005).
In general, animal models for psoriasis can be divided into several categories, 
the first one being mutant models which occurred spontaneously. The next 
category involves animals that are genetically engineered, either by the 
insertion of a foreign gene or knocking out specific genetic target. This 
category also involves manipulation of the epidermis, endothelium or 
component of the immune system e.g. leucocytes, and those that are 
induced (either by immune transfer or by xenotransplantation of skin from 
psoriatic patients).
1.4.1 Spontaneous animal model
1.4.1.1 Asebia (Ab) mouse
The asebia mutation was first reported about 30 years ago in a colony of 
BALB/c Crg/Ga mice. The Ab mutant is characterized by hypoplastic 
sebaceous and modified sebaceous glands (meibomian, preputial, clitoral, 
and ceruminous glands), the mutation mapped to the gene Stearoyl- 
Coenzyme A Desaturase 1 (SCD-1) (Sundberg et al. 2000). They have short 
sparse coat of hair, scaly skin, predisposed to corneal opacities development, 
and the livers are deficient in triglycerides and cholesterol esters (Miyazaki et 
al. 2001). Other similar mutation exists, such as the asebia-J and the asebia-2J 
(Sundberg et al. 2000).
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1.4.1.2 Flaky skin (Ttc7fsn/Ttc7fsn)
Flaky skin or fsn mice exhibit epidermal hyperproliferation, with mixed 
inflammatory infiltrate with neutrophils accumulating in epidermal 
microabscesses, and increased dermal vascularity with dilated blood vessels 
(Schon 2008). It is perhaps the best described animal model for psoriasis 
(Danilenko 2008). Unlike wild type mice which have thickened epidermis that 
thins after 2 weeks of age, this spontaneous mutant progressively undergoes 
epidermal thickening until reaching a point of stabilization. Dysregulation in 
T- cell activation in fsn mice is a trait commonly shared with the pathogenesis 
of psoriasis in human, thus the skin disorder developed in this mutant 
exhibits many biochemical and histopathological features found in some 
forms of psoriasis (Abernethy et al. 2000). Interestingly, the mutation on 
chromosome 17 which gives rise to this phenotype is homologous to the 
2p21-22 region of chromosome 1 in humans. This region has been identified 
to be a potential susceptibility region in human psoriasis (Bhalerao and 
Bowcock 1998)
1.4.1.3 Chronic proliferative dermatitis (Sharpincpdm/Sharpincpdm)
This mutation, mapped to chromosome 15, results in development of scaly 
lesions that begin as patches which subsequently will cover the entire length 
of the body. This is accompanied by erythema and thinning of hair. 
Histological examination of the epidermis shows hyperplasia that is patchy in 
young mice but diffuse in mice 5 weeks of age and older. The prominent 
features are acanthosis with orthokeratotic hyperkeratosis and patchy 
parakeratotic hyperkeratosis (Schon 1999). The epidermis and dermis both 
exhibit increased immune cell infiltration, particularly eosinophils. Severe 
pruritus, exacerbated by scratching leads to ulceration which may necessitate 
culling of older mice. Apart from the skin, several other organs are also
I 41
Chapter 1
affected, and the mechanism appears to be independent to T-cells (Schon 
2008). Along with the fsn, this mutation does not appear to respond to 
certain anti-psoriatic medication (Gijbels et al. 2000; Sundberg et al. 1994) 
and driven by cytokines of Th2, instead of the Th l and Th7 driven processes 
of psoriasis. As such it is not widely considered representative of the disease 
(Danilenko 2008).
1.4.2 Genetically engineered animal models
Alternatively, another approach in studying the pathophysiology of psoriasis 
in animal models involves modification of the genes central to the 
development of psoriasis. Transgenic and knockout animals constitute the 
largest form of animal models for psoriasis (Danilenko 2008). The genes 
involved include those which code for adhesion molecules, cytokines, 
transcription factors and other cellular mediators in which modulation in 
these proteins expression gives rise to psoriaform features. Examples of the 
molecules include transforming growth factor-a (TGF-a), interleukin-6 (IL-6), 
keratinocyte growth factor (KGF), IL-la, vascular endothelial growth factor 
(VEGF), bone morphogenic protein-6 (BMP-6), amphiregulin, p40, IL-20, 
collagenase, MEK1, leucocyte b2 integrins (CD18), IL-lra, and IRF-2 (Schon
2008).
1.4.2.1 Xenotransplant model
Transplantation of human psoriatic skin (both involved and non-involved) 
onto animals have been attempted successfully and had contributed largely 
to the understanding of psoriasis. In relation to the other models discussed 
earlier, this model is perhaps the best representative to psoriasis in human. 
On the other hand, it is the most difficult to maintain and achieving 
consistency can be a hindrance (Danilenko 2008). The discovery of the
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possible role of T-cells in psoriasis was a result of grafting skin from a 
psoriasis-susceptible patient to an athymic immunodeficient mouse 
(Nickoloff 2000). This model has been used extensively in the study of 
chimeric monoclonal antibody and fusion protein, in which the psoriatic 
lesions on the mice responded positively to agents such as infliximab, 
efalizumab and etanercept (Boyman et al. 2004; Xia et al. 2003). These agents 
were previously shown to work in humans, and the response of the animal 
models proves the close similarity to psoriasis.
1.5 Defolliculated, GsdmASP1/ *  (DfL) mouse -  a new model for
psoriasis
This mouse model (Figure 1.17) belongs to the spontaneous mutation 
category. The first incidence of DfL mouse was reported in Bonn, Germany 
(Porter et al. 2002) as a spontaneous mutation occurring in a colony of 
BALB/c mice. The mutation has been mapped to the gasdermin gene at 
chromosome 11. The association was discovered when the finnegan (fgn) 
mouse, induced by chemical mutagenesis, showed a similar phenotype with 
DfL (Lunny et al. 2005; Nolan et al. 2000).
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Figure 1.17 : Defolliculated, GsdmA3DfL/+ at 20 weeks of age
The exact function of gasdermin is yet unclear, however 
immunohistochemistry analysis revealed that it may have a role in the 
differentiation of the epidermis and associated appendages (Lunny et al.
2005). Specifically, the gene was found to be localized in cells at the later 
stage of differentiation of the upper epidermis, hair shaft and the inner root 
sheath, and sebocytes of the sebaceous, preputial, meibomium, ceruminous 
and anal glands. Both mutants exhibited a defective hair cycle leading to a 
predictable, non reversible destruction of hair follicles beginning at the age of 
9 weeks (Figure 1.18) (Lunny et al. 2005; Porter et al. 2002).
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Figure 1.18 : H&E stain of a DfL skin section of the back showing the early phases 
of hair follicle destruction
Due to the localization of the gene in sebocytes, sebum production is 
defective in DfL, leading to dryness of skin, formation of scales, shortened 
hair shaft (prior to total destruction of the follicles), and formation of corneal 
opacities in older mice (Figure 1.19) (Porter et al. 2002). In regards to the 
defects in sebum production, this model bears a resemblance towards the 
asebia mutant described previously, although in asebia the mutation occurs 
in an enzyme involved in sebum production (Sundberg et al. 2000). 
Immediately from birth, DfL mice in the litter can be recognized through their 
thick and folded skin. As they age, the gradual hair loss begins, followed by 
acanthosis and hyperkeratosis of the epidermis. Concurrently, the expression 
of proliferative markers such as Ki67, K6, K16, and K17 is increased (Porter et 
al. 2002).
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Figure 1.19 : Formation of corneal opacities and severe scaling in a 20 weeks old 
DfL
The dermis is highly populated with cells of the immune system. These 
include CD4+ T-cells, macrophages, fibroblast and mast cells, while the 
epidermis shows increased presence of CD3+ T cells. The continuous 
presence of immune cells during the period of hair loss led to the initial 
assumption that the destruction of hair follicles was immune-driven (Porter 
et al. 2002). A later study, however, suggested that both the phenotypic 
changes and the increased infiltration of the dermis and epidermis were in 
fact a result of the defect in sebum production (Lunny et al. 2005).
The hyperproliferative state of the epidermis and the increased infiltration of 
immune cells however are of interest in the study of psoriasis. As mentioned 
earlier, DfL mice show a resemblance toward another established psoriasis 
model, the ab mutation. Previously forwarded as a model for scarring 
alopecia in humans (Porter et al. 2002), it is now proposed that the mutation 
be studied as a model for psoriasis as an alternative to other existing animal 
models.
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1.6 Topical drug delivery
The vast majority of therapeutic agents are delivered into the body via the 
oral route. It is the easiest route, and provides a convenient way for patients 
to self administer their medication. However, certain issues, such as hepatic 
first-pass metabolism and lower bioavailability at the intended target in skin 
diseases, meant that direct application of the drug on the skin is much more 
preferable. Apart from targeting the disease directly at the site, higher 
bioavailability at the treatment site cuts down on the dose of the drug that 
needs to be given, in effect reducing the potential side effects caused by non­
specific modes of drug delivery. Often a major cause in decreased patient 
compliance, the reduction in toxicity also has the added benefit of increasing 
patient's acceptability and overall compliance (Berti and Lipsky 1995). Modes 
of drug delivery across skin can be categorized into topical, transdermal and 
transcutaneous. Topical delivery is intended to provide a local effect, with 
minimal absorption into systemic circulation. On the other hand, transdermal 
drug delivery involves delivery of the drug through the skin to provide a 
systemic effect. In transcutaneous delivery, the drugs are intended to be 
delivered into the tissues underlying the skin, for example muscles or joint 
tissues.
1.6.1 The skin as a physiological barrier
The skin (Figure 1.20), which represents 17% of total body mass, is the largest 
organ of the human body. The primary function of the skin is to serve as a 
barrier between the human body and the environment, providing protection 
against physical, chemical and radiation injuries, microbial invasion, and 
water loss. It is through the latter that the skin also acts a regulator of fluid 
and electrolyte balance (Berti and Lipsky 1995; Williams 2003).
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Figure 1.20 : A graphical representation of the skin structure (MacNeil 2007)
In relation to drug delivery into and across the skin, the most important layer 
is the epidermis. Separated from the dermis by a basement membrane, the 
epidermis can be further divided into 4 distinct layers (Figure 1.21). From 
outside to inside, they are the stratum corneum, stratum granulosum, 
stratum spinosum, and stratum germinatum or the basal layer. The top layer, 
stratum corneum, is made up of 10-15 layers of keratinized/cornified cells 
embedded in an intercellular lipid matrix. Underneath this layer is what has 
been termed the viable epidermis to distinguish it from the dead, anucleate 
cells of the SC (Berti and Lipsky 1995). The cornified cells or corneocytes are 
surrounded by a proteinaceous cell envelope, ~80% consisting of a and 0- 
keratin. This is then bound to a lipid envelope (consisting of multiple lipid 
bilayers) through glutamate moieties of the protein envelope (Williams
2003). The cohesion between individual corneocytes is further strengthened 
by structures called desmosomes.
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Figure 1.21: The layers of the epidermis (Williams 2003)
The intercellular lipid is constituted by 40% ceramide, while the remainder 
consists of cholesterol, cholesteryl esters, cholesteryl sulfate, free fatty acids 
(mainly long chain members, such as 22:0 and 24:0). Phospholipids and 
glycolipids are present in a very minor amount (Motta et al. 1993). In healthy 
skin, the unique lipid composition of the matrix is an important attribute to 
enable the SC to be an effective barrier for water loss and entry of external 
matter. The major lipid of the SC, the ceramides, can be divided into 9 types 
according to their structure. There are ceramides which contain sphingosine 
and phytosphingosine with amide-linked non-OH fatty acids, a-OH fatty acids 
or u)-OH saturated fatty acids of varying chain length (Bouwstra and Ponec
2006). Also present are ester linked ceramides, and ceramides covalently- 
bound to the protein envelope (Motta et al. 1993). In the topical delivery of 
drugs, the continuous lipid matrix represents the primary pathway and the 
major limiting barrier by which drug molecules traverse across the skin 
(Williams 2003).
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The integrity of the SC is also highly dependent on the water content. A well 
hydrated SC is important due to the presence of hydrolytic enzymes involved 
with SC desquamation and enzymes involved in the production of natural 
moisturizing factor, both regulated and mediated by water (Williams 2003).
1.6.2 Factors affecting drug delivery to the skin
The delivery of drug into skin is governed by several factors that can broadly 
be categorized into physiological and physicochemical factors.
1.6.2.1 Physiological factors
As with any pharmacological intervention, there exists a variation between 
individuals in terms of percutaneous absorption of drugs. With regards to in 
vitro studies with animal models of skin permeation, it is a pertinent point to 
acknowledge the variation that exists between different species as well. Age 
plays an important role in determining percutaneous absorption, in view of 
the structural changes associated with aging. In neonates, the dermis is 
approximately 60% the thickness of adults, while the SC is rudimentary and 
only a few cells thick. The majority of the evidence available suggests only 
minimal or negligible effects of aging over normal skin. Nevertheless, changes 
such as water content and hydration status (which decreases with age), 
effects of accumulated exposure to UV, chemicals and environment, and 
changes in blood flow, can theoretically affect drug absorption and clearance 
in the skin. Variation in SC thickness according to body sites is a huge 
contributing factor, as the SC is the principal barrier for drug delivery across 
the skin. This factor also influences the choice of treatment sites, particularly 
with transdermal formulations with intended systemic effects. In general, the 
genitals are considered to be the most permeable, followed by the head and
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neck, trunk, arm, and finally the leg. Significant differences exist in the skin 
between races, such as the SC water content and levels of 
pigment/melanocytes. As with aging, available data suggests minimal or 
negligible contribution of race to drug permeation into the skin. The most 
relevant factor to this study is the effect of pathological conditions or disease 
of the skin. In most diseases, the barrier function of the skin is compromised, 
owing to structural defects and changes in hydration and lipid profile of the 
skin, among others. As treatment progresses, the barrier properties change 
as the condition improves (Washington et al. 2002; Williams 2003).
1.6.2.2 Physicochemical factors
The physicochemical properties of the permeant form a major determinant 
for skin permeation and absorption. In order to traverse the multiple layers 
of the SC, a permeant must first partition into the skin. The octanol-water 
partition coefficient (LogPoctanoi/water) is an indicator of the lipophilicity of the 
permeants, with a value <1 indicative of a hydrophilic molecule, and >3 of a 
highly lipophilic molecule. The keratinized cells of the SC are hydrated, 
therefore a hydrophilic permeant is more likely to partition into the cell 
(intracellular route), while lipophilic permeants would partition into the 
lipoidal matrix surrounding the cells (intercellular route) (Williams 2003). The 
route chosen is not exclusive for any given permeants, as polar regions exist 
even within the lipoidal domain, e.g. desmosomes. Furthermore, even if a 
lipophilic molecule traverses mainly in the lipoidal domain, in order to exit 
the SC, it needs to partition into the highly hydrated viable epidermis. An 
ideal permeant would then need to be sufficiently soluble in both oil and 
water phases. Typically these molecules will then have a LogP value between 
1 to 3 (Williams 2003).
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The second factor is the molecular weight of the molecule. Most 
conventional agents selected for topical and transdermal delivery lie within 
the range of 100-500 Dalton. However, barrier defects in diseased states 
means that this rule may not be restrictive, as the delivery of larger 
molecules have been confirmed across diseased skin (Gribetz et al. 2004; 
Steele et al. 2005).
1.6.3 Barrier impairment in diseased state  -  psoriasis
In many skin conditions, the diseased skin is characterized by an impaired 
barrier function (Bouwstra and Ponec 2006). In psoriasis, the impairment is a 
result of several factors. Aberrant keratinization of the cells is a major 
contributor, with altered lipid content of the matrix also determined. There is 
an increase in free cholesterols, with a reciprocal reduction in cholestryl 
esters. Examination of psoriatic scales also revealed an alteration in the levels 
of phytosphingosine-containing ceramides, with 25% in psoriatic scale 
compared to 44% in normal SC. This is accompanied by a concurrent increase 
in sphingosine containing ceramides. The conversion of sphingosine to 
phytosphingosine has been determined to involve water; therefore, the 
reduction in phytosphingosine is associated with the increased water loss 
observed in the dry, scaly skin of psoriasis (Motta et al. 1993).
Another variation is the reduction of the uj-OH ceramides, the bound fatty 
acid chain consisting mainly of linoleic acid. This is surprising considering the 
reported evidence of increased free linoleic acid and fatty acid esters in 
psoriatic scale. The products of AA metabolism, such as LTB4 and PGE2, the 
precursor of which is linoleic acid, have also been found to be increased 
greatly in psoriasis (Logan 2005). The association with the reduction in 
linoleic acid bound ceramides is then thought to be due to impairment in the 
enzymatic process involved with the production of the co-OH ceramides.
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These defects in the barrier property in psoriatic skin undoubtedly alter the 
permeation of drug molecules across skin. Colomboa et al. (2003) reported 
an increase in the cumulative amount of 8-methoxypsoralen recovered from 
psoriatic skin compared to normal skin. Wang et al.(1987) observed a 
variation in the permeation of various anthralin preparations across psoriatic 
skin in relation to the stage of the disease. In all cases, the permeation was 
not limited by the SC, as observed in normal skin; rather, it depended on the 
rate of release from the vehicle. This suggested the defective barrier of 
psoriatic skin provides minimal resistance to travelling drug molecules.
The permeation of two experimental therapeutic agents for psoriasis were 
also investigated. A C-5 propyne-modified antisense oligonucleotide, which 
was found not to permeate normal SC, was successfully delivered intact to 
the basal layer of psoriatic skin (White et al. 2002). Meanwhile, Gould et al. 
(2003) reported a ten-fold increase in the permeability of involved psoriatic 
skin compared to uninvolved skin using a radio-labelled protein, plasminogen 
activator inhibitor 2, as a permeant.
These are only few examples which show the altered barrier state of the 
psoriatic skin, and indeed this irregularity has been exploited successfully in 
the delivery of anti-psoriatic medication across the skin. The cyclosporine-like 
tacrolimus and pimecrolimus, which in normal conditions would be 
notoriously difficult to deliver across skin owing to their high molecular 
weights (803 and 810 MW, respectively), have been used successfully in the 
treatment of psoriasis (Gribetz et al. 2004; Hebert et al. 2001; Steele et al. 
2005).
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1.6.4 Topical delivery of fish oii and EPA
Previous work involving EPA/fish oil involved mostly delivery via oral or 
intravenous routes. It is hypothesized that delivering n-3 fatty acids directly 
to the skin via topical application would result in a better outcome. In fact, 
trials with topically applied fish oil and n-3 mixtures have been attempted to 
varying effects. It has been proven that topical application of n-3 fatty acids 
led to its their incorporation in the cell membrane of animal models (Mani et 
al. 1999), a process previously observed with dietary supplementation 
(Chapkin et al. 1987).
Several clinical trials have reported the use of topically applied fish oil and 
pure n-3 fatty acids on psoriatic patients, with varying outcomes. Dewsbury 
et al. (1989) applied a commercial fish oil preparation (MaxEPA 10%) 
compounded in an ointment base in a small trial of eleven patients, with 
eight patients showing clinical improvements.
Escobar et al (1992) determined the efficacy of topically applied fish oil in 
reducing psoriasis symptoms compared to liquid paraffin. Both treatments 
were applied daily under occlusive dressing for 6 hours and the duration of 
treatment was for 4 weeks. The parameters investigated were erythema, 
scaling, plaque thickness (induration) and itching, on a weekly basis. It was 
found that both treatments improved erythema and scaling compared to 
base values, while there was a significant difference between the two 
treatments in reduction of plaque thickness and scaling.
In contrast, a further study by Henneicke-von Zepelin et al. (1993) which used 
a higher purity EPA, DCHA mixture (80% EPA-ethyl ester and 20% DCHA-ethyl 
ester) did not show any statistically significant improvement compared to 
control. The difference in response was attributed to a pharmacokinetic 
problem or poor formulation arising from the fact that pure forms of n-3 do
54
Chapter 1
not penetrate the skin as well as the mixed fish oil (Grimminger and Mayser 
1995).
1.6.5 Fish oil as a drug delivery enhancer
As mentioned previously in Section 1.6.1, the SC poses a substantial barrier 
for delivery of drug across skin. There are several strategies in which the 
delivery of drugs can be enhanced, e.g. iontophoresis, increasing hydration of 
the skin through occlusion and the use of chemical enhancers. One of the 
chemical enhancers used are fatty acids. The use of fatty acids has been 
demonstrated to enhance the delivery of estradiol, progesterone, acyclovir, 
5-fluorouracil, retinoic acid and salicylic acid, as examples (Williams 2003)
The mechanism of enhancement by fatty acids is related to the intercellular 
lipid domain, which, as mentioned previously, is the primary route of 
transport for drugs. The lipophilic nature of fatty acids allows it to traverse 
easily across the lipid domains of the stratum corneum. This fact can be 
utilized by polar drugs which are hydrophilic in nature.
In the study done by Heard et al. (2003), the delivery of NSAIDs were 
enhanced by EPA and DHA from a fish oil vehicle. It was found that the 
permeation rates of the NSAIDs were increased correspondingly with the 
increase in permeation rates of the vehicle and vice-versa, suggesting that a 
solute permeates skin complete with its vehicular solvation cage. This 
phenomenon was later termed the 'puli' or 'drag' effect (Heard et al. 2006). 
The effects of fish oil and delivery of NSAIDs were explored further (Puglia et 
al. 2005; Thomas and Heard 2004, 2007; Thomas et al. 2007b) and NMR 
studies suggested that the enhancement was due to a formation of complex 
between EPA and ketoprofen. Thus, the mechanism by which the delivery of 
ketoprofen was enhanced by EPA and vice versa can be explained by their
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different properties across the skin layers. Once the complex is formed, the 
triglyceride/free fatty acid could aid permeation of ketoprofen into the 
lipophilic stratum corneum via the pull effect. Once permeated, the process is 
taken over by the more hydrophilic ketoprofen leading the permeation of the 
triglyceride/free fatty acid through the epidermis.
1.7 Aims and objectives
The objective of this study was to investigate the effects of combining fish oil 
with commonly used anti-psoriatic medication both on the delivery and its 
activity.
The associated aims were as follows:
•  Determination of fish oil permeation and penetration profile across 
the skin
•  Determination of fish oil enhancing properties for delivery of 
common anti-psoriatic medications
•  Investigation of the anti-inflammatory properties of fish oil by its 
action on inflammatory markers and enzymes
•  Determination of in vivo response of a proposed animal model for 
psoriasis to anti-psoriatic medications and fish oil
56
Chapter 2:
In vitro transcutaneous delivery 
of bioactive oils across excised 
porcine ear skin
Chapter 2
2.1 Introduction
Bioactive oils are naturally occurring or synthetically produced lipophilic 
liquids which have an effect on or cause a reaction in living tissues. The action 
of these oils is dependent on the constituent fatty acids.
Fish oil, is one of the most commonly found bioactive oils in the market. 
Available in forms ranging from capsule to liquid suspension, the demand for 
fish oil is attributed to its many health benefits which were outlined in the 
Section 1.3.8 and 1.3.9. The principal fatty acids in fish oil are the omega-3 
fatty acids, namely EPA and DHA. Many manufacturers often fortify their fish 
oil preparations with additional EPA and DHA. Far from being just a 
nutritional supplement, fish oil has also been licensed as an adjuvant 
treatment for post-myocardial infarction patients and control of 
hypertriglyceridaemia when dietary controls are insufficient (Bays 2006).
Although previous work has demonstrated the skin delivery of EPA and DHA 
from fish oil (Thomas and Heard 2004) and GLA from borage oil (Ho et al.
2004), the phenomenon is considered unlikely according to regular skin 
permeation theory owing to the high lipophilicity of the fatty acids. In the 
current chapter it was considered important to confirm such findings and to 
determine if similar observations could be obtained with further bioactive 
oils; thus, the skin delivery of dihomo-y-linolenic acid (DGLA) and 15- 
Hydroxyeicosatetraenoic acid (15-HETE) were probed.
Figure 2 .1 : Chemical structure of dihomo-y-linolenic acid, 20:3,n-6
DGLA (Figure 2.1) is a 20 carbon long chain omega-6 fatty acid obtained from 
animal sources such as meat, egg, fish and breast milk (Kawashima et al.
2009). It is also available in precursor form (y-linolenic acid) obtained from
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sources such as evening primrose oil. It is derived from the desaturation and 
subsequent elongation of linoleic acid (C18:2, n-6). Unlike other n-6 fatty 
acids which are regarded as pro-inflammatory, e.g. arachidonic acid, DGLA 
possesses anti-inflammatory actions via production of 1-series prostanoids, 
thromboxanes and a 15-hydroxyl derivative which blocks the transformation 
of arachidonic acid (AA) to pro-inflammatory leukotrienes (Belch and Hill 
2000; Fan and Chapkin 1998). Similarly to the n-3 fatty acids, this is achieved 
by active competition with AA for binding sites on cyclooxygenases.
Figure 2.2 : Chemical structure of 15-(±) HETE
15-HETE (Figure 2.2) is derived from the metabolism of AA by 15-LOX 
(Vonakis and Vanderhoek 1992). Unlike products of 5- and 12-LOX 
metabolism, this monohydroxylated metabolite possesses anti-inflammatory 
activity by inhibiting the 2 enzymes; the products of which are pro- 
inflammatory in the skin (Fogh and Kragballe 2000; Fogh et al. 1988).
In the current study, the fatty acid content and delivery of fish oil, and 
refined oils containing 100% DGLA and 100% 15-HETE, across full-thickness 
porcine ear skin were investigated in vitro.
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2.2 Materials and methods
2.2.1 Materials
EQT-101 (DGLA, lot PK-E13), EQT-104 (15-HETE, lot PK-E26) were obtained 
from Equatec Ltd (Isle of Lewis, UK). Fish oil capsules (n-3 Fish Oil 1000 mg 
high strength, lot 118202) were obtained from a local Boots outlet. Butylated 
hydroxyanisole (BHA), and cetrimide BP were obtained from Sigma-Aldrich 
Company Ltd., Poole, UK. Fatty acid standards were obtained from Nu-Chek 
Prep.Inc., Elysian, USA). Analytical grade hexane, methanol, potassium 
bicarbonate, sodium chloride, sodium sulphate, and sulphuric acid were all 
obtained from Fisher Scientific (Loughborough, UK).
2.2.2 Methods
2.2.2.1 Determination of fatty acid content
To determine the fatty acid content of the oils used in the study, aliquots of 
the oil were diluted in hexane at 1 in 100 dilutions and analysed using gas 
chromatography (GC)
2.2.2.2 Gas chromatography
Preparation of fatty acid methyl esters (FAME) and GC analysis of fatty acids 
were performed according to methods adapted from Christie (2003).
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2.2.2.2.1 Preparation of fatty acid methyi esters (FAME)
FAMEs were prepared by transmethylation of the diluted aliquots with 2.5% 
H2S04 in the solution of dry methanol : toluene (2:1 v/v) in Teflon lined 
methylation tubes, which were then placed in a heating block for 2 hours at 
70°C. A known amount of internal standard (C15:0, 1 mg mL-1) was added to 
each sample before methylation to allow quantification analysis. 3 mL of 5% 
sodium chloride was added to each sample followed by 3 mL hexane. 
Samples were centrifuged for 5 minutes, and the upper lipid layer was 
removed to a clean 10 mL centrifuge tube and dried under a stream of 
nitrogen. Another 3 mL hexane was added and samples re-centrifuged. The 
resulting lipid layer was added to the first lipid layer, and the whole process 
repeated.
For additional purification, 3 mL of 2% potassium bicarbonate was added to 
each sample to neutralize any remaining acid. The upper lipid layer was 
removed, taking care not to disturb the interface. A spatula of anhydrous 
sodium sulphate was then added to remove any water and each sample was 
then re-dissolved in hexane and transferred to GC injection vials.
2.2.2.2.2 Gas chromatography analysis
GC analysis was done on a Clarus 500 gas chromatograph (Perkin Elmer, 
Norwalk, US) fitted with a flame ionizing detector (Perkin-Elmer 8500, 
Norwalk, US) and 30 m x 0.25mm i.d Elite 225 phenylmethylpolysiloxane 
(50% Cyanopropylphenyl) capillary column (Perkin Elmer). The temperature 
was programmed as follows: 170°C for 3 minutes, then heated to 220°C at 
4°C min*1, and heated at 220°C for 15 minutes. Injection temperature was 
200°C , and detection temperature was set at 220°C .The carrier was nitrogen 
at a flow rate of 20 m L min’1. Sample (5pl) was injected, and a split ratio of
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20:1 was employed. FAMEs were identified by comparing retention times 
with those obtained from fatty acid standards (Nu-Chek Prep). Limits of 
detection for EPA and DGLA were 0.4 pg mL'1 (1.32 x 10’3 pmol mL1) and 0.3 
pg mL 1 (9.78 x 10*4 pmol mL'1), respectively.
2.2.2.3 In vitro skin permeation analysis
2.2.2.3.1 Preparation of porcine ear skin membrane
In the current study (and the subsequent following chapters) the membrane 
of choice for in vitro skin permeation studies was from porcine ear skin, 
unless stated otherwise. The skin from this area of a pig has been validated to 
be a comparable substitute for human skin based on close similarities in the 
anatomy, physiology and biochemistry between pig and human (Simon and 
Maibach 2000b; Ute et al. 2007). Pig ears obtained from the abattoir were 
cleaned under running water and the skin of the outer side of the ear 
removed by blunt dissection using a scalpel. The hairs were trimmed close to 
the skin using a pair of clippers, and the skin cut into sections of 2 x 2 cm, 
with care taken to choose the areas of the ear which were free from scarring 
or other noticeable defects which can compromise barrier integrity or 
provide resistance to permeating compounds.
2.2.2.3.2 Receptor phase solution
Previous research by Thomas and Heard (2004) reported the use of a 30 mg 
mL 1 cetrimide solution as an optimal receptor phase for permeation studies 
of lipophilic compounds. It provides a good sink condition, and is anti­
microbial. It was also reported by Karim (2008) that the solution did not
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compromise membrane integrity. 12 g o f cetrimide was weighed, along w ith 
0.05% w /w  o f BHA as antioxidant, and dissolved in 400 mL deionized water to 
give a final cetrimide concentration of 30 mg m L'1. The resulting solution was 
stirred and then degassed by vacuum filtering through a 0.45 micron 
cellulose membrane.
2.2.23.3 In vitro skin permeation
The cut porcine ear skin sections were placed on pre-greased receptor 
compartment o f glass Franz-type diffusion cells w ith the stratum corneum 
side facing upward (Figure 2.3).
Figure 2.3 : Glass Franz-type diffusion cell mounted with a porcine ear skin 
membrane (Lau 2008)
Micro magnetic stirring bars were added before hand to ensure complete 
distribution o f permeating solutes in the receptor solution. The donor cells 
were then pinch clamped on top, and the receptor compartment filled w ith 
temperature equilibrated receptor solution using a syringe. The completed
Donor chamber
t o m  > p i
Skin section
Receptor compartment —  
Stirrer bar
Sampling arm
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cells were placed on a magnetic stirring plate (Variomag, Daytona Beach, 
USA) in a water bath maintained at 37°C, providing a skin surface 
temperature of 32°C. After 10 minutes, the cells were dosed with 1 mL of the 
oils from a pipette. Both the sampling arm and donor cells were occluded. Six 
replicates were prepared for each oil, with the control cell dosed with 
deionized water. Entire receptor phases were removed using Pasteur 
pipettes at predetermined time points (3, 6, 12, 24, 36 & 48 hours) and 
replaced with temperature equilibrated receptor solution. The collected 
receptor phases were frozen in -20°C prior to GC analysis, as outlined in 
Section 2.2.2.2. For the skin sections dosed with fish oil, only the permeation 
of EPA was investigated, as the major fatty acid in the commercial fish oil 
used in the study. As mentioned in Section 1.6.4, previous studies reported 
pharmacokinetic issues arising from the use of pure fatty acid (Grimminger 
and Mayser 1995). Hence, all the studies contained within this thesis were 
based on the delivery and action of EPA from an oil mixture instead of the 
pure form.
2.2.2.4 Data analysis
The data obtained were collected and analyzed using Microsoft Excel 2007, 
and expressed as mean ± SD. Statistical tests were performed with Instat3 for 
Windows (GraphPad Inc. Elysian, US). Confidence interval was 95%, with p 
value < 0.05 considered significant.
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2.3 Results and discussion
2.3.1 Determination of fatty acid content
2.3.1.1 Fish oil (Boots Super Strength 1000 mg)
The gas chromatogram and list of fatty acids contained within the fish oil are 
shown in Figure 2.4 and Table 2.1 respectively. As claimed by the 
manufacturer, the principal fatty acids contained within the capsule were 
EPA and DHA, with 33.46% and 20.9% respectively (listed contents -  33% EPA 
and 22% DHA). Other major fatty acids include oleic acid (6.88%), stearic acid 
(3.9%), C22:5 (2.57%), C20:l, n-12 (2.45%), C18:l, n-7 (2.43%) and 
arachidonic acid (2.23%). This particular brand of fish oil was fortified with 
additional EPA and DHA; both n-3 fatty acids that are marketed as a 
nutritional supplement of high value, the virtues of which have been 
discussed in the general introduction and explored further in the coming 
chapters.
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Figure 2.4 : Gas chromatogram of fish oil. Internal standard was found to elute at 
11.75 minutes, while EPA and DHA, the major fatty acids within the fish oil used in 
the experiment were found to elute at 27.4 and 39.56 minutes, respectively.
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Fatty acid Average content 
per 1000 mg (mg)
Percentage
(%)
Saturated
C10:0 0.45 ± 0.01 0.045
C14:0 (myristic acid) 0.28 ±0.03 0.028
C16:0 (palmitic acid) 10.72 ±0.11 1.072
C18:0 (stearic acid) 39.01 ±0.24 3.901
C22:0 (docosanoic acid) 0.55 ±0.05 0.055
Monounsaturated
C12:l 0.35 ±0.03 0.035
C14:l 0.17 ±0.02 0.017
C16:l 3.33 ±0.01 0.333
C18:l, n-9 (oleic acid) 68.79 ± 0.41 6.879
C18.1, n-7 24.32 ±0.12 2.432
C20:l, n-9 1.88 ± 0.21 0.188
C20:l, n-12 24.47 ±0.21 2.447
C20:l, n-15 9.73 ±0.22 0.973
C22:l (erucic acid) 14.43 ±0.1 1.443
C24.1 1.62 ± 0.11 0.162
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Polyunsaturated
C16:2 1.82 ±0.25 0.182
C16:3 0.94 ±0.05 0.094
C16:4 1.00 ± 0.06 0.1
C18:2, n-6 (LA) 9.64 ±0.13 0.964
C18:3, n-3 (ALA) 5.40 ±0.16 0.54
C18:3, n-6 (GLA) 6.10 ± 0.21 0.61
C20:2, n-6 3.35 ±0.22 0.335
C20:3, n-3
)
1.88 ± 0.22 0.188
C20:3, n-6 (DGLA) 2.92 ±0.012 0.292
C20:4, n-3 14.64 ±0.13 1.464
C20:4, n-6 (AA) 22.99 ± 1.47 2.299
C20:5, n-3 (EPA) 334.6 ± 1.35 33.46
C22:2 11.15 ±0.05 1.115
C22:3 0.44 ± 0.05 0.044
C22:4 3.78 ± 0.05 0.378
C22:5 25.74 ±0.11 2.574
C22:6, n-3 (DHA) 209.38 ± 0.86 20.938
TOTAL 847.45 84.745
Table 2 .1 : List of fatty  acids in Boots Super Strength 1000 mg fish oil capsule
From Table 2.1, it can be seen that EPA represents the highest percentage of fatty 
acids contained within the oil. Therefore, the effects observed throughout all the 
studies involving the same fish oil was assumed to be attributed to EPA. The 
possibility of involvement by other fatty acids, however, cannot be discounted.
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2.3.1.2 Equatec EQT-101 (DGLA)
The gas chromatogram for EQT-101 is shown below (Figure 2.5). The notable 
absence of other fatty acids bore proof of the purity of the oil, with an 
average of 97.85%.
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Figure 2.5 : Gas chromatogram of Equatec EQT-101 (DGLA). DGLA was found to 
elute at 16.94 minutes.
2.3.1.3 Equatec EQT-104 (15-HETE)
From the chromatogram (Figure 2.6), 15-HETE was not detected successfully 
with the GC. The presence of a DGLA peak instead was suggestive of several 
possibilities. The preparation of FAMEs based on acid-catalysed esterification 
and transesterification used in the study might not be optimal for 15-HETE 
(the structure of which, can be referred to Section 2.1), resulting in the
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hydroxylated fatty acid remaining as fatty acid. There could have been 
polymerisation or intramolecular esterification under the reaction conditions, 
the temperature could have been too hot and would degrade 15-HETE upon 
injection. In hindsight, other analytical method such as gas chromatography- 
mass spectrophotometry (GC-MS) coupled with derivatization methods such 
as acetylation or isopropylidene derivatives (Christie 2003) might prove to be 
more suitable for the analysis of 15-HETE.
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Figure 2.6 : Gas chromatogram of Equatec EQT-104 (15-HETE). Only DGLA was 
detected, suggestive of 15-HETE breakdown or unsuitable derivatization method 
and/or GC conditions
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2.3.2 In vitro skin permeation
2.3.2.1 EPA
From the permeation profile (Figure 2.7), the cumulative amount of EPA 
permeating across porcine ear skin was 0.038 ± 0.003 pmol cm'2, 
representing only 0.0034% percent of total EPA (contained within the fish oil) 
dosed on the skin. The remaining balance was not accounted for in this study. 
It was assumed that the majority remained within the donor phase, although 
further confirmation is needed to support this assumption. As comparison, a 
previous study done by Thomas (2006) reported an absence of EPA 
permeating across porcine ear skin using the same experimental setup. The 
low EPA amount can be attributed, at least in part, to the high lipophilicity 
(LogP = 6 .66) of EPA, rendering it less effective to permeate across the more 
polar viable epidermis and dermis. The maximum flux (Jmax) value was 
calculated to be 0.005 ± 0.083 pmol cm'2 h'1. Based on the permeation 
profile, the typical plot for an infinite dosing setup was not obtained, hence 
the inability to determine a pseudo-steady state for calculation of Jss (pseudo­
steady state flux). The reason for this deviation might be caused by an 
incomplete esterification of fatty acids or loss during derivatization, as the 
amount dosed was hugely in excess, effectively ruling out depletion of 
permeant, which would have resulted in the same profile.
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Figure 2.7 : Permeation profile o f EPA across porcine skin over 48 hours (n=6, ±SD). 
The maximum flux (Jmax) value was calculated to be 0.005 ± 0.083 pmol cm'2 h'1
2 3 .2 .2  EQT-101 (DGLA)
After 48 hours, the cumulative amount of DGLA permeated from EQT-101 
was 0.045 ± 0.003 pmol cm'2 and the Jmax value calculated to be 5 x 10*4 ± 5.7 
x 10'5 pmol cm'2 h'1. The plot obtained (Figure 2.8) again did not reflect a 
typical permeation profile of an infinite dosing protocol, with the possible 
reasons discussed earlier in Section 2.3.2.1.
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Figure 2.8 : Permeation profile of DGLA from EQT-101 over 48 hours (n=6,±SD). The 
maximum flux (Jmax) value was calculated to be 5 x 10-4 ± 5.7 x 1 0 5 pmol cm'2 h '1.
2.3.2.3 EQT-104
Analysis of the receptor phase collected from the skin section dosed with 
EQT-104, reflective of the analysis of the oil, only showed permeation of 
DGLA. Therefore the permeation profile shown in Figure 2.9 was based on 
DGLA values. The cumulative amount after 48 hours was 0.035 ± 0.0007 pmol 
cm'2 and the Jmax was 4 x 10"4 ± 6 x 10'5 pmol cm"2 h'1, which was not different 
statistically (p > 0.05) from the Jmax value for EQT-101.
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Figure 2.9 : Permeation profile of DGLA detected from EQT-104 (n=6,±SD). The 
maximum flux ( 7 ^ )  value was calculated to be 4 x ltT 4 ± 6 x 10'5 pmol cm'2 h'1
It is acknowledged that one major limitation of the study was the lack of 
validation on the efficiency of the derivatization process, which may have not 
provided a 100% yield of FAMEs. Therefore, this leaves room for 
improvement for future analysis of fatty acids, especially from bioactive oils 
such as the ones analyzed in this chapter.
2.4 Conclusion
EPA, the major fatty acid in a commercial fish oil preparation, and DGLA from 
custom manufactured oil was delivered successfully across porcine ear skin. 
However, the collected amounts were very low, considering the amount 
applied. This however does not necessarily affect their biological effect, as 
efficacy may be achieved with a small amount of the bioactive agent. The
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delivery of 15-HETE was not successfully determined, owing to several 
factors, which may include unsuitable derivatization and/or analytical 
method. Refinements in these aspects could be beneficial in providing a more 
precise set of data, hence a better picture of the transcutaneous delivery of 
these bioactive oils.
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3.1 Introduction
Eicosapentaenoic acid is a long chain n-3 polyunsaturated fatty acid. These 
are associated with anti-inflammatory properties, resulting from formation of 
less potent inflammatory eicosanoids compared to those derived from n-6 
fatty acids (Ziboh et al 2000). Trials using fish oil and EPA had shown that it 
can be beneficial in alleviating symptoms related to psoriasis (Mayser et al. 
2002; Riku et al. 1993). Furthermore, it has been proven that EPA enhanced 
the delivery of other compounds when co-formulated (Thomas and Heard 
2004; Thomas et al. 2007b).
Acetylsalicylic acid (ASA), more commonly known as aspirin, is the acetylated 
form of salicylic acid (SA) (Figure 3.1)
Figure 3 .1 : Salicylic acid (left) and acetylsalicylic acid (right)
ASA was the first discovered non-steroidal anti-inflammatory drug (NSAID). 
Its non-specific inhibition of cyclooxygenases led to its decline in use, 
superseded by more specific and less side effects inducing COX inhibitors. 
However, it remained an important drug in cardiovascular treatments, owing 
to its anti-platelet effect. Long-term use of aspirin in high risk patient lowers 
the incidence of myocardial infarction, stroke and blood clotting. In some 
parts of the world, it also remained a popular over-the-counter pain relief 
and anti-fever medication. The anti-inflammatory action of ASA is attributed 
to its ability to inhibit the pro-inflammatory enzymes, COX-1 and COX-2, and 
inhibiting production of prostaglandin E2 (Vane and Botting 2003).
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The parent compound for ASA, salicylic acid, has long been used in topical 
preparations for conditions, including psoriasis, acne, and warts, in different 
concentrations as a 'peeling' or desmosolytic agent (Loden 2000). It is 
believed to exert its action on the stratum corneum by affecting 
intercomeocyte cohesion and desquamation (Bashir et al. 2005), although 
the precise mechanism for this has never been elucidated.
The aim of this study was to investigate the plausibility of combining the two 
agents, namely acetylsalicylic acid in a fish oil vehicle by probing the 
permeation and penetration profile of both compounds. In particular, it was 
hypothesized that the EPA from fish oil could enhance delivery of ASA which 
would then exert an anti-inflammatory effect, while the breakdown of ASA to 
SA will promote desmosomolysis within the SC.
3.2 Materials and methods
3.2.1 Materials
Fish oil capsules lOOOmg (Boots Super Strength, lot 5647, Composition 33% 
EPA) were obtained from a local store. Acetylsalicylic acid (lot 045K0101), 
butylated hydroxyanisole (BHA), cetrimide BP, and EPA were obtained from 
Sigma-Aldrich Company Ltd., Poole, UK. Methanol, acetonitrile, ethanol, 
hexane (all HPLC grade), sulphuric acid and phosphoric acid were obtained 
from Fisher Scientific, Loughborough, UK. Adhesive tape (3M, Bracknell, UK) 
was obtained from a local stationer. All other reagents were of analytical 
grade or equivalent. Freshly excised pig ears were obtained from a local 
abattoir prior to steam cleaning.
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3.2.2 Methods
3.2.2.1 Preparation of test solutions
Saturated solutions of acetylsalicylic acid in fish oil were prepared by adding 
an excess amount of ASA into 10 ml. fish oil obtained from squeezing out the 
content of fish oil capsules. In fish oil, the solubility of ASA was calculated to 
be 0.471 mg mL' 1 (2.61 mol mL'1). This was determined by adding an excess 
of ASA to 1 mL of fish oil followed by vortex mixing. The tube was then placed 
on a blood tube rotator inside an incubator set at 32°C for 24 hours. This was 
followed by centrifugation of the solution, and the concentration of the 
saturated FO-ASA solution determined by HPLC (Section 3.2.23).
3.2.2.2 In vitro skin permeation and depth profiling
3.2.2.2.1 In vitro skin permeation
In vitro skin permeation was carried out according to the method outlined in 
Section 2.2.2.3.3. Porcine skin sections mounted on glass Franz-type diffusion 
cells were dosed with 1 mL of the ASA-FO mixture using a pipette and rubbed 
gently using a glass rod. The receptor phase was a solution of 30 mg mL' 1 
cetrimide with 0.05% w/v BHA as an anti-oxidant. In this solution, the 
solubility of ASA and SA were determined using the method elaborated in 
Section 3.2.2.1, with the value calculated to be 4.34 ± 0.38 mg mL'1 (24.1 ±
2.1 pmol m l 1) and 8.7 ± 0.48 mg mL 1 (62.9 ± 3.48 pmol mL1) , respectively. 
The solubility of FO and EPA were determined by sequentially adding aliquots 
of FO into the cetrimide solution until it turned cloudy. The solubility of FO 
was determined to be 5.0 ± 0.91 pg mL"1. With EPA representing 33% of the
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011, this equated to a 1.65 ± 0.3 pg mL'1 (5.45 x 10'3± 0.99 x 10'3 pmol m L'Vor 
EPA in cetrimide. Six replicates were prepared with one cell dosed with 
deionized water as a control. Whole receptor phases were removed at 3, 6,
12, 24, 36, and 48 hours and replaced with fresh temperature-equilibrated 
cetrimide solution. Aliquots of the receptor phase was immediately analysed 
after sampling for ASA and SA and the remainder stored at -20°C prior to GC 
analysis for EPA.
3.2.2.2.2 Depth profiling via adhesive tape stripping
Tape stripping (Loffler et al. 2004) was carried by placing adhesive tape on 
the permeated area of the skin sections after completing the permeation 
experiment for 24 hours. Excess test solutions were first wiped off and the 
first 2 strips were discarded. 20 strips were taken from the skin by applying 
the tape with a constant pressure and removing it with a constant velocity 
using stainless steel forceps. The 20 strips were then grouped 2 per vials (1- 
10) containing 5 mL methanol as an extracting solution and placed on a 
rocker overnight to desorb the penetrants from the strips. The remaining skin 
was also placed in methanol and left overnight. The solvent was then 
evaporated using a vacuum oven and 1 mL methanol was added to each vial 
and then centrifuged at lOOOOrpm for 10 minutes. The supernatants were 
then transferred to autosampler vials for HPLC analysis. It must be noted that 
the constituents of the adhesive used on the tape were not evaluated, and 
theoretically, might interfere with the detection of the penetrants. This 
possibility was minimized by analyzing samples from the control cell and 
comparing it with the chromatogram obtained from the cells dosed with the 
ASA-FO mixture, and comparing the retention time for ASA, EPA and SA as 
obtained with standards.
Chapter 3
3.2.23 High Performance Liquid Chromatography (HPLC) analysis
ASA, SA and EPA from tape strip samples were analysed using an Agilent 
series 1100 HPLC system using a Gemini Cul8 150 x 4.6mm column 
(Phenomenex, Macclesfield, UK), fitted with a Phenomenex Securityguard 
guard column. The wavelength was set at X = 210 nm. The mobile phase was 
methanol (95%) and deionized water (5%), pH adjusted with phosphoric acid 
to pH 2.5. The flow rate was 1 mL min'1, the sample injection was 20 pL and 
the runtime was 15 minutes. SA (Figure 3.2), ASA (Figure 3.3) and EPA (Figure 
3.4) were found to elute at 3.6 minutes, 4.4 minutes and 7.8 minutes, 
respectively. The HPLC method for EPA analysis was an adaptation of the 
method reported by Thomas (2006).
Figure 3.2 : HPLC chromatogram for salicylic acid, A=210 nm. The retention time 
was 3.6 minutes with 95:5 methanohdeionized water, pH adjusted to 2.2 with 
phosphoric acid at a flow rate of 1 mL m in1
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Figure 3.3 : HPLC chromatogram for acetylsalicylic acid, A=210 nm. The retention 
time was 4.4 minutes with 95:5 methanohdeionized water, pH adjusted to 2.2 with 
phosphoric acid at a flow rate of 1 mL min'1
Figure 3.4 : HPLC chromatogram of EPA from fish oil, A=210 nm. The retention time 
was 7.8 minutes with 95:5 methanohdeionized water, pH adjusted to 2.2 with 
phosphoric acid at a flow rate of 1 mL m in1
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Standard calibration curves were constructed over the range of 1-20 pmol 
mL 1 for ASA and SA, both with an R2 value of >0.99. Standard curve for EPA 
was constructed over the range of 0.002-0.05 nmol mL'1. Concentrations of 
the permeants were then calculated from the area under the curve. The limit 
of detections for SA and ASA were 0.12 pg mL1 (8.69 x 10'4 pmol mL1) and 
0.09 pg mL 1 (4.99 x 10 4 pmol m l 1), respectively, while the LOD for EPA was 
0.6 pg mL 1 (1.98 x 1 0 3 pmol mL1).
3.2.2.4 GC analysis
EPA from permeation samples was analysed using GC with the method 
described previously in Section 2.2.2.2
3.2.2.5 Data analysis
The data obtained were collected and analyzed using Microsoft Excel 2007, 
and expressed as mean ± SD. Statistical tests were performed with Instat3 for 
Windows (GraphPad Inc. Elysian, US). Confidence interval was set at 95%, 
with p value < 0.05 considered significant.
3.3 Results and discussion
3.3.1 In vitro transcutaneous delivery
3.3.1.1 ASA and SA
Both ASA and SA were found within the receptor phases at all sampling 
points (Figure 3.5). The pseudo-steady state fluxes (Jss) were 0.17 ± 0.07 and 
0.18 ± 0.03 pmol cm'2 h 1 for ASA and SA, respectively {p 0.8012). The
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presence of SA may be contributed by several possible sources. Hydrolysis of 
ASA prior to usage (attributed to less than optimal storage conditions i.e. 
exposure to water/water vapours), hydrolysis of ASA in the donor phase 
(ASA-FO mixture), enzymatic breakdown within the skin sections, or 
hydrolysis of permeated ASA within the receptor solution. Up to 12 hours, 
the cumulative amount of ASA and SA were significantly different, at 1.41 ± 
0.42 and 0.80 ± 0.20 pmol cm'2, respectively (p 0.0099). Over the 48 hours 
duration of the study, the amount of SA detected continued to increase, until 
the difference from ASA amount was not statistically significant (p 0.8548), 
with 7.79 ± 2.74 and 7.56 ± 1.54 pmol cm'2 ASA and SA, respectively.
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Figure 3.5 : Permeation profile of ASA and SA from a saturated solution of aspirin 
in fish oil (n=6, ±SD)
This was further illustrated with the molar ratio of SA to ASA, as shown in 
Table 3.1. In the first 12 hours, the ratios were significantly different over the 
time period, with p 0.026. As the amount of SA present in the receptor phase 
increased over the next 36 hours, the ratios of SA to ASA became statistically 
insignificant (p 0.8257).
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Timepoint (h) Molar ratio ± SD
3 0.1052 ±0.09
6 0.4246 ± 0.26
12 0.5693 ±0.19
24 0.9291 ±0.21
36 1.0170 ±0.27
48 0.9698 ± 0.25
Table 3 .1 :  M o lar ratio o f SA to  ASA at the sampling timepoints (0=6,150)
The rise in SA amount over time was presumably a total sum of permeated 
SA originating from the donor phase, skin metabolism of SA, and conversion 
of ASA in the receptor phase, as mentioned previously. Hypothetically, as 
time progress, it is a possible scenario that the amount of SA will continue to 
rise, until eventually all ASA are hydrolysed and only SA will be detected.
33 .1 .2  EPA
The permeation profile for EPA is shown in Figure 3.6. After 48 hours, the 
cumulative amount of EPA permeated was 0.0148 ± 0.001 pmol cm'2 and the 
Jss was calculated to be 0.0003 pmol cm 2 h'1. The amount permeated 
represented 0.0014% of total applied EPA contained within the oil, 
approximately half from the amount of EPA permeated from fish oil alone 
(Section 2.3.2.1). This suggested that the presence of ASA appeared to retard 
the delivery of EPA.
The molar ratio of EPA to ASA and SA is shown in Table 3.2. Analysis of 
variance (ANOVA) for the molar ratio across the time points revealed a
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significant difference for EPA:ASA (p 0.0011), while it was the opposite for 
EPA:SA ,with p 0.818.
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Figure 3.6 : Permeation profile for EPA from a fish oil-ASA mixture (n=6,±SD). After 
48 hours, the cumulative amount of EPA permeated was 0.0148 ± 0.001 pmol cm'2 
and the Jss was calculated to be 0.0003 pmol cm"2 IT1
Time (h) Molar ratio EPA/ASA 
±SD
Molar ratio EPA/SA 
1 SD
3 0.00024 ± 0.0001 0.0025 1 0.002
6 0.00072 1 0.0002 0.0018 10.001
12 0.002110.0005 0.0036 1 0.0001
24 0.0023410.0021 0.0022 10.001
36 0.0026 1 0.0018 0.0023 1 0.001
48 0.0022 1 0.0013 0.002110.005
Table 3.2 : Molar ratio of EPA to ASA and SA (n=6,iSD)
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3.3.2 Depth profiling
Permeation data is of limited value for a topical anti-psoriasis formulation. Of 
greater importance is the level and location of drug localized within the skin 
tissue.
3.3.2.1 ASA and SA
Analysis of the permeant recovered from the adhesive tapes revealed only a 
small amount of ASA present across the layers and in the remaining skin 
(Figure 3.7). The highest amount was found in the first 2 strips and the 
remaining skin, at 0.013 ± 0.004 and 0.014 ± 0.002 pmol respectively. The 
total amount of ASA recovered from the tape strips, excluding the remaining 
skin, was 0.052 ± 0.01 pmol. The depth profile obtained for SA is shown in 
Figure 3.8.
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Figure 3.7 : Depth profile for ASA (n=6, ±SD). RS= remaining skin
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The highest amount was again recovered from the first 2 strips and the 
remaining skin, at 0.15 ± 0.03 and 1.91 ± 0.47 pmol. The ratio of SA to ASA is 
shown in Table 3.3. The total amount of SA recovered from the tape strips 
was 0.687 ± 0.23 pmol.
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Figure 3.8 : Depth profile for SA (n=6, ±SD). RS= remaining skin
Number of strips removed Molar ratio ± SD
2 14.6 ± 7.95
4 10.8 ± 4.75
6 5.97 ± 2.38
8 10.87 ± 2.61
10 5.87 ± 0.87
12 8.12 ±3.84
14 12.7 ± 5.72
16 9.85 ±6.21
18 8.35 ± 6.90
20 5.77 ± 1.82
Remaining skin 128.18 ±10.4
Table 3.3 : Molar ratio of SA to ASA across the tape strips and remaining skin. 
(n=6±SD)
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The unusually high ratio of SA to ASA (compared to the molar ratio of 
permeated SA and ASA) was suggestive of continuous skin exterases activity, 
hydrolyzing ASA molecules which had penetrated across the skin layers. 
There was also the contribution of liberated SA within the donor phase, as 
discussed in Section 3.3.1.1, these donor phase SA were readily available to 
traverse the skin, as opposed to being liberated from ASA within the skin. 
LogP of the 2 compounds may also be an important factor. At 2.26, SA has a 
higher calculated LogP value compared to ASA (1.19) (Virtual Computational 
Chemistry Laboratory 2005), hence, according to skin permeation theory, 
would partition more easily across skin.
Several clinical trials of topically applied ASA have been reported previously 
(De Benedittis and Lorenzetti 1996; Schmelz and Kress 1996; Steen et al. 
1995, 1996). Although all of these publications reported successful outcomes 
in relieving pain, none of them discussed permeation data of ASA and SA. 
Additionally, there are now commercially available topical aspirin 
preparations marketed to relieve pain and inflammation arising from shaving, 
e.g. Paula's Choice Skin Relief Treatment (Paula's Choice Europe B.V., 
Amstelveen, Holland). The manufacturer's website listed "stabilized 
acetylsalicylic acid" in the ingredients of the lotion (Paula's Choice 2009), 
although no further details were available regarding the stabilization process 
and in vitro permeation and deposition of ASA/SA with the preparation.
3.3.2.2 EPA
The depth profile for EPA is shown in Figure 3.9. In this instance, the highest 
amount recovered was from the first 2 strips, with 0.203 ± 0.05 pmol, while 
the amount recovered from the remaining skin was 0.0865 ± 0.013 pmol. The 
total EPA recovered from the 20 strips was 0.654 ± 0.25 pmol. The retention
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of EPA in the skin layers (as opposed to traversing the skin) is of particular 
importance in the treatment of psoriasis, with regards to the intended target, 
which is the basal layer of epidermis. This layer contains keratinocytes, which, 
in psoriatic skin, are in a state of hyperproliferation. The high metabolic 
activity of this layer increases metabolism of EPA to its hydroxylated 
metabolite, 15-hydroxyeicosapentaenoic acid (15-HEPE); which has been 
reported to have even more potent anti-inflammatory activity compared to 
EPA (Thomas and Heard 2007).
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Figure 3.9 : Depth profile for EPA (n=6, ±SD). RS remaining skin
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3.4 Conclusion
The successful delivery of all three principal components of the mixture 
exhibited a potential in combining ASA with fish oil, either as a vehicle or a 
possible co-formulation. ASA, SA and EPA all possess anti-inflammatory 
activity, while SA has the added use as a desmosomolytic agent to soften and 
remove scales, making it useful in diseases such as psoriasis, where inhibition 
of inflammation is key, and the formation of plaques represents a challenge 
in topical drug delivery.
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4.1 Introduction
In the treatment of dermatological diseases, keratolytic agents, as they are 
generally known, are often included as part of the therapeutic regiment. 
Treatment of diseases such as acne, wart and psoriasis often require the 
sloughing or removal of thickened skin resulting from the hyperkeratinization 
commonly associated with those conditions. The term 'keratolysis' however, 
does not properly reflect the mechanism involved in removal of the stratum 
corneum. Proteolysis of desmosomes, which form a junction between 
keratinocytes, thus reducing cellular cohesion, are believed to be the main 
mechanism involved with most common keratolytic agents (Waller et al. 
2006). Therefore, in this experiment, the term 'desmosomolysis' and 
'desmosomolytic' will be used.
Retinoic acid, or in general retinoids, exert several effects when applied 
topically. Among others, they include comedolysis, alteration of keratinocyte 
proliferation, and thinning of SC (Bershad 2001; Boswell 2006). Benzoyl 
peroxide is most commonly used in the treatment of acne as a strong anti­
microbial agent. It is also a mild anti-inflammatory and comedogenic agent, 
available in preparations ranging from 1-10% (Gollnick and Schramm 1998)
This main purpose of this study was to compare the desmosomolytic activity 
of two dermatological drugs, namely all-trans retinoic acid (RA) and benzoyl 
peroxide (BP), with a widely used desmosomolytic agent, salicylic acid (SA), in 
a formulation containing betamethasone dipropionate (BD) and fish oil (FO). 
To achieve this, adhesive tape stripping combined with protein assay, as 
previously described by Dreher et al. (2005), was employed.
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4.2 Material and Methods
4.2.1 Materials
Fish oil capsules lOOOmg (Boots Super Strength, lot 0336000100A, 
Composition 33% EPA) were obtained from a local store. BD (lot 066K1212), 
and cetrimide BP were obtained from Sigma-Aldrich Company Ltd., Poole, UK. 
Salicylic acid (lot A016882401), benzoyl peroxide (lot A0239820) and all-trans 
retinoic acid (lot A01533801) were obtained from Acros Organics, New Jersey 
UK. Sodium hydroxide and phosphoric acid were obtained from Fisher 
Chemicals, Loughborough, USA. Emulsifying ointment B.P (lot 72FG) was 
obtained from Thornton and Ross, Huddersfield, UK. All other reagents were 
of analytical grade or equivalent. Freshly excised pig ears were obtained from 
a local abattoir prior to steam cleaning.
4.2.2 Methods
4.2.2.1 In vitro skin permeation and adhesive tape stripping
4.2.2.1.1 Preparation of test formulations
Five test formulations were prepared for the purpose of the experiment, as 
shown in Table 4.1. Emulsifying ointment (5 g) was melted at 40°C, and the 
required amount of BD, BHA, SA, BP and RA were weighed and added to the 
melted base and stirred to ensure uniform distribution of the drugs. For 
formulations incorporating fish oil, the melted base was allowed to cool 
before squeezing the content of the fish oil capsule into the mixture and
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stirring. All the formulations were kept at 4°C and excluded from light before 
use.
Formulation Contents
BSA 20% fish oil, 0.1 % betamethasone dipropionate, 0.05 % 
butylated hydroxyanisole, 2% salicylic acid in emulsifying 
ointment B.P
BBP 20% fish oil, 0.1 % betamethasone dipropionate, 0.05 % 
butylated hydroxyanisole, 2% benzoyl peroxide in 
emulsifying ointment B.P
BRA 20% fish oil, 0.1 % betamethasone dipropionate, 0.05 % 
butylated hydroxyanisole, 0.05% all-trans retinoic acid in 
emulsifying ointment B.P
BFO 20% fish oil, 0.1 % betamethasone dipropionate, 0.05 % 
butylated hydroxyanisole in emulsifying ointment B.P
Base 0.05% butylated hydroxyanisole in emulsifying ointment 
BP
Table 4.1: Test formulations containing different desmosomolytic agents
4.2.2.1.2 Receptor solution
A 30 mg m L1 cetrimide solution was chosen as receptor phase, as it provides 
a good sink condition apart from possessing intrinsic anti-microbial 
properties. The required amount of cetrimide was weighed, along with 0.05% 
w/w of BHA as antioxidant, and dissolved in distilled water. The resulting 
solution was stirred and then degassed by vacuum filtering through a 0.45 
micron cellulose membrane.
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4.2.2.1.3 In vitro skin permeation
In vitro skin permeation was performed using full thickness porcine skin 
according to the method outlined in Section 2.2.2.3.3. The skin sections were 
dosed with approximately 0.5 g of each formulation (n=3), the receptor phase 
was cetrimide 30mg mL'1 with 0.05% w/v BHA.
4.2.2.2 Adhesive tape stripping and protein assay
The tape stripping and protein assay procedures were adapted from the 
method outlined by Waller et al. (2006). Adhesive tapes were placed on the 
skin sections after completing a regular permeation for 24 hours. 20 strips 
were taken from the skin by applying the tape with a constant pressure and 
removing it with constant velocity with a pair of forceps. The first 2 strips 
were discarded. The subsequent strips from every cell were grouped into 
glass vials containing 5 strips each with lOmL 1M NaOH as an extraction 
solvent. The vials were then placed on a mechanical rocker overnight to 
ensure complete extraction of the stripped SC from the adhesive tape.
Subsequently, 400 pL of the NaOH solution from each vial was transferred 
into 1.5 mL disposable polystyrene cuvettes and neutralized with an equal 
amount of 1M HCI. To the neutralized solutions, 200 pL of Coomassie 
(Bradford) Protein Assay Reagent (Pierce, Rockford, Illinois, USA) was added 
and left to stand for 15 minutes. The optical density of each sample was 
measured at 595nm using a Hitachi U-3000 spectrophotometer (Hitachi Ltd., 
Japan) with deionized water as blank. The readings were then converted into 
pg mL' 1 1M NaCI using a calibration curve constructed with albumin, with a 
concentration range of 0.015625 to 2mg (R2 >0.99).
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4.2.2.4 Data analysis
Statistical analysis was performed using lnStat3 (GraphPad Inc.). Assuming 
the data was not normally distributed, Kruskal-Wallis analysis with Dunn's 
Multiple Comparisons test was conducted. Graphical representation of the 
data was constructed with Microsoft Excel 2007.
4.3 Results and discussion
III
BFO Control Untreated 
(base)
Formulation
Figure 4.1: Average SC mass removed per tape strip after 24 hours (n=3,±SD)
Protein analysis of the samples revealed that the average SC mass removed 
after 24 hours was significantly higher (p <0.05) from skin treated with 
formulations incorporating the 3 test compounds (BSA, BRA, BBP) than 
untreated skin (Figure 4.1). It was also the case when comparing the 3 
formulations with BFO and vehicle control (ointment base), with the
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exception of BRA which showed no significant difference from both BFO and 
vehicle control.
The cumulative amount of SC removed (Figure 4.2), however, was not 
statistically significant (p>0.05) among the 3 desmosomolytic agents, namely 
BSA (5.24 ± 0.37 mg), BBP (4.87 ± 0.11 mg) and BRA (4.62 ± 0.11 mg). The 
same was observed with the 3 remaining treatments, BFO (2.21 ± 0.01 pg), 
Base (2.27 ± 0.21 mg, and untreated skin (2.02 ± 0.46 mg), where no 
statistical difference was observed in regard to the amount of SC removed.
BRA 0.5%
■ Control
Untreated
5 10 15 20
Tape strips removed
Figure 4.2 : Cumulative SC amount removed after 24 hours (n=3, ±SD)
The data suggest that since there were a significant differences between the 
treatments and untreated skin, and the fact that there was no difference 
between untreated skin, FO, (the other major component of the 
formulation), and base (vehicle control), the increased SC removal was due to 
the presence of the desmosomolytic agents (SA, BP, RA).
Analyzed collectively in groups of 5 strips (Figure 4.3), SA was found to 
remove the highest amount of SC followed by BP and RA in the first 5 strips;
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otherwise it was comparable across the remaining strips. As comparison, 
Waller et al (2006) also reported that SA removed the highest amount of SC 
in the first 10 strips, followed by BP and RA. However, for layers 11-25, BP 
was found to remove the most followed by SA and RA. It must be noted that 
the duration of the experiment differed (24 hours versus 6 hours).
BRA 0.5%
Untreated
Layer 1-5 Layer 5-10 Layer 11-15 Layer 20-25
Figure 4.3 : Amount of SC removed -  layer by layer comparison (n=3,±SD)
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4.4 Conclusion
Employed widely in treatment of hyperkeratotic diseases (Loden 2000), it was 
hypothesized that SA would remove the highest amount of SC. The 
mechanism by which this is achieved was mentioned before, with a proposed 
additional effect of the beta-hydroxy acid increasing the hydration and 
softening of scales by pH reduction of the applied area (Davies and Marks 
1976). Interestingly, BP which is prescribed mainly for its anti-microbial 
activity possesses comparable desmosomolytic activity to established agents 
such as SA and RA, a finding confirmed by an earlier study (Waller et al.
2006). It is noted that one of the major side effects in topical acne therapy is 
peeling and scaling of the skin (Gollnick and Schramm 1998; Krowchuk 2000). 
This 'inconvenience' could in fact prove to be beneficial in other skin 
conditions which would require removal of skin layers with the added benefit 
of an anti-microbial. Another point of note is the relative potency of the 3 
drugs used in this study. RA at a concentration of 0.05% exhibited a similar 
effect to 2% SA and BP. According to Bergfeld (1996) RA is a very potent 
comedolytic which acts by normalizing skin desquamation of epithelium, with 
the major drawback being the numerous associated side effects reported 
with higher concentrations.
As reflected from the data obtained, it can be suggested that since all 3 drugs 
have similar desmosomolytic properties, the selection of which to use in 
hyperkeratosis of the skin depends on the added benefit that the individual 
drug possess. Furthermore, the fact that BP, which previously was prescribed 
mostly for its activity against microbes, is also a desmosomolytic further 
widens the therapeutic options available for clinicians and encourages 
further assessment of other dermatological drugs for the same property.
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5.1 Introduction
Corticosteroids, such as betamethasone and clobetasol, have long been a 
mainstay in the topical therapy of mild to moderate psoriasis. This class of 
drug exerts its anti-psoriatic effect via several mechanisms, including 
immunosuppression, anti-proliferation, and anti-inflammation via interaction 
with steroid receptors and modulation of gene transcriptions involved in the 
aetiology of the disease. In general, corticosteroids penetrate poorly into the 
skin. In order for these steroids to penetrate the skin, esters of these drugs 
have been synthesized, resulting in increased lipophilicity. These esters are 
then taken up by the skin and cleaved into the parent corticosteroid by skin 
esterases. Preparations containing esters such as betamethasone 
dipropionate and betamethasone valerate, to name a few, are available in 
different forms (lotions, creams, ointments) and classed according to their 
potency ranging from superpotent (Class 1) to the least potent (Class 7) 
(Kruger and Ellis 2003).
SA, on the other hand, does not exert an anti-psoriatic effect per se; instead 
its keratolytic action is employed to increase delivery of other topical agents 
by softening and removing the hyperkeratinized scales which pose a 
substantial barrier for drug delivery across the skin. Formulations containing 
2-10% salicylic acid are the most commonly prescribed, although stronger 
concentrations (up to 20%) are also available to remove very thick plaques 
(Lebwohl 2005).
Often given separately, these 2 drugs are now also available as single, 
combined formulations. Examples include Diprosalic* (Schering-Plough) 
ointment, containing 0.05% betamethasone dipropionate and 3% salicylic 
acid. It has been reported that the delivery of non-steroidal anti­
inflammatory drugs (NSAIDs), such as ketoprofen, was enhanced when co­
formulated with EPA/fish oil and vice-versa (Thomas and Heard 2004).
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The aims of the current study were to investigate the effects of fish oil 
addition to the delivery of BD & SA in a combination formulation replicating a 
commercially available preparation via adhesive tape stripping. In this study, 
also, the effects of freezing on skin permeability and the activity of skin 
esterase were probed.
5.2 Materials and methods
5.2.1 Materials
Fish oil capsules lOOOmg (Boots Super Strength, lot 0336000100A, 
composition 33% EPA) were obtained from a local store. Betamethasone 
dipropionate (lot 066K1212), cetrimide BP, EPA and Hanks balanced salts 
were obtained from Sigma-Aldrich Company Ltd., Poole, UK. Salicylic acid 
(batch number A016882401) was obtained from Acros Organics, New Jersey 
US. Methanol and phosphoric acid were obtained from Fisher Chemicals, 
Loughborough, UK. Emulsifying ointment B.P (lot 72FG) was obtained from 
Thornton and Ross, Huddersfield, UK. All other reagents were of analytical 
grade or equivalent. Freshly excised pig ears were obtained from a local 
abattoir prior to steam cleaning.
5.2.2 Methods
5.2.2.1 Preparation of test formulations
Three test formulations were prepared. The first formulation (labelled 0% 
FO), intended to contained 3% salicylic acid, 0.05% betamethasone 
dipropionate (BD) in emulsifying ointment base with an addition of 0.05%
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BHA as an antioxidant. The second formulation (20% FO), contained the same 
components as above in the same percentages, plus 20% fish oil obtained by 
squeezing the contents of fish oil capsules into the formulation. The content 
of EPA in this formulation was worked out to be approximately 6 .6%. 
Emulsifying ointment was melted at 40°C, and the required amount of BD, SA 
and BHA were weighed and added to the melted base and stirred for 5 
minutes to ensure uniform distribution of the drugs. The third formulation 
consisted of only the emulsifying ointment and BHA, to be employed as a 
control. All the formulations were kept at 4°C under light exclusion prior to 
use.
5.2.2.2 In vitro skin permeation
In vitro skin permeation was carried out using glass Franz-type diffusion cells, 
using the method outlined in 3.2.2.2.1. The receptor phase was again 
cetrimide 30 mg mL’1 added with 0.05% w/v BHA. Solubility of BD and SA in 
this solution was 2.67 ± 0.14 (5.29 ± 0.27) and 8.7 ± 0.48 (62.98 ± 3.47) pmol 
mL'1, respectively. Fish oil solubility was 5.0 ± 0.91 pL mL'1. 500 mg of the test 
formulations were dosed on to the skin. To compare the effects of freezing 
on skin permeation, the skin sections used in the current study consisted of 
porcine ear skin sections which had been stored at -20°C (n=3) and freshly 
excised sections (n=3).
5.2.2.3 Tape stripping
Adhesive tape stripping of the permeated areas was carried out according to 
the method outlined in Section 3.2.2.2.2.
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5.2.2.4 Hydrolysis of BD in homogenized porcine skin
To study the activity of skin esterases on BD in viable skin, freshly excised 
porcine ear skin was homogenized to release the enzymes from the skin. 1 g 
of the homogenate was then placed in vials containing a known 
concentration of BD dissolved in Hank's balanced salt buffer solution (HBSBS) 
incubated in 37°C. At t= 0, 6, 12 and 24 hours, aliquots of the BD solution in 
each vial were analysed using HPLC to determine changes in concentration.
5.2.2.5 HPLC analysis
BD and SA were analysed using an Agilent series 1100 HPLC system using a 
Gemini Cul8 150 x 4.6mm column (Phenomenex, Macclesfield, UK), attached 
to a Phenomenex Securiguard guard column. The wavelength was set at 
A=254nm. The mobile phase was methanol (85%) and deionized water (15%), 
pH adjusted to 2.2 with phosphoric acid. The flow rate was 1 mL min*1, the 
sample injection was 20pl and the runtime was 10 minutes. BD was found to 
elute at 6 minutes (Figure 5.1). Standard calibration curve for BD was 
constructed over the range of 1-20 pmol mL'1, with an R2 value of >0.99. 
Concentrations of the permeants were then calculated from the area under 
the curve. SA and EPA were analysed according to the method previously 
outlined in Section 3.2.2.2.3. The LOD for BD, was 100 ng mL'1 (1.98 x 10"4 
pmol mL'1), while the LODs for SA and EPA were reported previously in the 
same section.
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Figure 5.1 : HPLC chromatogram of BD, A=254 nm. BD was found to elute at 6 
minutes with 85:15 methanohdeionized water, pH adjusted to 2.2, Flow rate was 
set at 1 mL min'1.
5.2.2.6 Data analysis and statistical test
Data from the HPLC analysis were then analysed using Microsoft Excel 2003 
and statistical tests done with SPSS version 11.0
5.3 Results and discussion
5.3.1 Depth profile -  frozen skin sections
5.3.1.1 BD
The depth profile for BD obtained from the frozen skin sections are shown in 
Figure 5.2. Comparison of the amount of betamethasone found within the
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layers of the skin between the two test formulations shows that more BD was 
recovered from the first 20 layers treated with formulation containing 0% 
w/w fish oil (0% FO), which was significantly different from the skin treated 
with the formulation containing 20% w/w fish oil (20% FO), with a p value of 
0.007. However, a higher amount of BD was recovered in the remaining skin 
treated with 20% FO. Again, a statistical difference was observed with a p 
value of 0.032 using Mann-Whitney test for two independent samples.
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Figure 5.2 : Comparative depth profile of BD from frozen skin sections (n=3, ±SD). 
RS= remaining skin
The presence offish oil in the second formulation (20% FO) appeared to alter 
the deposition of BD within the skin layers, as seen in the plot above. It was 
suggestive of a reduced retention of BD, leading to enhanced delivery to the 
remaining layers of the skin. The exact localisation of the penetrants in the 
remaining skin (RS) in all the results was undetermined, as the remaining skin 
could possibly retain several layers of unstripped epidermis, in addition to the 
dermis. As such, the values for RS were a total sum of all remaining layers 
from the skin sections.
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5.3.1.2 SA
A similar observation was made for the depth profile of salicylic acid between 
the 2 formulations (Figure 5.3), however the difference was not statistically 
significant for both the first 30 layers of skin (p 0.218) and the remaining 
epidermis and dermis (p 1.00). It appeared that the enhancement seen with 
BD was less apparent with SA.
□  0% FO
□  20% FO
2 4 6 8 10 12 14 16 18 20 RS
Number of strips removed
Figure 5.3 : Comparative depth profile of SA from frozen skin sections (n=3, ±SD). 
RS= remaining skin
5.3.1.3 EPA
The depth profile for EPA is shown in Figure 5.4. The highest mass of EPA was 
recovered from the first 2 strips, with 0.31 ± 0.08 pmol. The total amount 
recovered from the tape strips was 0.53 ± 0.09 pmol while the amount 
recovered from the remaining skin was 0.014 ± 0.0069 pmol.
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Figure 5.4 : Depth profile o f EPA from frozen skin sections (n=3, ±SD). RS= 
remaining skin
5.3.2 Depth profile -fresh skin sections
5.3.2.1 BD
Analysis of BD depth profiles obtained from the fresh skin sections (Figure 
5.5) revealed the same observations with the profile obtained with frozen 
skin (Section 5.3.1.1). The BD amount recovered from the first 20 strips were 
not statistically significant between the 2 formulations, with p 0.7394, while 
there was a marked increase in the amount of BD recovered in the remaining 
skin treated with the combination formulation, with p 0.001. However, it was 
observed that the overall amount of BD recovered with the fresh skin section 
was greatly reduced. The highest amount recovered was from the remaining 
fresh skin sections in both 0% FO (9.24 x 10‘3 pmol) and 20% FO (1.83 x 10'2 
pmol). This, however represents only 17% and 21%, respectively, of the 
amount recovered from the frozen skin sections. It was also reflected in the
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total amount recovered from the 1st 20 strips with 9% (0% FO) and 19% (20% 
FO), respectively.
0.02
0.015
o.oi
□  0% FO
□  20% FO0.005
10 14 16 18 20 RS
-0.005
Number of strips removed
Figure 5.5 : Depth profile of BD from fresh skin sections (n=3, ±SD). RS= remaining 
skin
The presence offish oil in the second formulation (20% FO) appeared to alter 
the deposition of BD within the skin layers, as seen in both frozen and fresh 
skin sections. The data suggested decreased localisation of BD within the skin 
tissue. It was assumed that the presence of the fish oil made binding of BD to 
skin tissue less favourable. Therefore, there was more BD free to diffuse 
through the tissue, as evidenced by the 'remaining skin' data.
One possible explanation is that the excess fish oil effectively saturated the 
tissue, creating a lipoidal environment which would facilitate the movement 
of the lipophilic BD molecules (LogP = 4.07), at least partially solvated by the 
PUFA (Thomas et al. 2007b). This is generally referred to as the 'pull 
effect'(Heard et al. 2006; Kadir et al. 1987).
The interaction of long chain fatty acids, such as oleic acid (and other 
enhancers, including Azone) with the lipids of the stratum corneum has been 
reported previously. The classic explanation is that perturbation of the SC
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lipids increases the fluidity of these lipids, and hence, leads to enhanced 
permeation. Lipid 'domains' within the barrier lipids of the stratum corneum 
in the presence of the fatty acid have also been suggested (Williams 2003). It 
is felt that such considerations are too simplistic to explain the current 
results, due to the fact that the fatty acid in question (EPA) was found to 
penetrate skin layers, and as will be seen in the following chapter (Chapter 6), 
found to permeate across skin along with the other two permeants (BD and 
SA).
S.3.2.2 SA
From the depth profile for SA shown in Figure 5.6, it can be gathered that the 
SA amount recovered from both the first 20 strips and remaining skin were 
not significantly different between the 2 formulations, with p 0.4183 and 0.9 
respectively. In this instance, the amount recovered from the first 20 strips 
was higher (though not statistically significant) in the presence of FO, while 
the opposite was seen in the remaining skin. Comparing the frozen and fresh 
skin sections, the first 20 strips of the fresh skin sections recorded only 13.5% 
and 29.8% of the frozen skin. For the remaining skin, however, the amounts 
recovered were close between fresh and frozen, with 74.5% and 56.6% for 
0% FO and 20% FO, respectively.
Chapter 5
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Figure 5.6 : Depth profile of SA from fresh skin sections (n=3,±SD). RS= remaining 
skin
5 3 .2 .3  EPA
In contrast with the depth profile obtained with frozen skin, the highest EPA 
amount in the fresh sections was recovered from the remaining skin (Figure 
5.7). The EPA recovered from the 1st 20 strips (0.289 pmol) which 
represented 54.8% of the amount recovered in frozen sections. Comparing 
the effect of fresh and frozen sections, the EPA recovered from the remaining 
skin, however, was approximately 30 times the EPA recovered from the 
latter.
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Figure 5.7 : Depth profile of EPA from fresh skin sections (n=3, ±SD). RS= remaining 
skin
One possible explanation of this reversed effect is the freezing process may 
have disrupted the intercellular lipid matrix, which theoretically is the route 
favoured by the highly lipophilic EPA. The intact lipid in fresh skin then 
resulted in higher deposition of EPA to the lower layers.
In both cases (frozen vs. viable skin), the receptor phase was not analyzed for 
permeated BD, SA and EPA. While the data indeed showed an alteration in 
the delivery, particularly for BD, it is acknowledged that for a more complete 
picture on the effects of fish oil and in general, the fatty acids, on 
transcutaneous delivery of drugs the amount permeated across the 
membrane and amount remaining in the donor phase need to be accounted 
for. The efficiency of extraction from both the adhesive tape and skin 
sections, which were not validated, could also impact on the total recovered 
amount of penetrants in the study. These considerations must be taken into 
account for future studies of this nature.
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5.3.3 Hydrolysis of BD in homogenized porcine skin
BD is one of the several esters of betamethasone developed specifically to 
increase their lipophilicity, hence increase their permeation across skin. In 
the skin, the ester bond is cleaved by esterases, liberating the parent 
compound.
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Figure 5.8 : % remaining BD incubated with homogenized porcine skin over time.
(n=3, ±SD)
Analysis of the concentration o f BD, expressed as a percentage over the 
starting concentration, revealed that the concentration of BD declined 
progressively over 24 hours (Figure 5.7). The decline was most apparent after 
12 hours incubation, the concentration at 72.22 ± 8.3% of the original 
concentration. After 24 hours, the remaining concentration was only 39.61 ± 
15%. This indicated continuous esterase activity in viable skin homogenate 
for up to 24 hours. The result also corresponded to the earlier depth profile, 
where the amount o f BD recovered from fresh skin sections were 
approximately 20% of that from frozen skin.
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The addition of fish oil in the test formulation replicating a commercially 
available corticosteroid appeared to enhance the delivery of BD, particularly 
to the lower layers of the skin. The lower basal layer of the epidermis is of 
particular importance, as this layer is metabolically active (Thomas and Heard
2007), and, in conditions such as psoriasis, are continuously dividing, 
presenting an important target for therapeutic agents such as BD. Enhancing 
delivery of these agents would, in theory, increase the efficacy and would 
allow dose reduction, particularly in view of the side effects commonly 
associated with prolonged use of corticosteroids, as discussed in Section
1.2.1.1. The addition of EPA, apart from the observed enhancement of 
corticosteroid delivery across the skin, possesses the extra benefit of 
reducing inflammation via production of less potent inflammatory mediators, 
inhibition of skin inflammatory enzymes, and promotion of the resolution 
phase of inflammation, as reported by several studies (DeFilippis and Sperling 
2006; Riku et al. 1993; Schwab and Serhan 2006; Thomas et al. 2007a)
The effect of freezing on transdermal drug delivery and skin permeability has 
indeed been studied previously (Ahlstrom et al. 2007; Babu et al. 2003; 
Bosman et al. 1998; Shaikh et al. 1996). The majority of the studies were in 
agreement that the fluxes of topically applied compound across frozen skin 
were greatly increased, although permeation characteristics of the test 
compounds remained the same. The duration of freezing also were found to 
be crucial, with the suggestion that the longer the skin were frozen the 
greater the increase in flux (Ahlstrom et al. 2007; Babu et al. 2003; Bosman et 
al. 1998). The difference has been attributed to a variety of factors, from 
rearrangement of molecules within the skin (Weber 1993), structural damage 
and protein denaturation, and the release of protease and free radicals as a 
result of the freezing and thawing process (Kearney 1998).
The difference in metabolic capacity between fresh and frozen skin should 
also be considered. In a study looking at the activity of esterases, it was found
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that one week- frozen porcine skin sections maintained enzymatic activity, 
although it was markedly reduced compared to fresh skin (Lau 2008). 
Contrastingly, Shaikh et al. (1996), using 8-methoxypsoralen as a test 
permeant, found that the metabolic capacity remained constant between 
frozen and fresh skin, despite increased permeability with the former. 
Perhaps the difference depended on the particular enzyme involved, the 
nature of the permeating compound, and factors such as the temperature 
and the length of storage in the different studies.
5.4 Conclusion
Based on the comparative depth profiles obtained, it is of a particular benefit 
to incorporate EPA or fish oil in topical formulations to employ both its anti­
inflammatory activity and the enhancement properties of this n-3 fatty acid. 
The difference observed in the use of frozen/non-viable skin in the results 
highlights the importance of storage conditions and factors that may 
contribute to the outcome of permeation studies. Although there may be 
contrasting reports on the effects of freezing, the use of viable skin is logically 
more preferable to provide an in vitro condition as close as possible to in vivo 
conditions.
116
Chapter 6:
In vitro transcutaneous delivery 
of topical anti-psoriatic 
medication and fish oil across 
excised defolliculated mouse skin
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6.1 Introduction
In chapter 5, the delivery of BD, SA and EPA from FO across excised porcine 
ear skin was investigated. It was found that the addition of FO enhanced the 
delivery of BD and SA to the lower layers of the epidermis. As the first part of 
the study involving DfL mouse as a model for psoriasis, the transcutaneous 
delivery of the same agents was investigated. The aim of this study was to 
determine whether the same enhancing effect observed in porcine ear skin 
can be replicated in DfL mouse skin, in vitro. This was achieved through 
permeation studies using Franz-type diffusion cells and depth profiling via 
adhesive tape stripping.
6.2 Materials and methods
6.2.1 Materials
The materials used in this study were the same as listed previously in Section
5.2.1. D-squame© adhesive discs (CuDerm Corporation) were obtained from 
Fisher Scientific (Loughborough, UK). Excised DfL mouse back skin was 
obtained from Dr. Rebecca Porter of the Department of Dermatology, Cardiff 
University and frozen in -80°C prior to use. All skin sections were from mice 
of 15 weeks and above when the destruction of hair follicles is complete.
6.2.2 Methods
6.2.2.1 In vitro skin permeation of EPA from FO
To look at the delivery properties of EPA from FO across DfL skin, the 
contents of fish oil capsules were squeezed into a clean glass vial and 0.05% 
w/w BHA added as a preservative. lmL of the mixture was then dosed onto
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excised DfL skin (n=3) mounted on Franz cells with cetrimide 30mg mL'1 
added with BHA as a receptor solution. Permeation experiment were then 
carried out according to the method outlined in Section 2.2.2.3.3 with whole 
receptor phases removed at 3, 6,12, 24 and 48 hours.
6.2.2.2 In vitro skin permeation and depth profiling of topical
formulation containing BD, SA and EPA from FO
6.2.2.2.1 In vitro skin permeation
Permeation experiments were carried out according to the method 
previously described in Section 2.2.2.3.3. The skin sections were dosed with 
100 mg of the formulations listed in Table 6.1 (n=3). The formulations were 
prepared according to the method described in Section 5.2.2.1. The required 
amount of each formulation was then weighed and massaged gently on to 
the skin sections. Whole receptor phases were collected at 3, 6, 12 and 24 
hours.
Formulation Contents
BDO 0.05% BD, 3% SA, 0.05% BHA in emulsifiying ointment
BF 20% FO, 3% SA, 0.05% BHA in emulsifying ointment
BDF 0.05% BD, 20% FO, 3% SA, 0.05% BHA in emulsifying 
ointment
Control 0.05% BHA in emulsifying ointment
Table 6.1 : The test formulations used in permeation and depth profiling studies 
across excised DfL skin
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6.2.2.2.2 Depth profiting
Skin sections from the above permeation experiments were sequentially 
stripped with D-squame© adhesive discs (CuDerm Corporation, Dallas, US) 
after 24 hours of permeation studies according to the method outlined in 
Section 3.2.2.2.2. Excess formulations were wiped off before stripping, with 
the first 2 strips discarded. The following 20 strips were then collected in 
batches of 2 and placed in methanol as an extracting solvent.
6.2.2.3 Analysis of EPA
Analysis of EPA from permeation experiment (Section 6.2.2.1) was conducted 
using GC with the method previously described in 2.2.2.2. The LOD of EPA for 
the GC analysis was reported previously in the same section. For depth 
profile studies, EPA was analysed using HPLC according to the method first 
described in Section 3.2.2.3. Both methods were adaptations of previously 
reported validated analysis (Christie 2003; Thomas 2006). However, in this 
study, the two methods were not validated against each other and was 
determined as a possible limitation.
6.2.2A Analysis of BD and SA
Quantification of BD and SA by HPLC used the same method described 
previously in Section 5.2.2.5. The LOD for BD and SA were also reported 
previously in the same section.
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6.2.2.5 Data collection and statistical analysis
Data from both GC and HPLC were collated using Microsoft Excel 2007 and 
statistical analysis done with InStat 3 for Microsoft Windows (GraphPad Inc., 
Elysian, US).
6.3 Results and discussion
6.3.1 In vitro skin permeation of EPA from FO across excised DfL
skin
The plot for cumulative amount of EPA over area across 48 hours is shown in 
Figure 6.1. After 48 hours, the amount of EPA permeated across DfL skin was 
0.356 ± 0.07 pmol cm'2. As a comparison, the amount of EPA permeated 
across porcine ear skin over the same time period was 0.046 ± 0.003 pmol 
cm'2. Thus DfL skin was more permeable than porcine ear skin by a factor of 
10. Mann-Whitney test for the fluxes (Table 6.2) of the two different skins 
also revealed a very significant difference, with p 0.0017, with EPA flux across 
porcine skin calculated to be 1.23 x 1 0 3 ± 8.46 x lO '4 pmol cm'2 h'1, compared 
to 1.07 x 10'2 ± 1.25 x 10'3 pmol cm'2 h 1 across DfL skin.
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Figure 6.1: Permeation profile of EPA across excised DfL mouse skin (n=3 ± SD).
Skin Flux, Jss ± SD (pmol cm'2 h'1)
Porcine
DfL
1.23 x l0 '3 + 8.46 xlO -4 
1.07 x 10'2 ± 1.25 x 10'3
Table 6.2 : Average pseudo-steady state flux of EPA across porcine and DfL skin 
(n=3,±SD)
The pig epidermis has an average thickness of 60-85 pm (Ute et al. 2007). The 
skin of the back of a DfL mouse of 15 weeks and above, contrastingly, has an 
epidermis which is between 13-40 pm. At this age, the DfL have already lost 
their hair follicles and there is a certain degree of epidermal 
hyperproliferation. Taking this into account, the DfL epidermis is still 
considerably thinner than the porcine ear. It was interesting to note that only 
0.033% of the total EPA was detected across DfL skin, considering the 
thinness of the epidermis. With the porcine skin, only 0.0042% of total EPA 
was detected. This was comparable to the amount reported in Section 2.3.2.1 
(0.0034% of total EPA)
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It must be noted that, although the findings in this study were essential to 
determine the delivery properties of these agents prior to an in vivo study 
with live DfL mice, porcine ear skin is an established model for human skin in 
transdermal and transcutaneous studies (Simon and Maibach 2000a; Ute et 
al. 2007). Thus, the results obtained from DfL mice may not reflect conditions 
in humans; the same however, must be said even with the more established 
porcine model.
6.3.2 In vitro skin permeation of topical formulations containing
BD, SA, and EPA from FO across DfL skin
6.3.2.1 BD
As clearly evident from the permeation plot of BD for both BDO and BDF, the 
addition of fish oil altered the delivery of BD. The cumulative amount of BD 
retrieved over 24 hours (Figure 6.2) from BDF was higher, at 9.12 pmol cm'2, 
compared to BDO (4.99 x 10'3 pmol cm"2). The Mann-Whitney test for 2 
independent samples showed a significant difference between the 
cumulative amounts permeated from the two formulations, with p 0.0208. 
This was suggestive of an enhancing effect on behalf of fish oil on the delivery 
of BD.
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Figure 6.2 : Permeation profile of BD from BDO and BDF across excised DfL skin 
(n=3, ± SD). Addition of fish oil increased the flux of BD (p 0.032), hence, increased 
cumulative amount of BD recovered (p 0.0208) from skin sections dosed with BDF.
The enhancing effect of fish oil on BD delivery was further strengthened by 
the Jss value determined from the 2 formulations, shown in Table 6.3.
Formulation Flux, (pmol cm'2 h'1)
BDO
BDF
1.43 x 10*4 ± 0.98 x 10'4 
4.11 x 10"4 ± 0.08 x 10*4
Table 6.3 : Average pseudo-steady state flux of BD from BDO and BDF across DfL
skin. Presence of fish oil appear to  increase the flux of BD by approximately 3 
times.
In the presence of fish oil, the flux for BD increased by approximately 3 times 
(p 0.032). The exact mechanism of this enhancement on BD was not 
determined, however, several possibilities were discussed earlier in Chapter 
5, and more importantly, the delivery enhancing effects of fish oil have been 
reported previously (Thomas et al. 2007b).
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6.3.2.2 SA
From Figure 6.3, the cumulative amount of SA permeated over 24 hours was 
the highest from BF, followed by BDO and finally, BDF. These values however 
were not statistically significant, with p 0.0734.
The SA fluxes from all three formulations (Table 6.4) were also not 
significantly different (p 0.4979), suggesting there is no enhancement of SA 
delivery either by BD, FO, or both of them when co-formulated with SA. This 
was in contrast with the enhancement seen earlier with BD. It did, however, 
concur with the findings in Chapter 5, whereby the delivery of SA was not 
enhanced significantly in both fresh and frozen porcine skin sections.
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Figure 6.3 : Permeation profile of SA from BDO, BDF, and BF across DfL skin.
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Formulation Flux, Jss (pmol cm 2 h'1)
BDO 0.189 ±0.014
BDF 0.164 ±0.012
BF 0.201 ± 0.002
Table 6.4 : Average pseudo-steady state flux of SA from BDO, BDF and BF 
(n =3,±SD)
6.3.1.3 EPA
Analysis of samples that were treated with FO-containing formulations (BF 
and BDF) by GC revealed that the levels of EPA were under the limit of 
detection in both cases. Considering that only 0.033% of EPA permeated 
when delivered as the stock oil (containing 330 mg EPA), the non-detection of 
EPA, which in both formulations constituted only 6.6 mg per 100 mg, was not 
surprising. This did not reflect poorly on the overall delivery of EPA, as will be 
discussed further in the following depth profiling studies.
6.3.3 Comparative depth profiling of BD, SA, and EPA from topical 
formulations across excised DfL skin.
6.3.3.1 BD
Figure 6.4 shows the comparative depth profile of BD from two different BD 
formulations. After 20 strips, the amount of BD recovered from BDO and BDF 
were 8.03 x 10 3 and 7.35 x 10'3 pmol, respectively. The difference was not 
statistically significant, with p 0.5787. For the remaining skin, however, there 
was a huge difference (p 0.0067) with the amount of BD recovered from the
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combined formulation (2.99 x 10*3 pmol), at 3 times higher compared to BDO 
(9.95 x 10"4 pmol). This again was suggestive of an enhancing effect of EPA on 
the delivery of BD, as discussed in Chapter 5, and concurred with the 
permeation results in Section 6.3.2.1
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Figure 6.4 : Comparative depth profile of BD recovered from BDO and BDF treated 
DfL skin (n=3, ±SEM). RS = remaining skin
It was stated earlier in Chapter 5, that this enhancement may, in part, be 
attributed to the 'pull7 effect. It was also stressed that the basal layer of the 
epidermis contains metabolically active cells, and IHC staining (will be 
explained in Chapters 7 & 8) also revealed that major inflammatory enzymes 
within the epidermis were localized in this layer.
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6.3.3.2 SA
Analysis of the depth profile for SA (Figure 6.5) found no significant 
difference (p 0.0539) in the amount of SA recovered from BF, BDO, and BDF 
within the first 20 strips. The amount of SA recovered from the remaining 
skin was highest in BDF, followed by BDO, and BF (p 0.0001). This was the 
opposite of the permeation profile in Section 6.3.2.2; the low amount of SA 
permeating from the combined BD, SA and FO formulation translated to a 
higher deposition in the remaining skin. It was noted that the deposition 
within the skin was influenced by the presence of BD instead of EPA.
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Figure 6.5. : Comparative depth profile of SA recovered from BF, BDO and BDF 
treated DfL skin (n=3, ±SEM). RS= remaining skin.
6.3.3.3 EPA
Comparative depth profile of EPA (Figure 6.6.) obtained from the two FO- 
containing formulations (BF and BDF) revealed that less EPA was recovered 
from the first 20 strips in the combined BD+FO formulation. However, Mann-
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Whitney test for two independent samples revealed no statistical difference, 
with the p value at 0.7394. Meanwhile, the amount recovered from the 
remaining skin was 0.086 pmol for BF and 0.113 pmol for BDF. This supported 
the observation of the 'puli' effect between EPA and BD reported in 6.3.3.1. 
Flowever, this difference was not statistically significant, with p 0.1650.
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Figure 6.6 : Comparative depth profile of EPA recovered from BF and BDF treated
DfL skin (n=3, ± SEM). No significant difference (p > 0.05) was observed in the 
amount of EPA from the 2 formulations for both the first 20 strips and remaining 
skin (RS).
In Chapter 5, we have discussed the depth profile of these agents in porcine 
skin. To recap, the amount of BD in the remaining skin was significantly 
higher with the presence of FO. In the case of salicylic acid, the difference in 
the amount recovered was not significant, although, again, there was an 
increase in its delivery to the lower layers of the epidermis.
These findings were replicated with the depth profiles obtained using DfL 
skin. Note however, that the total amount being recovered was lower
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compared to the study using porcine ear skin. The vast difference in thickness 
between the two types of skin and impaired barrier meant that DfL skin were 
more permeable to the compounds, hence the reduced deposition within the 
skin layers.
6 .4  Conclusion
The study into the transcutaneous delivery of topical anti-psoriatic agents 
using DfL skin showed that BD, SA and EPA were delivered successfully. The 
delivery enhancement action of EPA seen with porcine skin was again proven 
in this murine model; however, there were differences in the extent and the 
amount of drug recovered. These findings represent the first step towards 
establishing this spontaneous mutant in an in vivo setting, which will be 
explored in Chapters 12 and 13.
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Enhanced anti-inflammatory 
activity of a betamethasone 
dipropionate formulation 
containing fish oil
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7.1 Introduction
In Chapters 5 and 6, it was found that delivery of a corticosteroid (BD) was 
enhanced, especially to the lower layers of the skin, when co-formulated with 
SA and fish oil. Depth profiling of porcine and DFL skin treated with a 
formulation containing BD, SA and 20% FO showed a higher deposition of BD 
in the remaining skin retrieved post-adhesive tape stripping compared to a 
same formulation without FO. The purpose of this work was to investigate 
whether this enhancement translates to an increased biological activity in 
vitro, determined here by immunohistochemistry (IHC) staining and Western 
blot (WB) analysis.
Cyclooxygenase 2 (COX-2) and 5-lipooxygenase (5-LOX) are the main enzymes 
involved in the production of inflammatory mediators or eicosanoids within 
the arachidonic acid (AA) cascade, otherwise known as the inflammation 
cascade. The products of this cascade, such as leukotriene, prostaglandin, 
and thromboxane, help to protect the body from injury; released act in 
response to noxious stimuli (Yamazaki et al. 2006). Prolonged inflammatory 
processes have been implicated as the main cause of diseases, such as 
cardiovascular problems, asthma, and skin diseases such as psoriasis (Gil 
2002). Modulation of cellular fatty acid components from the pro- 
inflammatory arachidonic acid to n-3 fatty acids, such as EPA, has been 
reported to improve symptoms and ameliorate inflammatory diseases.
Considering their important role in inflammation, these two enzymes were 
chosen in this study, and how fish oil and anti-psoriatic medication affect 
their expression was investigated.
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7.2 Materials and methods
7.2.1 Materials
Fish oil capsules 1000 mg (Boots Super Strength, lot 0336000100A, 33% EPA) 
were obtained from a local store. Betamethasone dipropionate (lot 
066K1212) was obtained from Sigma-Aldrich Company Ltd., Poole, UK. 
Salicylic acid (lot A016882401) and bromophenol blue (lot A0251435) were 
obtained from Acros Organics, New Jersey US. COX-2 (#4842) and 5-LOX (lot 
123241-12342) antibody were obtained from Cell Signalling Technology and 
Cayman Chemical Company, respectively. Aprotinin, glycine, leupeptin, 
ammonium persulphate (APS, lot 16531JH), p-actin (A2228), bovine serum 
albumen (BSA), acrylamide/bis-acrylamide (30% solution v/v, 29:1 ratio), 
dimethyl sulphoxide (DMSO), di-n-butylphthalate in xylene (DPX) tissue 
mounting media, dithiothreitol (DTT) 1M in water, methyl green, N,N,N',N'- 
tetramethylene-diamine (TEMED, lot 0768871), phosphate buffered saline 
(PBS), Ponceau S, sodium chloride (NaCI), sodium dodecyl sulphate (SDS, lot 
0806443), and Trizma (Tris base) were purchased from Sigma-Aldrich, Poole, 
UK. Bromophenol blue was sourced from BDH Chemicals Ltd, Poole, UK. 
Chemiluminescent Supersignal* West HRP substrate (Pico, Dura and Femto) 
came from Pierce and Warriner Ltd, Chester, UK. Rainbow™ protein 
molecular weight markers (RPN800E, 12-225 kDa) were from GE Healthcare 
Life Sciences (Buckinghamshire, UK). Emulsifying ointment B.P (lot 72FG) was 
obtained from Thornton and Ross, Huddersfield, UK. All other reagents were 
of analytical grade or equivalent. Freshly excised porcine ears were immersed 
in Hanks balanced salt buffer solution (HBSBS) and used within 1 hour of 
slaughter. The hair was removed with a clipper and full thickness skin from 
the dorsal side of the ear was then excised and cut into sections of 
approximately 2x2cm.
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7.2.2 Methods
7.2.2.1 Preparation of test formulations
Two test formulations were prepared. The first formulation (0% FO), 
intended to replicate the dosage of commercially available formulation 
(Diprosalic* ointment, Schering-Plough) contained 3% salicylic acid and 0.1% 
betamethasone dipropionate in emulsifying ointment base with an addition 
of 0.05% BHA as an antioxidant. The second formulation (20% FO), contained 
the same components as above in the same percentages, plus 20% fish oil. 
The content of EPA in this formulation is approximately 6.6%. Emulsifying 
ointment was melted at 40°C, and the required amount of BD, SA and BHA 
were weighed and added to the melted base and stirred to ensure uniform 
distribution of the drugs. All the formulations were kept at room temperature 
under light exclusion prior to use.
7.2.2.2 IHC staining
IHC is a technique used to determine the localization of a protein within a 
tissue. It is based on the principle of specific binding between an antibody 
and an antigen, which can then be visualized in several ways. Common 
visualization strategies include antibodies bound to a fluorescent molecule, 
or an enzyme which, in the presence of a substrate, results in a coloured 
product (Ramos-Vara 2005).
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7.2.2.2.1 In vitro permeation & tissue fixation
Freshly excised porcine skin sections mounted on Franz-type glass cell were 
treated with 100 mg of the test formulations gently rubbed onto the sections 
using a glass rod. The cells were maintained in a water bath set at 37°C and 
both the donor and receptor phase occluded. The diffused area was excised 
at 0, 3, and 6 hours post application, placed in disposable cassettes and fixed 
in 4% formaldehyde overnight.
7.2.2.2.2 Dehydration of tissues and embedment in wax
The skin sections were dehydrated with ethanol of increasing concentration 
and chloroform according to the protocol shown in Table 7.1.
Solution Time
70% ethanol 2 x 30 mins
90% ethanol 2 x 30 mins
100% ethanol 2 x 30 mins
Chloroform l x l  hour, followed by 2
x 30 mins
Table 7 .1 : Solutions used for tissue dehydration
The cassettes were then immersed in 3 different wax baths containing 
molten embedding medium according to the protocol in Table 7.2.
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Wax bath Instructions
1 Vacuum turned off for 15 mins, on for 10 mins, and 
turned off again for 5 mins
2 Vacuum turned off for 10 mins, on for 15 mins, and 
turned off again for 5 mins
3 Vacuum turned off for 10 mins, on for 15 mins, and 
turned off again for 25 mins
Table 7.2 : Protocol for the wax baths
The sections were then taken out from the cassettes, placed in moulds, and 
arranged on their sides so the layers of the skin were perpendicular to the 
surface of the mould. In this position, molten medium were then poured on 
from a reservoir ensuring no bubbles were formed. The cassettes, with their 
lids removed, were then quickly placed on top of the molten medium and 
allowed to solidify overnight. The blocks (Figure 7.1) were then taken out of 
the mould for sectioning.
Figure 7.1: Porcine skin section embedded in paraffin wax blocks. Sections of 5 pm 
thicknesses were then cut from these blocks
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7.2.2.23 Sectioning
Sections of 5 pm thicknesses were microtomed from the wax blocks using a 
Shandon Finesse microtome and mounted on pre-cleaned Super Frost ™ 
microscope slides (Surgipath). To ensure the slices were completely flat 
before mounting, the wax slices were floated on a beaker of water heated to 
40°C which will then automatically remove any kinks or folding. The slices 
were then quickly picked up using the slides. They were then allowed to dry 
in an oven set at 40°C overnight.
7.2.2.2.4 Dewaxing and rehydration
Prior to staining, the slides need to be dewaxed by first placing the slides in 
an oven set at 60°C. This is to facilitate dewaxing by melting the embedding 
medium. Complete removal of the paraffin was ensured by soaking the slides 
in 2 x 7 minutes chloroform. Rehydration of the tissues was done using 2 x 3  
minutes of ethanol in decreasing concentrations (100, 90 and 70%). The 
slides were then soaked in distilled water followed by PBS at 5 minutes each.
7.2.2.2.5 Blocking of endogenous peroxidases
Blocking of endogenous peroxidases is an important step in immunostaining 
with HRP linked antibodies. Using HRP conjugated antibody may result in 
high, non-specific background staining caused by the peroxides (Gao et al. 
2008). 3% Hydrogen peroxide (H20 2) is the traditional blocking reagent, and 
was applied on the skin sections for 5 minutes. Afterwards, excess H20 2 was 
removed and the slides washed in 2 changes of PBS for 3 minutes.
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7.2.2.2.6 Antigen retrieval
Antigen retrieval or recovery is conducted to retrieve the antigen of interest 
that might have been masked during the fixation process. This step also 
allows for a better staining (Shi et al. 2001). This entails a simple process of 
boiling the slides in a suitable buffer. For this study, the slides were 
microwaved in 1 litre citrate buffer, prepared by dissolving 2.94 g sodium 
citrate in deionized water and adjusting the pH to 6 with hydrochloric acid. 
The boiling time was 15 minutes, followed by in situ cooling for 30 minutes 
and under running tap water for 20 minutes. The slides were then rinsed with 
PBS and the skin sections outlined with a wax pen (Dako).
7.2.2.2.7 Blocking
Sections were blocked to reduce unspecific binding by incubating the slides in 
PBS-Tween for 20 minutes. This step and the subsequent ones were all done 
inside a humidity chamber to avoid desiccation of the slides.
7.2.2.2.B Primary antibody
The principle behind an indirect IHC detection is the application of an 
unlabelled primary antibody directed toward the antigen or protein of 
interest. This is followed by a second labelled antibody, directed towards the 
immunoglobulin of the species in which the primary antibody was raised, e.g. 
anti-rabbit, anti-mouse. Excess blocking solution was removed and 75 pL 
primary antibody for COX-2 at 1 in 50 dilution pipetted on the sections and 
left overnight at room temperature. The stock antibody was diluted with the
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necessary volume of PBS. The following day, the slides were washed with PBS 
followed by PBS-Tween.
7.2.2.2.9 Detection & staining
Detection was conducted using Dako Envision+ System horseradish 
peroxidase labelled polymer anti-rabbit, which consisted of a polymer 
backbone conjugated with streptavidin-horseradish peroxidase on one end 
and secondary antibody on the other end. This reagent was applied to the 
section direct from the dispenser and left for 2 hours at room temperature. 
This was followed by rinsing in PBS and PBS-Tween. The next step of the 
detection involved a substrate which reacts with the HRP. The Dako 
Chromogen system contains 3, 3'-Diaminobenzidine (DAB) that change colour 
to brown in the presence of hydrogen peroxide. One drop of the stock 
solution was made up to 1 mL with the buffer and applied to the sections for 
10 minutes, followed by rinsing in deionized water.
7.2.2.2.10 Counterstaining
The sections were counterstained using an aqueous solution of 0.5 % methyl 
green for 2 minutes, followed by rinsing in deionized water. The slides were 
then left to dry before mounting in DPX and covered with cover slips. The 
slides were examined and imaged using a microscope (Optihop, Nikon 
Corporation, Tokyo, Japan) equipped with image capture facilities (Axiovison 
LE, Carl Zeiss Ltd., Welwyn Garden City, UK).
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7.2.23 Western blot analysis
The expression of both COX-2 and 5-LOX were determined using Western 
blot with a method adapted from Leong et al. (1996). The principle behind 
WB analysis is the detection of specific proteins from a tissue or cellular 
lysate/extract combining separation of proteins using gel electrophoresis 
with immunoprobing of the separated proteins blotted on to a membrane 
(Burnette 1981). Freshly excised porcine skin sections were mounted on 
Franz-type glass cells with HBSBS solution as a receptor phase and treated 
with both formulations and left for 6 hours in a water bath maintained at 
37°C. After 6 hours, the diffused area was excised, homogenized and 
incubated with 1 mL of radioimmunoprecipitation assay (RIPA) buffer (Sigma 
Aldrich, lot 096K6068) added with lpL aprotinin and 50 pL leupeptin. The 
samples were then centrifuged at 10000 rpm for 15 minutes twice and the 
resulting supernatant kept frozen at -20°C prior to use.
7.2.2.3.1 Protein estimation
Protein estimation was done using a method based on the Coomassie 
(Bradford) protein assay and the values obtained from a calibration curve 
constructed from bovine serum albumin (Sigma Aldrich) with a range of 5-25 
pg mL' 1 diluted in deionized water. Sample protein lysates were diluted 1 in 
200, also in deionized water. 800 pL of each standard concentration and 
protein samples (in duplicates) was prepared in 1.5 mL disposable cuvettes. 
Afterwards, 200 pL of protein assay reagent (Bio-rad, Munich, Germany, lot 
no 107862) was added to each cuvette and mixed by turning the cuvettes 
upside down several times and left to stand for at least 10 minutes. The 
intensity of the resulting blue colour was then read at 595 nm using an UV 
spectrophotometer (Cecil Instruments CE2041, Cambridge, UK. The
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concentration of protein in each diluted sample can then be obtained using 
the standard curve, and the concentration in the total sample worked out by 
multiplying by the dilution factor.
7.2.23.2 Polyacrylamide gel electrophoresis (PAGE)
Aliquots of the sample equating to 30-40 pg protein were added with equal 
amounts of loading/sample buffer (10% SDS, glycerol, 1M Tris-HCI 20mM pH 
6 .8, bromophenol blue, 0.1M DTT in water) were denatured at 100°C for 5 
minutes. The denatured samples were then stored at -20°C or used straight 
away for PAGE.
PAGE was done using Xcell SureLock™ 1-D electrophoresis system 
(Invitrogen, Paisley UK) pictured in Figure 7.2. Separating gel (3.3 mL 30% 
acrylamide, 4 mL deionized H20, 2.5 mL 1.5M tris HCL (pH 8 .8), 0.1 mL 10% 
SDS, 0.1 mL 10% APS, lOpL TEMED) was cast in disposable plastic cassettes, 
allowing 20-30 minutes for it to set. Then, stacking gel solution (1.7 mL 30% 
acrylamide, 5.8 mL deionized H20, 2.5 mL 1.5M tris HCL (pH 6 .8), 0.1 mL 
10% SDS, 0.1 mL 10% APS, lOpL TEMED) was pipetted on top of the 
separating gel, and a well-casting comb applied. Gel setting time was 
approximately 15 minutes. Once set, the comb was removed and the wells 
washed with deionized water, before locking the cassette in the apparatus, 
lx  running buffer (lOx stock solution -15  g Tris, 72 g glycine, 5 g SDS, diluted 
with deionized water) was pipetted into the wells and filled up the tank 
followed by application of sample and 5 pL protein molecular weight 
markers. Electrophoresis was conducted at 125 V until separation of protein 
markers had reached the desired molecular weight. The cassette was then 
removed and broken apart to remove the gel for Western blotting.
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Figure 7.2 : Invitrogen Xcell SureLock PAGE and blotting module as used in the 
study
7.2.2.3.3 Western blotting
In preparation for blotting, filter paper and sponge pads were pre-soaked in 
western blot buffer (3.03 g Tris Base, 14.4 g glycine, 200 mL methanol in 800 
mL deionized water) and transfer membrane wetted in methanol and then 
shaken in deionized water. The gel was then assembled on a flat surface in 
this order: filter paper, gel, transfer membrane, filter paper. The whole 
assembly was then placed on sponge pads and into the blotting module 
(XCell II™, Invitrogen). The module was filled with western blot buffer and 
placed in a tank filled with deionized water. Running time was 1-2 hours, with 
a voltage set at 25 V.
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7.2.2.3.4 Immunohistochemistry
The resulting blot from the previous procedure was then subjected to 
immunohistochemistry procedure for the protein of interest. To ensure 
protein loading was equal and the transfer was complete, the blot was placed 
in a solution of Ponceau S (0.1% w/v Ponceau S in 5% acetic acid) for several 
minutes followed by deionized water. The intensity of the resulting red 
colour on each band was directly correlated to the relative amount of protein 
present. The blot was cleared using Tris Buffered Saline with 0.1 % v/v 
Tween-20 (TBS-Tween) made up with a stock lOx solution (24.2 g Trizma 
base, 80 g NaCI) diluted to lx.
The blot was blocked using 5% milk (Marvel™ Original Dried Skimmed Milk, 
Chivers Ireland Ltd.) in TBS-Tween for 1 hour in room temperature with 
constant rocking. This was followed with COX-2 and 5-LOX antibody (1/1000 
dilution) first for 1 hour in room temperature and then overnight at 4°C. After 
washing with 2 changes of TBS-Tween (5 minutes, then 25 minutes) the blot 
was incubated with secondary antibody (horseradish peroxidase linked anti­
rabbit IgG) at 1/10000 dilution in TBS-Tween with 1% milk for 1 hour. 
Visualization of the blot was done using Chemiluminescent Supersignal® 
West HRP substrate (Pierce) and exposed to radiography film (Kodak) for 5 
minutes before development.
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7.3 Results and discussion
7.3.1 IHC staining
Figure 7.3 illustrates the change in COX-2 levels over 6 hours. The brownish- 
red stain observed denotes the presence of the enzyme which was found to 
be localized in the viable epidermis. For the first 3 hours, no discernable 
changes were observed for both treatments. However, at t=6 hours, a 
reduction in the intensity of the staining, i.e. anti-inflammatory effect, was 
observed with 20% FO especially exhibiting a marked effect.
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Figure 7.3 : IHC staining for COX-2 at 40x magnification. After 6 hours, the relative 
levels of COX-2 was greatly reduced in the combined BD-FO treatment compared 
to BD alone.
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7.3.2 Western blot analysis
5-LOX
0% FO 20% FO
COX-2
0% FO 20% FO
Figure 7.4 : Western blot for 5-LOX and COX. The expression of 5-LOX and COX-2 
was found to be decreased with addition of FO. This reduction is attributed to the 
inhibitory effects of n-3 fatty acids on both enzymes, by a mechanism yet to be 
determined.
Figure 7.4 shows the results obtained from the Western blot analysis. The 
blot on the left represents 0% FO, and on the right, 20% FO. As observed, 
there is an appreciable decrease in the size of the blot signifying the 
reduction of the enzyme level in the protein sample, noticeably for 5-LOX. 
Although the same is observed with COX, it was less apparent. Since the 
Western blot was done qualitatively, it was not known whether the 
difference in the enzyme levels was statistically significant. However, both 
results alluded to an enhanced anti-inflammatory effect in the sample 
treated with 20% FO.
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Since both formulations contain the same percentage of both salicylic acid 
and betamethasone dipropionate, a known anti-inflammatory, the increased 
effect observed in both experiment can be attributed to the presence of fish 
oil in 20% FO.
Two possibilities are suggested to explain this apparent enhancement. First, 
fish oil, which is rich with essential fatty acids, has been reported to possess 
anti-inflammatory effect both in vitro and in a clinical setting. Indeed, several 
trials with fish oil and/or the fatty acids (in particular EPA) have proven the 
benefits of fish oil in improving inflammatory skin diseases, such as psoriasis 
(Dewsbury et al. 1989; Escobar et al. 1992). Incorporation of EPA into cellular 
membranes (through ingestion or application) and its subsequent release 
results in production of less potent eicosanoids through competition with 
arachidonic acid (AA), with the net effect of reducing the extent of 
inflammation. In relation to this experiment, Thomas et al (2007a) concluded 
that fish oil has a direct inhibitory effect on both COX-2 and 5-LOX, 
demonstrated via ICC staining on skin dosed with fish oil alone or co­
formulated with ketoprofen. Again, an additive effect was observed when 
fish oil was present in the formulation along with a known anti-inflammatory. 
A similar observation was noted by Puglia et al. (2005) with transcutaneously 
delivered fish oil.
The second possibility can be attributed to the enhancement of BD delivery 
across skin, as discussed previously in Chapters 5 and 6 . The increased 
amount of BD present would then translate to a greater inhibition of the 
enzymes by BD.
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7.4 Conclusion
This study showed that the addition of 20% FO in a corticosteroid formulation 
resulted in an increased inhibition of COX-2 and 5-LOX, two main 
inflammatory enzymes found in the epidermis. This was reflected from the 
reduced staining observed with ICC (COX-2), and the reduction of the blot 
size, hence, the level of the protein/enzyme from WB analysis (COX-2 and 5- 
LOX). It is uncertain how FO enhanced the inhibition and arrested the 
inflammatory process, but it was postulated that it is achieved via a two 
pronged mechanism: Enhanced delivery of BD and possession of intrinsic 
anti-inflammatory effect.
Although the data represented here is qualitative, this would only encourage 
further research into the plausibility of incorporating FO into the topical 
regiment of dermatological drugs, with a view of targeting inflammatory skin 
diseases, such as dermatitis and psoriasis. It is hoped that quantification of 
the WB results, coupled with other methods, such as cell culture would 
further strengthen the available data and ultimately highlight the benefits of 
topically applied FO/EPA.
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Chapter 8:
IHC staining and WB analysis for 
COX-2 and 5-LOX in porcine skin 
sections treated with 
betamethasone dipropionate, 
salicylic acid and fish oil
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8.1 Introduction
An earlier study using a combined formulation of an anti-inflammatory agent 
(ketoprofen) and fish oil reported an additive inhibitory effect of FO towards 
COX-2 and LOX (Thomas et al. 2007a). This also was supported with the 
previous work in Chapter 7, which combined betamethasone dipropionate 
and salicylic acid, intended to replicate a commercially available anti-psoriatic 
medication, with the addition of fish oil. Therefore, the current study would 
look further into the effect of each individual component on epidermal COX-2 
and LOX via immunohistochemistry (IHC) staining and quantitative WB 
analysis.
In WB assays, although care is taken to ensure an equal amount of protein is 
loaded during electrophoresis, errors are invariably present. In order to 
minimize loading error, apart from replication, the result for the protein of 
interest is often normalized with other proteins that are found in abundance 
within tissues. One such protein is (3-actin (Figure 8.1). The 42 kDa protein is
Figure 8.1: (3-actin (42 kDa) (Schutt et al. 1993)
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one of the cytoskeletal actins, with primary functions in cell motility, 
structure and integrity (Gunning et al. 1997).
8.2 Materials & method
8.2.1 Materials
Monoclonal antibody for p-actin (clone AC-74 produced in mouse, A2228) 
was obtained from Sigma Aldrich (Poole, UK). Western blot stripping buffer 
(Restore™ Western Blot Stripping Buffer) was from Thermo Scientific 
(Loughbororugh, UK). All other reagents and materials were the same as 
listed in Section 7.2.1
8.2.2 Methods
8.2.2.1 Preparation of test formulation
Five test formulations (Table 8.1) were prepared according to the method 
outlined in section 5.2.2.
Group Treatment
BD 0.05% w/w BD, 0.05% w /w  BHA in emulsifying ointment 
BP
BF 20% w/w FO, 0.05% w/w BHA in emulsifying ointment BP
SA 3% w/w SA, 0.05% w/w BHA in emulsifying ointment BP
BDF 0.05% w/w BD, 20% w/w FO, 0.05% w/w BHA in 
emulsifying ointment BP
Control 0.05% w/w BHA in emulsifying ointment BP
Table 8 .1 : Test formulations used in the current study
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8.2.2.2 In vitro skin permeation
Approximately 100 mg of each formulation was applied with gentle rubbing 
using a glass rod onto excised porcine ear skin sections mounted on Franz 
diffusion cells with HBSBS as a receptor solution (n=6)
8.2.2.3 IHC staining
At t=0 h, 3, 6 and 24 hours, the diffused areas were excised and fixed in 
formaldehyde overnight. The following procedures for tissue processing and 
the subsequent IHC staining were explained previously in Section 1.2.2.2
8.2.2.4 PAGE and western blot analysis
At t=0 h, the diffused areas were excised and lysed in 1 mL of RIPA buffer and 
stored at -20°C. The amount of protein lysate from each treatment 
equivalent to 30 mg total protein were denatured and subjected to PAGE and 
western blotting as outlined previously in Section 7.2.23. The resulting blots 
were then subjected to immunohistochemistry procedures using primary 
antibodies for COX-2 and 5-LOX (both 1/1000 dilution in 5% w/v Marvel milk 
in TBS), and developed. Afterwards, the blots were soaked in 10 mL of WB 
stripping buffer for 15 minutes with gentle shaking at room temperature to 
remove all traces of the chemiluminescent agent used in the previous 
development. The blots were then washed with TBS-Tween 3 times for 5 
minutes. Subsequently, the blots were incubated with primary antibody for 
p-actin (diluted 1 in 50 000 in 5% w/v Marvel milk in TBS) for 1 hour in room 
temperature, followed by the secondary antibody (anti-mouse) at 1 in 10 000 
dilution also for 1 hour.
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After development, the film for the COX-2 and 5-LOX blot and the 
corresponding 0-actin film were scanned and analysed using a densitometer 
(GS-690 Imaging Densitometer, Bio-Rad Laboratories Ltd, Herts, UK) 
equipped with Alpha DigiDoc software. The levels of COX-2 and 5-LOX in each 
lysate were normalized with the levels of 0-actin of each corresponding blot, 
and presented as a percentage, with control = 100%.
8.3 Results and discussion
8.3.1 IHC staining
8.3.1.1 COX-2
All the skin sections exhibited an expression of COX-2 (Figure 8.2) at t=0, 
presumably due to the trauma inflicted during removal of the porcine ears at 
the abattoir. A noticeable reduction can be seen in the skin section treated 
with BD (Figure 8.2A) at 3 hours, and especially more pronounced at 6 hours 
post-treatment.
Treatment with SA (Figure 8.2B) showed a slight reduction in the staining 
after 3 hours; however, from 6 hours onward, there was a noticeable 
increase, signifying continuous expression of COX-2. The skin treated with FO 
(Figure 8.2C) however, showed no discernable changes over 6 hours, while 
the control displayed increasing levels of COX-2 over the same time period. 
For all skin sections, the staining pattern at t=24 hours revealed a general and 
widespread staining, suggesting a non-specific staining and/or the lost of 
viability in the skin sections (Thomas et al. 2007a).
B : Salicylic acid 3% ( l- r ) : Oh, 3h, 6h, 24h)
C : Fish Oil 20% (l-r): Oh, 3h, 6h, 24h)
D : Control (l-r): 0h; 3h; 6h, 24h 
Figure 8.2 : COX-2 IHC staining at 0, 3 ,6 , and 24 hours (40x magnification)
B : Salicylic acid 2% ( l- r ) : Oh, 3h, 6h, 24h)
C : Fish Oil 20% (l-r): Oh, 3h, 6h, 24h)
D : Control (l-r): Oh, 3h, 6h, 24h)
Figure 8.3 : 5-LOX IHC staining at 0, 3 ,6 , and 24 hours (40x magnification)
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8.3.1.2 5-LOX
Figure 8.3 shows the expression of 5-LOX obtained qualitatively from IHC 
staining. Apart from a slight reduction at t=6 hours in the skin treated with BD 
(Figure 8.3A), no noticeable change was observed in all the treatments across 
the sampling period. While the control (Figure 8 .3D) exhibited increased 
staining over 6 hours, SA (Figure 8.3B) and FO (Figure 8.3C) remained relatively 
unchanged. As with IHC staining for COX-2, all the skin sections showed a 
widespread staining at t=24 hours.
8.3.2 WB analysis
8.3.2.1 COX-2
The blot obtained for COX-2 and the corresponding 0-actin in the tissue lysates 
collected from all the treatments after 6 hours is shown in Figure 8.4. 
Quantification of the protein levels was achieved by normalizing the values 
with that of 0-actin. It was found that relative to control, BD exhibited the 
greatest reduction of COX-2 at 97.2 %, (p 0.0001) followed closely by FO (90.8 
%, p 0.0001), SA at 71.33 % {p 0.0001), and the combined BD-FO (BDF) at 44.41 
% (p 0.0002) (Figure 8.5). The reduction in COX-2 level by BD and FO 
corresponded with the previous IHC staining. The combined treatment also 
significantly inhibited the expression of COX-2, although in this instance it did 
not appear to enhance the inhibition. Interestingly, in contrast to the IHC 
staining, SA on its own also reduced the expression of COX-2 at t=6. It was 
noted however, that at t=3 hours the COX-2 expression was reduced in the IHC 
staining, before the noticeable increase at t=6 hours.
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COX-2
(3-actin
Control BDF SA FO BD
Figure 8.4 : Representative blots for COX-2 (top) and [3-actin (bottom ). The 
intensity of the bands is directly correlated to the amount of the protein of 
interest.
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Figure 8.5 : The percentage of normalized COX-2 level relative to control (n=3, 
±SD),*= p < 0.05
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8.3.2.2 5-LOX
The blots obtained for 5-LOX are shown in Figure 8.6, while the relative 5-LOX 
levels for each treatment are shown in Figure 8.7. The BD only formulation 
again proved superior to the other treatments in reducing the levels of 5- 
LOX, with 95.13% reduction (p 0.001). Similarly with COX, this was followed 
by the FO-only formulation (51.94%, p 0.0177). As observed with the IHC, SA 
increased 5-LOX expression by 2.4%, although compared to control it was not 
statistically significant (p 0.9222). The combined formulation, although 
resulted in a significant reduction (p 0.02) again did not translate to a greater 
inhibition, with only 41.96% reduction. It did not however differ significantly 
(p 0.5827) from the reduction caused by the FO-only formulation.
5-LOX
(3-actin
C ontro l BDF SA FO BD
Figure 8.6 : Representative blots for 5-LOX (top) and 0-actin (bottom )
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Figure 8.7 : The percentage of normalized 5-LOX level relative to control. (n=3, 
±SD). * = p <  0.05
From the results, one might have expected BD to have an inhibitory effect on 
both inflammatory enzymes. Being a mainstay of topical therapy particularly 
psoriasis (Stein 2005), BD and the corticosteroids in general are effective 
immunosuppressors and anti-inflammatory, exerting their effects through 
binding with intracellular receptors and the regulation of transcription for 
genes coding for cytokines (Hughes and Rustin 1997).
It has now been demonstrated that FO on its own possesses the ability to 
inhibit the expression of both inflammatory enzymes, particularly in the WB 
analysis. This supported the long standing belief in the anti-inflammatory 
properties of fish oil and its primary fatty acids (Mayser et al. 2002; Puglia et 
al. 2005; Thomas et al. 2007a; Wolters 2005).
Contrary to this, Chene et al. (2007) reported that n-3 and n-6 fatty acids, in 
fact induced the expression of COX-2 in human keratinocyte cell lines. This, 
however, was not readily apparent with the current study, as no observable 
increase in COX-2 level was seen. It was also suggested that this enzyme, 
which is pro-inflammatory, also plays an important role in the resolution of
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inflammation in the later phase via production of PGD2, one of the products 
of AA metabolism by COX-2 (Rajakariar et al. 2006). This would be at odds 
with the belief that the anti-inflammatory effects of FO/fatty acids are due to 
direct antagonism of AA. It also highlights the need for a better 
understanding of the inflammation cascade.
Combining BD and FO in this instance however, did not result in a greater 
inhibition of both COX-2 and 5-LOX, as seen with the IHC and qualitative 
staining in Chapter 7. To put delivery issues in perspective, the delivery of BD 
was found to be increased in the lower layers of the skin (Chapter 5). 
Therefore, with the two mechanisms involved (increased delivery and 
intrinsic anti-inflammatory properties of both BD & FO) it was anticipated 
that an enhancing effect would be seen. One possible explanation is the 
saturation of binding sites on the enzyme by FO, thus rendering the effects of 
BD less apparent in the combined formulation.
SA, unlike its acetylated form aspirin, is more often used as a desmosomolytic 
agent in the treatment of dermatological diseases. Generally, salicylates, in 
their various forms (acetylated, methylated), have been used in anti­
inflammatory preparations and pain relief medications by acting on COX and 
prostaglandin E2 production (Vane and Botting 2003). As aspirin is rapidly 
metabolized to SA, it is long believed that the anti-inflammatory action of 
aspirin is a result of its parent metabolite. However, opinions are still divided 
on the true extent of SA's contribution (Amann and Peskar 2002).
It was reported that both aspirin and salicylic acid are equipotent PGE2 
inhibitors, although there exists a difference in their activity against 
cyclooxygenase. Aspirin, by virtue of its acetyl group, exerts its effect by 
acetylating the enzyme; a process impossible to salicylic acid by the absence 
of the functional group. This paradox between anti-inflammatory activity and 
differences in COX inhibition by salicylic acid and aspirin was partly explained 
when it was found that SA inhibited PGE2 production through a pathway
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independent of COX-2 inhibition (Amann and Peskar 2002; Xu et al. 1999). It 
can be concluded then, although SA is anti-inflammatory, it does not affect 
the expression of COX. Therefore the reduction seen with the WB analysis, a 
direct contrast to the IHC staining at the same time point is attributed to the 
difference in COX-2 levels in the different tissue samples. With regards to SA 
activity on lipooxygenases (LOX), the LOX are generally not regarded as a 
target for salicylate action (Lapenna et al. 2009), which was clearly 
demonstrated in both IHC and WB analysis in the current study.
8.4 Conclusion
The current study provided strong evidence of the intrinsic anti-inflammatory 
nature of FO in the skin via its action of epidermal inflammatory enzyme. This 
explained the finding in Chapter 7, and shed light on the possible mechanism 
by which FO potentiates activity of BD. However, contrasting results on the 
effects of the combined formulation deserved further study, particularly with 
regards to the ideal composition of both components in the formulation.
Chapter 9:
Investigating the effects of 
topical formulations on skin 
levels of prostaglandin E2 (PGE2)
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9.1 Introduction
In Section 1.3.7 the AA inflammation cascade was discussed, along with its 
potential modulation by n-3 fatty acids. One of the end-products of the 
cascade is a series of mediators or prostanoids termed prostaglandins.
OH
HO
HO
Figure 9 .1 : Prostaglandin E2 (PGE2)
PGE2 (Figure 9.1) is the most abundant prostaglandin in the human body 
(Serhan and Levy 2003), produced both constitutively and in response to 
stimuli or trauma from cellular AA via the action of cyclooxygenases and 
prostaglandin E2 synthase (PGES), as shown in Figure 9.2 Like all 
prostaglandins, PGE2 is synthesized de novo and there is no cellular reservoir. 
Delayed synthesis of PGE2 (in response to stimuli and injury), mediated by 
COX-2 and microsomal PGES-1 (mPGES-1) has been implicated in the 
pathophysiology of many inflammatory diseases, fever, and cancer (Nakatani 
and Kudo 2002). PGE2 plays a major role in tissue oedema, hyperalgesia, and 
IL-6 production at sites of inflammation (Ruzicka et al. 1986). This effect on 
IL-6 leads to induction of activator protein-2 mRNA and protein production by 
keratinocytes. Subsequently, this causes skin inflammation, and this has been 
shown to lead to hyperproliferation in the growth of keratinocytes (Oyama et 
al. 1999).
\ 165 i
Chapter 9
PLA2: phospolipase A2 
COX: cydooxygenase 
PGES: PGE2 synthase
Phospholipids 
PL A-
cPLA2 (constitutive enzyme) 
sPLAj (inducible enzyme)
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COX!
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IPGES
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Figure 9.2 : Conversion of cellular phospholipids to PGE2 (Nakatani and Kudo 2002)
Therefore, PGE2 is an attractive marker to probe modulations within the 
inflammation process. The aim of this chapter was to investigate the effect of 
fish oil and other common anti-psoriatic medications on the levels of PGE2 in 
an ex vivo porcine ear skin model of inflammation.
9.2 Materials and method
9.2.1 Materials
Fish oil capsules 1000 mg (Boots Super Strength, lot 0S36000100A, 33% EPA) 
were obtained from a local store. Betamethasone dipropionate (lot 
066K1212), BHA, RIPA buffer (lot 096K6068), and Hanks' balanced salts were 
obtained from Sigma-Aldrich Company Ltd., Poole, UK. Pure water was from 
Fisher Scientific (Loughborough, UK) Emulsifying ointment B.P (lot 72FG) was
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obtained from Thornton and Ross, Huddersfield, UK. Enzyme immunoassay 
(EIA) kit for prostaglandin E2 (PGE2) (lot 0408969) was obtained from Cayman 
Europe, Estonia. All other reagents were of analytical grade or equivalent. 
Freshly excised porcine ears were immersed in Hanks balanced salt buffer 
solution (HBSBS) and used within 1 hour of slaughter. The hair was removed 
with electric clippers and full thickness skin from the dorsal side of the ear 
was then excised and cut into sections of approximately 2x2cm. During 
excision, the ear was continuously bathed with HBSBS and the cut sections 
soaked in the same buffer prior to mounting on the diffusion cells.
9.2.2 Methods
9.2.2.1 Preparation of formulations
The test formulations used in the current study were the same as the ones 
used in Chapter 6, namely BD, BF, BDF and control containing the blank 
ointment base.
9.2.2.2 In vitro skin permeation
Freshly excised porcine skin sections were mounted on Franz-type glass cells 
with HBSBS solution as a receptor phase and treated with the formulations 
and left for 6 hours in a water bath maintained at 37°C. After 6 hours, the 
diffused area was excised, homogenized and incubated with 1 mL of RIPA 
buffer added with endogenous protease inhibitors aprotinin (1 pL) and 
leupeptin (50 pL). The samples were then centrifuged at 10 000 rpm, 4°C for 
10 minutes twice and the resulting supernatant kept frozen at -20°C prior to
s 167
Chapter 9
enzyme immunoassay (EIA). EIA was conducted with a kit specific for PGE2 
according to the manufacturer's instructions.
9.2.2.3 Enzyme immunoassay (EIA)
The principle behind the EIA, as depicted in Figure 9.3, is the competition 
between a constant amount of tracer molecules (acetylcholinesterase linked 
to PGE2) and PGE2 in the sample for a limited amount of monoclonal antibody 
towards PGE2. The amount of bound PGE2 tracer is thus inversely 
proportional to the amount of PGE2 available in the sample. Incubated 
together, the PGE2- or tracer-antibody complex then binds with IgG pre­
coated in the wells, directed towards the PGE2 antibody. Subsequently, a 
reagent containing a substrate of acetylcholinesterase is added. The 
enzymatic reaction produces a coloured substance which absorbs strongly at 
412 nm. Using a spectrophotometric plate reader (Sunrise™, Tecan UK Ltd., 
Reading, UK), the intensity of colour is proportional to the amount of bound 
tracer. In using this assay the relative modulation of PGE2 could be used to 
compare an anti-inflammatory (or pro-inflammatory) response to the 
formulation dose onto the ex vivo skin.
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Figure 9.3 : Schematic of the EIA for PGE2 (Cayman Europe, Estonia)
9.3 Results and discussion
The levels of PGE2 in all 4 treatments after 6 hours are shown in Figure 9.4. 
The greatest reduction was seen with BD (398.12 pg mL-1), representing a 
54% reduction from control levels (p 0.0258). This was followed by BF, with a 
level of 473.23 pg mL'1 (p 0.0435), and the combined formulation, BDF with 
505.85 pg mL"1 (p 0.0362). It was interesting to note that fish oil alone had 
the ability to reduce PGE2 levels comparable to that of BD (p 0.1552), 
indicative of an intrinsic anti-inflammatory action. The combination of both 
BD and fish oil in a single formulation did not translate to a greater inhibition, 
although compared to BD and FO the levels were not statistically significant 
(p 0.2242 and 0.6745 respectively).
1. Incubate with tracer, 
antibody. and either 
standard or unknown 
sample.
3. Develop die vrdl with 
Etlman's Reagent.
• = Goat polyclonal anti-mouse IgG
■ ■ ■  s Blocking proteins
■O = Acetylcholinesterase linked 
to PG E , (Tracer)
j -  = Specific antibody to PGE2
O = Free P G E ,
Chapter 9
1200
1000
800
etc
3  600
co
ro
£  400 
c  «  o
o 200
Control BD BF BDF
Formulation
Figure 9.4 : Levels of PGE2 after 6 hours post treatment (0=3,150) (*= p <0.05).
This finding is significant in view of the role played by PGE2 in inflammatory 
diseases. Suction blisters of psoriasis for example, were found to have up to 5 
times higher PGE2 levels compared to non-psoriatic skin (Reilly et al. 2000).
On the other hand, there is a conflicting view of the role played by PGE2 in 
psoriasis. Namazi (2004, 2005) observed a low incidence of psoriasis in an 
African population. In his report, he attributed this fact to the high intake of 
corn and corn based products, a staple diet of Africans. Corn is rich with 
linoleic acid (LA), the precursor of PGE2 (Calder and Gimble 2002). This in turn 
implied that the increased production of PGE2 in the tissues is, in fact, 
protective against psoriasis. This is achieved via the ability of PGE2 to 
suppress certain components of cellular immunity, i.e. interleukin-1, 
interferon-gamma and tumour necrosis factor alpha.
However, there is considerable evidence contrary to the above report. Logan 
(2005) questioned the validity of the assumption by directing the attention 
towards the effects of increased n-6 consumption. It is known that psoriatic
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patients display elevated levels of the n-6 arachidonic acid (AA), which is 
derived from linoleic acid (Reilly et al. 2000). Furthermore, leukotriene B4 
(LTB4), an important product within the inflammation cascade, is also 
elevated with increased LA intake. It is widely reported that the levels of AA 
and LTB4 have been found to be elevated in the scales, epidermis, serum and 
suction blister fluid of psoriatic patients (Grimminger and Mayser 1995; Ikai 
1999) and the presence of LTB4 in early lesions implicates it in the 
pathogenesis of psoriasis (Fogh et al. 1989). It is apparent now that any 
increase in LA level would be detrimental in psoriasis.
As mentioned in previous sections, n-3 fatty acids provide an active 
competition with AA for binding sites on COX-2, the catalytic enzyme 
responsible for prostaglandin synthesis. The production of the less potent 
PGE3 from EPA contributes to the overall natural anti-inflammatory processes 
in the body (Traub and Marshall 2007).
Another plausible explanation on the reduction of PGE2 by fish oil can be 
related to its inhibitory action on COX-2, as mentioned in Chapter 7. In a 
similar finding, fish oil on its own appear to inhibit COX-2. Although the 
mechanism of this inhibition remains inconclusive, the reduced presence of 
COX-2 will only impair the production of PGE2.
It was anticipated that the anti-inflammatory property demonstrated by FO 
would impart an additive or synergistic effect and provide a greater reduction 
of PGE2. This, surprisingly, was not the case, as clearly evident from the assay.
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9.4 Conclusion
One facet of the anti-inflammatory property of fish oil could be explained by 
its inhibitory action on pro-inflammatory prostanoids, either directly or 
indirectly through inhibition of associated enzyme. As demonstrated in 
Chapters 7 and 8, fish oil exerts an appreciable anti-inflammatory activity on 
its own, although in this experiment co-formulation with BD did not impart a 
potentiation effect.
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10.1 Introduction
Cell culture is a collection of technique and processes in which cells are 
grown in a controlled environment. The availability of immortalized cell lines 
by mutation or modification allows specific cells to be grown indefinitely, 
providing a continuous source for researchers (Arnetz et al. 1985). Cell 
culture has been used in various areas of biomedical research, from 
development of vaccines, and understanding the mechanism of cancer. It 
also served as the basis for tissue culture and tissue engineering.
The development of the spontaneously transforming HaCaT cell line was first 
reported by Boukamp et al. (1988), the designation given based on its origin 
(Human adult keratinocytes) and growth conditions (low Ca2+ and elevated 
temperature). Prior to this discovery, the only available transformed 
keratinocyte cell lines were obtained via simian viral infection and DNA 
transfection. These cells had altered growth properties and substantial 
reduction of normal keratinization, as well as partial re-expression of fetal 
characteristics (Boukamp et al. 1988).
This immortal cell line possesses the capacity to differentiate normally with 
specific stable marker chromosomes even after multiple passages, providing 
a stable model to study keratinization. It is also non-tumourigenic and non- 
invasive upon in vivo transplantation; it has the capacity to reconstitute a 
well structured epidermis, and spatial distribution of epidermal 
differentiation products indicate a normal degree of morphologic 
differentiation. Expression of keratins was also found to be similar to 
transplanted normal keratinocytes.
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The aims of the current study were to start and maintain HaCaT cell line 
cultures and investigate the growth characteristics of the culture via 
generation of growth curves. The inhibitory effect of BD and FO were also 
studied.
10.2 Materials and methods
10.2.1 Materials
Gibco* Dulbecco's modified Eagle medium lx  (DMEM, high glucose, with L- 
glutamine and phenol red, no HEPES, no sodium pyruvate), foetal bovine 
serum, trypsin 0.05% with EDTA-4Na lx  were obtained from Invitrogen 
(Paisley, UK). Amphotericin B (250 pg mL'1) and penicillin (10,000 units)- 
streptomycin (10,000 pg) mixture were purchased from Lonza Group Ltd, 
(Basil,Switzerland). Corning cell culture flasks, 24- and 96-well plates, 
disposable pipettes, dimethylsulfoxide (DMSO) and ethanol were obtained 
from Fisher (Loughborough, UK). Betamethasone dipropionate, Dulbecco's 
phosphate buffered saline (DPBS) and 3-(4,5-dimethylthiazol-2-yl)-2,5- 
diphenyltetrazolium bromide (MTT) were obtained from Sigma-Aldrich (Poole, 
UK).
10.2.2 Methods
10.2.2.1 Routine cell culture
All cell culture procedures were carried out in aseptic conditions inside MDH
Class II laminar-flow safety cabinet in a tissue culture suite. Before any 
procedures were carried out, all work surfaces, including any equipment, 
consumables and reagents brought into the cabinet, were disinfected with
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70% ethanol. This was repeated after completion of work, followed by 1 hour 
of UV light. The HaCaT cells were grown in DMEM supplemented with 10% 
heat-inactivated FBS and 1% penicillin-streptomycin mixture (100 pg mL1 and 
100 U mL' 1 respectively). 50 mL Aliquots of the medium were prepared from 
the stock. Inactivation of the FBS was achieved by placing the serum in 56°C 
for 30 minutes.
Temperature of the incubator was set at 37°C and flow of C02 at 5%. The 
medium was replenished every 2 days to keep the cells healthy, until the 
monolayer cultures reached 70-80% confluency. Once the suitable 
confluency is achieved, the cultures were passaged or split to maintain cells 
in exponential growth (Masters and Stacey 2007).
10.2.2.2 Cell splitting/passaging
Flasks of cells ready to be passaged were taken out of the incubator into the 
safety cabinet. The cells were then washed with 2 changes of DPBS, followed 
by incubation with trypsin-EDTA (the volume used determined by the size of 
the flask) at 37°C for 5 minutes or until all the cells had detached. Detached 
cells can be determined visually under the microscope; they appear as 
rounded, individual cells and fast flowing within the suspension. Detachment 
can be aided by gently tapping the flask to dislodge the cells or by the use of 
a cell scraper. The trypsin was then deactivated by pipetting a small amount 
of DMEM. The cell suspension was then transferred to a sterile centrifuge 
tube and centrifuged at 1000 rpm for 5 minutes. The resulting supernatant 
was removed carefully so that the cell pellet remained undisturbed. 8-10 mL 
Fresh medium was then added, followed by re-suspending the cells by gently 
pipetting the suspension up and down several times. The suspension was 
then ready to be used to seed cells in new flasks, frozen down for storage, 
used for experimental work and for cell counting.
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10.2.2.3 Cell counting
The counting of cells is necessary to determine the number of cells required 
for seeding, and are particularly important when constructing the growth 
curve. This procedure is made possible by the use of cell counters or 
haemocytometers (Figure 10.1).
Figure 10.1: A typical Improved Nuebauer haemocytometer used for counting cells
Originally devised to count blood cells, they are also now used to count other 
cell types. The most commonly used haemocytometers are the improved 
Neubauer haemocytometers. The device consists of a heavy glass microscope 
slide with 2 indentations or counting chambers. These chambers are divided 
into 9 x 1mm2 squares etched in a grid, both of them separated by a trough. 
The edge of the trough is raised by 0.1 mm off the grid. With the cover slip in 
place and cell suspension loaded into filling notches at either end of the
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chambers, each square has a defined volume of liquid. Graphical description 
of the chambers and grids are shown in Figure 10.2.
Counting
chamber
Cover yldss Filling notch
Mounting
s u p p o rt
Overflow
area
Figure 10.2 : Diagram showing the counting chamber and grid on a 
haemocytometer
As mentioned earlier, the chambers are divided into 9 squares of 1 mm2. The 
corner squares are further divided into 16 squares of 0.0625 mm2. The 
central square meanwhile is divided into 25 squares of 0.04 mm2; each of 
them further divided into squares of 0.0025 mm2. The volumes of each 
different level of squares are shown in the Table 10.1.
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A rea (m m 2) V o lu m e (nL)
1 100
0.0625 6.25
0.05 5
0.04 4
0.025 0.25
Table 10.1 : Volumes of each level of squares on the counting grid of a 
haemocytometer
From the cell suspension prepared earlier, 10 pL was loaded in each counting 
chamber. Dispersion of the suspension was aided by capillary action. It is 
assume that this volume is a random sample of the whole suspension. 
Thorough mixing is important to ensure that the cells do not clump, which 
would give a less accurate result. If the number of clumps is more than 10%, 
fresh sample should be taken. The haemocytometer is then placed under a 
microscope set at lOOx magnification. In an improved Neubauer 
haemocytometer, the cells to be counted are those that lie within the area 
bordered by the 3 lines; the cells overlying those lines are not counted. It is 
important to be thoroughly consistent in choosing whether or not a cell 
should be counted. Five squares are counted from each chamber (typically 
the central 1 mm2 square and the 4 corner squares). The total number of cells 
per mL can be obtained by multiplying the average number of cells from the 
10 squares with 10 000.
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10.2.2.4 Freezing cells for storage
Although caution is exercised during handling of the cells, often 
contamination might occur which would lead to cell death and depletion of 
supply. In order to counteract this possibility, the cells can be frozen to 
provide a cache of cells for long-term storage. The cell suspension, as 
obtained in Section 10.2.2.2 was placed in suitable cryo tubes. Next, 
dimethylsulfoxide (DMSO) was added slowly to the tubes dropwise to avoid 
osmotic breakdown of the cells. An equal volume of DMSO must be added to 
the volume of serum enriched medium, giving a total of 1 mL. The tubes 
were allowed to chill on ice for 30 minutes. The tubes were then placed in a 
pre-chilled freezing box, insulated by wrapping the tube with cotton wool. 
The box was placed in a -80 °C freezer overnight for slow cooling before 
transferring the tubes into liquid nitrogen for indefinite storage.
10.2.2.5 Thawing frozen cells
The key point to remember when thawing cells is to avoid osmotic shock to 
the cells. In order to achieve this, thawing must be carried out rapidly, 
followed by a slow dilution of the suspension. As soon as the suspension had 
thawed, the contents were transferred to a larger centrifuge tube and pre­
warmed medium was added drop by drop to a suitable volume. Before use, 
the tube was spun down and the medium replaced to remove the DMSO. The 
re-suspended cells could now be seeded to flasks and allowed to grow for 2 
passages before any experimental procedures were to be conducted.
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10.2.2.6 HaCaT cell growth study
Before further experiments were conducted using the HaCaT cell lines, the 
growth characteristics of the cell line in the current laboratory setting were 
determined. The growth pattern can be determined via counting of cells over 
a certain period of time, and plotting a growth curve as a function of cell 
number over time. From a growth curve, the lag time, population doubling 
time, and saturation density can be determined (Mather and Roberts 1998). 
A typical cell growth curve can be divided into several distinct phases: 
inoculation/lag phase, exponential/log phase, stationary phase and death 
phase (Figure 10.3).
cel growth
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Figure 10.3 : A typical cell growth curve. Adapted from Tan (2001)
During the lag phase, the cells are acclimatizing to the growth 
surroundings/conditions, and cell division hardly occurs. As the cells enter the 
log/exponential phase, it is characterized by cell doubling at a constant rate, 
which can be determined by the slope of the resulting linear plot. During the
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stationary phase, the growth rate is slowed down by the depletion of nutrient 
within the medium and the accumulation of cellular waste and toxic by­
products. This phase can be prolonged as long as nutrients continue to be 
replenished. Otherwise, cellular growth will enter the death phase, whereby 
the remaining nutrient can no longer sustain growth of cells and leads to cell 
death.
Cells were seeded by preparing a cell suspension of 1 x 104 cells mL'1 in 
medium and placing 1 mL of the suspension in each well of a 24 well plate, 
which has a surface area of 2 cm'2. This will give a cell density of 5 x 103 cells 
per cm2. Two plates were prepared for the study. The plates were then 
placed in the incubator at the setting mentioned earlier (37°C, 5% C02) and 
allowed to settle for 24 hours before the first counting was performed. For 
each sampling time, 2 wells were counted by first aspirating the medium, 
washing with DPBS and 1 mL of trypsin pipetted into the wells. The trypsin 
was allowed to dislodge the cells from the well surfaces for 10 minutes at 
37°C, before being neutralized with an equal amount of medium. The 
resulting suspensions were then sucked out, placed in a micro-centrifuge 
tube and counted using the method described in Section 10.2.2.3. The cells 
were counted every 24 hours to a maximum of 8 days with the medium being 
replenished every 2 days. The number of cells versus the sampling time was 
plotted to construct the growth curve.
10.2.2.7 MTT colorimetric assay
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay is 
one of the common assays used to determine cell viability. The principle 
behind this colorimetric assay is the ability of viable cells to reduce MTT into 
insoluble purple formazans via mitochondrial reductase. The insoluble dye 
will then be dissolved in a solvent, such as DMSO, and the absorption of the
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resulting solution measured using a spectrophotometer at a wavelength 
between 500 to 600 nm. The absorption values are directly correlated with 
the number of viable cells present, as the reductase enzyme are only active in 
viable cells. The assay is also commonly used to assess toxicity of a 
compound, based on the compound's ability to induce cell toxicity, hence 
decreased viability. From this, a dose response curve of a compound can be 
plotted.
For the assay, HaCaT cells were seeded into 96-well plates at a density of 5 x 
104 cells per mL. Each well had a surface area of 0.16 cm2 and working 
volume of 200 pL. After seeding, the wells were left overnight in the 
incubator. Stock solution of BD was also prepared by diluting in DMSO and 
mixing it with DMEM (containing 10% v/v FBS) to provide a series of 
concentrations ranging from 0.78125 mg mL'1 to 2 mg mL1. The stock 
solution was prepared with care taken to limit the final DMSO concentration 
in the medium at 0.5% v/v. Mixing of the solution was done aseptically by 
filtering the stock BD solution with a syringe attached with a 0.2 pm filter 
before addition to DMEM. 4 Wells were filled for each concentration (at 200 
pL per well), with a further 4 wells filled with DMEM containing 0.5% v/v 
DMSO (without BD) as vehicle control and 4 wells with only DMEM and 10% 
v/v FBS as control. The cells were allowed to grow within the treated medium 
for 48 hours in the incubator. After this period, the medium was removed 
from all the wells, and replaced with 20 pL of MTT in DPBS at a concentration 
of 5 mg mL'1. The plates were incubated for a further 4 hours. Afterwards, all 
the wells were aspirated, leaving only the formazan precipitate at the bottom 
of the wells. 100 pL of DMSO was then pipetted into each well to dissolve the 
formazans, and the absorption of each well was read at 550 nm using a 
spectrophotometer (Sunrise™, Tecan Trading, Switzerland) after 20 minutes, 
preceded by a gentle shaking of the plates for 15 seconds to completely 
dissolve the formazans. The number of viable cells was calculated as a 
percentage of the absorbance of the test wells over the vehicle control. The
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% inhibition was obtained by subtracting the number from 100. The results 
were then plotted as a dose response curve (% inhibition versus logio BD 
concentration). The Gl50 value for BD, which will be used in all further cell 
experiments, was determined by extrapolating the concentration of BD which 
resulted in 50% growth inhibition in the dose response curve.
The assay was also repeated using a combination of BD at GI5o and fish oil. It 
was found that the maximum amount of fish oil that can possibly be 
dissolved in the medium was limited by the amount of ethanol allowed in cell 
medium. Typically, this is kept at 0.5% v/v or lower. Therefore, the fish oil 
was dissolved in ethanol at a 2:1 ratio, and the final concentration of the fish 
oil solution in the medium was 1% v/v (the ethanol concentration in the final 
medium solution kept at 0.5% v/v). 5 x 8  Wells were dosed with medium 
containing BD at Glso, and an equal number of wells were dosed with medium 
containing BD at GI50 and 1% v/v FO:EtOH (equating to 0.66 mg mL'1 EPA in 
each well of a 96-wells plate). As control, 2 x 8  wells were dosed with 
medium containing DMSO and EtOH, the vehicles used to dilute BD and FO at 
0.5% v/v each.
10.3 Results and discussion
10.3.1 HaCaT growth curve
The growth curve obtained for HaCaT cells is shown in Figure 10.4. The 
typical growth curve pattern was achieved, with the different phases clearly 
shown. From the linear section of the plot, the cell doubling time was 
calculated to be 22.1 hours, while the lag time was 20.6 hours. Any further 
experiments with HaCaT cells were conducted at least 20.6 hours after 
seeding and ran for a minimum of 22.1 hours. For these reasons, the
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subsequent growth assay and the ICC staining in Chapter 11 were carried out 
according to these times.
5.5
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Figure 10.4 : Growth curve for HaCaT cells over 7 days
10.3.2 MTT assay -  BD dose response curve and Glso determination
The dose response curve for BD is shown in Figure 10.5. Extrapolation of the 
plot revealed that the Gl50 value was 0.22 mg mL'1. To facilitate preparation 
of test solutions, the concentration was rounded to 0.25 mg mL'1, and all 
subsequent studies were conducted using this value.
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Figure 10.5 : BD dose response curve. The Glso determined from this curve was
0.22 mg mL1. For convenience, this value was rounded up to 0.25 mg mL'1 and 
used in all subsequent assays.
In this study, the solubility issue surrounding fish oil, as mentioned in Section
10.2.2.7 made it impossible to obtain Gl50 value for fish oil. Initial growth 
inhibition assay at the maximum fish oil concentration allowed only resulted 
in an average of 7.63 ± 3.66 % growth inhibition. All subsequent assays 
involving fish oil (either alone or in combination) were then performed at the 
maximum allowed concentration as reported in Section 10.2.2.7.
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10.3.3 MTT assay -  growth inhibition of HaCaT cells by BD and
effects of FO addition
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Figure 10.6 : % inhibition of BD and BD-FO mixture on HaCaT cells, n= 4 ± SD. The 
addition of fish oil increased the inhibition of HaCaT cells by 27.2%, from 43.15 to 
70.35 % compared to BD alone (p 0.034)
The mechanisms by which BD exert its activity in the treatment of psoriasis 
include anti-proliferative effects via disruption of DNA synthesis (Gottlieb 
2005b). In this study, the treatment of HaCaT cells with BD at Gl50 led to 
43.15 ± 3.14 % (p 0.0001) growth inhibition. The addition offish oil appeared 
to increase cellular growth inhibition, raising it up to 70.35 ± 3.74 % (p 0.034). 
This was suggestive of a synergism in inhibitory action between BD and fish 
oil. The exact mechanism of this synergism is unknown. Although at the 
maximum fish oil concentration used in this study growth inhibition was only 
less than 10%, the anti-proliferative effects of fish oil and its constituent fatty 
acids have been repeatedly demonstrated in many cell lines, particularly 
tumour cells (Chen and Auborn 1999; Kapoor 2009). The effect of EPA, one of 
the primary fatty acids found in fish oil, on the growth of cultured 
keratinocytes has also been reported (Riku et al. 1993). This inhibition is
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believed to be attributed to the ability of EPA to modulate the various steps 
of signal transduction by growth factors (Terano et al. 1997).
10.4 Conclusion
The findings from the growth assay provide further support to combining fish 
oil with conventional anti-psoriatic medications. In previous chapters, we 
have seen the enhancing effects offish oil on inflammatory enzyme inhibition 
by BD, and also the added benefit of modulating the delivery of BD across 
epidermal layers. It is now also proven, on a cellular level, another 
mechanism by which FO and the n-3 fatty acids exert their effects on 
keratinocytes, supporting the findings by which supplementation or 
treatment with FO can be advantageous in inflammatory skin diseases such 
as psoriasis.
Chapter 11:
Immunocytochemical staining in 
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11.1 Introduction
In Chapter 10, the basic principles of culturing HaCaT cell lines were 
discussed. The dose response curve of BD was also determined. 
Investigations on the effects of both BD and FO to cellular growth revealed 
that addition of FO enhanced cellular growth inhibition by BD. In this chapter, 
the effects of FO and BD on apoptosis were investigated by looking at the 
relative levels of the apoptotic marker cleaved caspase 3 (Aspl75) by 
immunocytochemistry, a variation of IHC methods used earlier in Chapters 7 
and 8 . Using ICC, the expression of COX-2 after exposure of HaCaT cells to the 
agents was also investigated.
Caspase-3 (Figure 11.1) is a member of the cysteine-aspartic acid protease 
(caspase) family, associated with cellular apoptosis (Janicke et al. 1998). 
Sequential activation of caspases is an important process in the execution- 
phase of apoptosis (Nicholson 1999). Physiologically, it is available as an 
inactive proenzyme, which will undergo proteolysis and dimerization to form 
the active enzyme. The larger fragment resulting from the enzyme activation 
(17/19 kDa), cleaved at the Aspl75 site, is a novel epitope which is not 
present in normal cells, thus providing a sensitive and unique indicator of 
apoptosis. This has led to the development of cleaved caspase-3 detection as 
an improved assay for determination of apoptotic cells (Gown and 
Willingham 2002).
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Figure 11 .1 : Caspase-3 (Chao-Zhou et al. 2003)
Apoptosis, as a physiological process, is a series of biochemical events 
culminating in cell death (Fadeel and Orrenius 2005). This programmed cell 
death is initiated by the cell itself or from surrounding and inflammatory cells 
when a cell is damaged beyond repair, as a result of infection, DNA damage 
from ionizing radiation and toxic chemicals or stress. It also has an important 
role in embryonic development of organs, for example the formation of limbs 
and digits (Guha et al. 2002); and maintaining the balance in the number of 
cells within a living organism (Thompson 1995).
In psoriasis, the induction of apoptosis is found to be impaired as a result of 
overexpression of Human 3-defensins (HBD), cathelicidin, psoriasin and other 
anti-microbial peptides in psoriatic plaques (Peric et al. 2009). With reduced 
cell death, the population of keratinocyte increases at a great rate, creating 
an imbalance in cell numbers and development of epidermal 
hyperproliferation and thickening which is characteristic of the disease.
As mentioned in section 7.1, the cyclooxygenases are important components 
in inflammation; catalyzing the production of mediators central to the whole 
process, e.g. prostaglandins. The COX-2, in particular, is almost undetectable 
or present at low levels in normal, non-neoplastic tissue. Distribution of this 
inducible enzyme is limited to certain tissues, including the epidermis
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(keratinocytes). In the epidermis, it is highly inducible by UV rays and has 
been implicated in the pathogenesis of skin tumours (Flockhart et al. 2008).
In this chapter, the effects of fish oil and BD on cellular apoptosis, using 
caspase-3 as a marker, and expression of COX-2 were investigated using ICC 
on a HaCaT cell line treated with the two compounds and the effects of 
combining the two. In Chapter 7, BD and FO individually inhibited the 
expression of COX-2 in a full thickness porcine ear skin model of 
inflammation, and in combination resulted in a greater inhibition. It is of 
particular interest to see whether the same can be replicated on a cellular 
level.
11.2 Materials and methods
11.2.1 Materials
Gibco® Dulbecco's modified Eagle medium lx (DMEM, high glucose, with L- 
glutamine and phenol red, no HEPES, no sodium pyruvate), foetal bovine 
serum, trypsin 0.05% with EDTA-4Na lx  were obtained from Invitrogen 
(Paisley, UK). 3-Aminopropyltriethoxysilane, dimethylsulfoxide (DMSO), 
ethanol, formaldehyde, methyl green, PBS sachets, and sodium chloride were 
from Fisher (Loughborough, UK). Dulbecco's phosphate buffered saline 
(DPBS), and Tween 20 were obtained from Sigma-Aldrich (Poole, UK). 
EnVision+ System HRP Labelled Polymer Anti-Rabbit, liquid DAB+ substrate 
Chromagen System were from Dako (Ely, UK). Antibodies for cleaved caspase 
3 Aspl75 (#9664) and COX-2 (#4842) were both from Cell Signalling. Fish oil 
capsules (Boots n-3 Fish Oil lOOOmg high strength) were obtained from a 
local store. 3-Aminopropyltriethoxysilane (TESPA) covered microscope slides 
were coated in-house
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11.2.2 Methods
11.2.2.1 Cell seeding and treatment
HaCaT cells were seeded at a density of 1 x 105 per cm2 onto a TESPA-coated 
cover slip inside tissue culture treated dishes with a culture area of 8cm2. 
Post-seeding, the cultures were left overnight to allow the cells to attach to 
the surface of the cover slip. The following day, the medium in each dish was
replaced with medium containing the test compounds. The incubation time
was 24 hours at 37°C and 5% C02. The treatments used were BD (in DMSO) at 
0.25 mg mL'1, a 2:1 mixture of FO: EtOH at 1% v/v, a combination of 0.25 mg 
mL'1 BD and the FO: EtOH mixture (also at 1% v/v) and control containing the 
vehicles (0.5% v/v DMSO, 0.5% v/v EtOH) and 10% v/v FBS in medium.
11.2.2.2 Fixation and ICC staining
Fixation of cells was carried out at the end of the incubation period using 
formalin saline (4.5 g NaCI, 50 mL formaldehyde in 450 mL water) by first 
removing the medium and replacing it with 1 mL of formalin saline and 
leaving it for 10 minutes. This was followed by 1 mL of 100% EtOH for 5 
minutes, and 2 changes of PBS at 5 minutes each. At each rinse, the cover 
slips were lifted up with forceps to ensure complete washing and to release 
trapped medium beneath the cover slips.
The dishes were then transferred to a humidity chamber to avoid desiccation 
of the cover slips. The slips were given another rinse of PBS, this time with 
the addition of a few drops of PBS-Tween for 15 seconds as a blocking 
reagent. Prior to incubation with primary antibody of the desired proteins, 
the blocking solution was completely removed. The primary antibodies were 
prepared in PBS at 1 in 100 dilutions for cleaved caspase-3 (Aspl75) and 1 in
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50 for COX-2. 75-80 pL of the antibody were applied on top of each cover slip 
and incubated at room temperature and incubation time of 1 hour for 
Aspl75 and overnight for COX-2.
Post-incubation, the cover slips were rinsed with 3 counts of PBS at 5 minutes 
each, followed by PBS Tween. The cover slips were then incubated with Dako 
Envision+ secondary antibody at 25 °C for 90 minutes. The cover slips were 
then washed with PBS for 3 min followed by PBS Tween ( 2 x 5  minutes). 
Visualization of the protein was achieved by incubating the cover slips with 
75 pL of DAB chromogenic HRP substrate (Dako) for 10 minutes at room 
temperature. The cover slips were then rinsed with deionized water ( 3 x 2  
minutes) and counter-stained using an aqueous solution of 0.5% methyl
green solution for 35 minutes. The cover slips were rinsed several times with
deionized water and then left in an oven set at 40°C to dry overnight. They 
were then mounted onto pre-cleaned microscope slides using DPX and dried 
at 60°C before inspection and imaged under a microscope (Nikon Optihop, 
Tokyo, Japan) equipped with image capture facilities (Axiovison LE, Carl Zeiss 
Ltd., Welwyn Garden City, UK)
11.3 Results and discussion
11.3.1 Cleaved caspase-3 (Aspl 75)
Figure 11.2 shows the ICC staining for Aspl75. The staining of nuclei to brown 
indicates the positive presence of the protein, and the number of positive 
nuclei was a direct indication of the extent of cellular apoptosis in each slides. 
The BD treated cells showed approximately 75% of nuclei positive for Aspl75, 
compared to the almost complete absence in the control slide. In cells 
treated with FO, approximately 25% were positive, while it was increased to
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approximately 50% when combined with BD at the same concentration as 
the first treatment. The number of positive nuclei however was less than with 
BD alone.
BD FO
% v < W i
BD+FO Control
Figure 11.2 : ICC staining for Cleaved Caspase-3 (Aspl75). BD = BD 0.25 mg mL'1, 
FO = 1% FO-EtOH, BD+FO = BD 0.25mg m L1 + 1% FO-EtOH.
The efficacy of corticosteroids, e.g. betamethasone and other anti-psoriatics, 
in the treatment of psoriasis depends, among others, on their ability to exert 
anti-proliferative effects on keratinocytes. Although the mechanism of action 
varies between the agents, most of the treatments possess the ability to 
induce apoptosis in keratinocytes (Ceovic et al. 2007).
The ability of fish oil/n-3 fatty acids to induce apoptosis in tumour and other 
cell lines has been well-documented (Hong et al. 2003; Sanders et al. 2004;
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Siddiqui et al. 2001). In a study done by Pupe et al. (2002), it was reported 
that markers of cellular apoptosis were increased in UVB-irradiated 
keratinocytes following pre-treatment with EPA compared to the 
monounsaturated FA oleic acid. The mechanism involved has been identified 
to be a synergistic over-expression of TNF-a between EPA and UVB 
irradiation itself. This supported the protective ability of fish oil in reducing 
the incidence of skin cancer as a result of UV exposure by inducing death of 
damaged cells that can potentially induce tumour formation.
In the current study, the ability of FO to induce apoptosis was again 
demonstrated in HaCaT cells, an immortalized keratinocyte cell line, again 
supporting the role of FO in the treatment of psoriasis. It was also interesting 
to note the apparent potentiation of action observed in the combined 
corticosteroid-FO treatment. The slightly reduced number of positive cells 
may not be due to reduced effectiveness. It can also be influenced by the 
possible variation in the number of cells seeded initially, or even reflective of 
the greater number of dead cells that might have been detached from the 
cover slip as a function of increased efficacy of the combined treatment.
11.3.2 COX-2
Figure 11.3 shows representative images for COX-2 staining. Again, the 
presence of brown staining indicates the positive presence of COX-2 in the 
cytoplasm. The control slides indicated that COX-2 was expressed, though at 
a very low level. Treatment with BD, FO and combined BD+FO all resulted in a 
reduction of COX-2 staining, indicative of an inhibitory effect on COX-2 
expression. These findings correspond to the study carried out on an excised 
porcine skin model of inflammation, outlined in Chapter 7 & 8 . As a brief 
recap, the expression of COX-2 was found to be inhibited by BD, and by FO
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alone. The greatest inhibition was also observed when the two agents were 
combined in a single formulation, suggesting a potentiation effect.
BD \ FO
BD+FO Control
Figure 11.3 : ICC staining for COX-2 : BD = BD 0.25 mg mL'1, FO = 1% FO-EtOH, 
BD+FO = BD 0.25mg mL'1 + 1% FO-EtOH.
In the current study, the effect on COX-2 was more pronounced compared to 
experiments using excised skin, as the primary cells of interest were directly 
exposed to the treatments, as opposed to the substantial barrier posed by 
the layers of keratinized dead cells before reaching the viable epidermis.
Interestingly, the study done by Chene et al. (2007) found that the expression 
of COX-2 in a HaCaT cell line was enhanced by both n-3 (EPA) and n-6 (y- 
linoleic acid) mediated by peroxisomal proliferator-activated receptor 
(PPAR)-y. It was also suggested that the protective/anti-inflammatory effect
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of n-3 PUFAs was in fact dependent on COX-2. This sheds light on the 'duality" 
of the inducible enzyme. It is traditionally viewed as a pro-inflammatory 
enzyme, and the deleterious effects of excess inflammatory mediators 
produced by COX-2 metabolism in diseases, such as colorectal cancer, is well 
established (Dommels et al. 2003). However, it was also discovered that, in 
the resolution phase, products of COX-2 metabolism such as PGD2 and PGF2a 
possess pro-resolution/anti-inflammatory activity (Bertolini et al. 2001; Gilroy 
et al. 1999). Considering the activity of COX-2, which encompasses both ends 
of the spectrum (strongly pro-inflammatory through to strongly anti­
inflammatory), it is reasonable to assume that induction of COX-2 might 
prove to be beneficial, or deleterious, depending on the phase of 
inflammation.
Contrastingly, several studies showed that induction of PPAR-y by its ligands 
had an inverse relation with COX-2 expression (Kulkarni et al. 2008; Yang and 
Frucht 2001). Both EPA and DHA have been found to activate PPAR-y (Allred 
et al. 2008; Li et al. 2005; Yang and Frucht 2001), and this activation is central 
to the anti-tumour effects of fish oil. Several publications extolled on the 
virtues of PPAR-y ligands as a potential new class of therapeutic agent for 
psoriasis and psoriatic arthritis, given its action on cell proliferation and 
inhibition of pro-inflammatory mediators (Bongartz et al. 2005; Ellis et al. 
2000; Friedmann et al. 2005). It is in this regard that the induction of COX-2 
as reported by Chene et al. (2007) requires further investigation, particularly 
in the knowledge that the opposite was observed in the current study 
involving HaCaT cells and also in Chapters 7 and 8.
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11.4 Conclusion
In this chapter, it was shown that FO was able to induce apoptosis in an 
immortalized keratinocyte cell line. This supported numerous other studies 
reporting the effects of fish oil in inducing programmed cell death. The value 
of this in psoriasis therapy has also been elaborated, further supporting the 
use of FO. Mirroring the inhibition seen with a model of skin inflammation, 
the expression of COX-2 was inhibited on a cellular level. There seem to be 
contrasting reports on the action of FO/n-3 PUFAs on COX-2 in different cell 
lines, although the majority reported an inhibitory effect and accepted this as 
the basis of the anti-inflammatory action of FO/n-3 PUFAs. The importance of 
COX-2 in the resolution phase of inflammation is noted, bringing the issue of 
addressing the balance between inhibition and induction of COX-2 into focus.
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12.1 Introduction
Among the prominent characteristics of DfL mice are the epidermal 
thickening and formation of scales. One of the targets in the treatment of 
psoriasis is a reduction of epidermal thickness, as many of the agents 
currently being used exert an anti-proliferative action on keratinocytes, for 
example corticosteroids, retinoids, and anthralin (Section 1.2)
Optical coherence tomography (OCT) is a technique of obtaining slice images 
of three-dimensional objects (Fercher et al. 2003). In simple terms, OCT can 
be described as the optical equivalent of ultrasound imaging, which is based 
on soundwaves (Drexler and Fujimoto 2008a). One of the main applications 
of this rapidly developing technique is to provide a real time, rapid, non- 
invasive imaging method for sub-surface tissue structures with micrometer 
resolutions. The principles behind the operation of OCT involves 
measurement of echo time delay and the magnitude of a backscattered light 
generated from a broadband light source employing super-luminescent 
diodes or extremely short pulse lasers (femtosecond lasers) (Drexler and 
Fujimoto 2008a; Schuman et al. 2004)
OCT works best in acquiring images from clear or transparent objects, of 
which the prime example is ocular media. The structural images of the retina 
obtained with OCT were of the quality unparalleled with other non-invasive 
diagnostic techniques, hence ophthalmic imaging and diagnostics are the 
most clinically developed OCT applications at the present time (Drexler and 
Fujimoto 2008b; Schuman et al. 2004).
The technology is currently finding more biomedical applications outside the 
field of ophthalmology. It has been successfully utilized to image the invasion 
of cancer cells in the liver (Kuo et al. 2009), bladder lesions (Karl et al. 2009),
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determination of gastric cancer in murine models (Xiong et al. 2009), imaging 
of dentin and the pulp chamber of human teeth (Fonseca et al. 2009), and 
cardiology (Brezinski 2006; Regar et al. 2003; Tanaka et al. 2009). Of the 
highest relevance in the current study is the imaging of the skin and diagnosis 
of skin cancers (Kirillin et al. 2009; Mette et al. 2009; Yang et al. 2009).
The aim of this study was to investigate the effects of commonly used topical 
anti-psoriatics and fish oil on DfL mouse via changes in epidermal thickness. 
This study was also designed to compare the relatively new method of 
measuring epidermal thickness using OCT, compared to the more 
conventional method of H&E staining coupled with microscopy. One of the 
advantages in using the OCT is that it allows a reduction in the number of 
animal used in studies, as the same animal can be monitored progressively 
over time, and stress to the animals is reduced compared to methods such as 
punch biopsy.
12.2 Materials and methods
12.2.1 Materials
BD, BHA, and SA were obtained from Sigma Aldrich (Poole, UK). Fish oil 
capsules (Boots n-3 Fish Oil lOOOmg high strength) were obtained from a 
local store. Emulsifying ointment and isoflurane were from Thornton and 
Ross and Merial Animal Health Ltd. (Harlow, Essex, UK) respectively. Tissue- 
Tek* O.C.T™ Compound (OCTC) was from Sakura Finetek Europe B.V 
(Zoeterwoude, Holland). All other reagents were of analytical grade or 
equivalent.
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12.2.2 Methods
12.2.2.1 Breeding and maintenance of DfL colony
DfL mice were bred by mating the mice with C57BL/6, often referred to as 
"C57 black 6" or just "black 6", which is a common inbred strain of lab mouse. 
It is probably the most widely used "genetic background" for genetically 
modified mice for use as models of human disease. They are the most 
commonly used lab mouse strain due to the availability of congenic strains, 
easy breeding, robustness, and their relationship to GM models, making 
them ideal controls. The C57BL/6 mice were obtained from Harlan UK Ltd. 
(Loughborough, UK).Typically, half of the litter will be DfL. In order to prevent 
contamination and infections, the mice were housed in scantainers (Figure 
12.1) operated under negative pressure up to the commencement of the 
study. The mice were fed with regular diet of pellets and water and put under 
a 12 hour light cycle. All procedures within this study were conducted under 
Home Office license and with prior review by the local Ethical Review 
committee.
All the mice used in the study were between 20-22 weeks of age, a stage 
where hair follicle destruction is complete. They were further divided into 4 
treatment groups according to Table 12.1. These formulations were the same 
as used in Chapter 6. The formulations were prepared according to the 
method outlined in section 5.2.2
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Figure 12.1: A representative scantainer cage containing a single DfL mouse.
Group Treatment
BDO 0.05% w/w BD, 3% w/w SA, 0.05% w/w BHA in 
emulsifying ointment BP
BF 20% w/w FO, 3% w/w SA, 0.05% w/w BHA in 
emulsifying ointment BP
BDF 0.05% w/w BD, 3% w/w SA, 20% w/w FO, 0.05% 
w/w BHA in emulsifying ointment BP
Control 0.05% w/w BHA in emulsifying ointment BP
Table 12.1: The treatment groups of the study and its corresponding formulation. 
Each formulation was applied on a daily basis for 10 days
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12.2.2.2 Epidermal thickness measurement
Figure 12.2 shows the area where the formulations were applied and 
scanned for thickness measured. The area was approximately 2x2 cm. This 
area was chosen as it was considered the area least accessible for the mice to 
groom off the formulation. To further avoid this, the formulations were 
applied as a thin layer with gentle rubbing using a glass rod to ensure uniform 
distribution on the applied area. At the beginning of the study, an initial 
measurement was made to provide baseline values of epidermal thickness, 
and the area marked with indelible, non toxic pen to ensure the same site 
was used consistently throughout the whole study, thereby the data 
obtained were directly compatible. Each treatment group consisted of 5 mice 
of mixed gender to offset any possible variation in response between male 
and female mice.
Figure 12.2 : The outlined area showing the site of formulation application and 
epidermal thickness measurement
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Approximately 100 mg of the formulations were then applied on a daily basis 
and the mice scanned under anaesthesia. This was done in order to keep the 
animal as still as possible without the need for any physical restraint. 
Induction of anaesthesia was done with the aid of an anaesthetic chamber 
(Figure 12.3), using Isoflurane at a rate of 5 L min'1 with oxygen as a carrier.
Figure 12.3 : Typical setup of an anaesthetic chamber connected to a scavenger 
machine
Following this, maintenance of anaesthesia was achieved with the use of an 
anaesthetic mask, with the flow rate reduced to 1-2 L min1. Prior to being 
connected with the mask, the eyes were lubricated with eye drops since 
these mice have a tendency to develop dry eyes, which can be further 
exacerbated by the gas flowing through the mask. For this reason also, the 
scan was only done on alternate days to minimize distress to the mice as a 
result of the anaesthesia. The setup for scanning is shown in Figure 12.4. The 
OCT system used was THORLABS swept source OCT imaging system (Thorlabs 
Ltd., Ely, UK). The wavelength for the laser used for the OCT was set at 800 
nm. Spectral width was set at lOOnm and axial-scan rate was 16kHz. Scanning 
dimensions were set at 5, 5, and 3 mm at the x, y and z axes. Post-scanning,
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the mice were allowed to regain consciousness in warmed cages and full 
recovery was ensured before returning to the holding area. Any animal which 
showed signs of illness or deterioration of health was excluded from scanning 
and observed until deemed fit to undergo the procedure. These animals, 
however, continued to receive topical application of the test formulations.
!
OCT probe
Laser source
Computer
Halothane
OCT probe
To computer
Figure 12.4 : Top : The OCT system connected to a laser source and computer 
processor. Bottom : Close up of the setup for measuring epidermal thickness of the 
mice
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The OCT scans were then processed using ImageJ software 
(http://rsbweb.nih.gov/ij/); 5 measurements were taken from each scan and 
the values tabulated with Microsoft Excel 2007.
12.2.2.3 Tissue harvesting
At the conclusion of the experiment, all the mice were killed using Schedule 1 
methods and the treated areas harvested for post-processing and analysis.
The skin from this area was cut into 2 thin strips of approximately 3 cm x 0.5
cm, the first strip embedded in OCTC tissue embedding medium and allowed 
to solidify on a bed of dry ice. The remaining strip was soaked overnight in 
PBS-buffered formalin prior to embedding in paraffin wax.
12.2.2.4 H&E staining
Sections allocated for H&E staining were embedded in Paraplast embedding 
medium (Sigma) and then cut into sections of 5 pm on pre-cleaned X-tra™ 
Adhesive microscope slides (Surgipath). Prior to staining, the sections were 
dewaxed by first placing the slides in an oven set at 60°C for 30 minutes and 
then soaked in 2 changes of xylene, followed by descending concentrations of 
ethanol (100%, 90%, 70%) in duplicates. Subsequently, the sections were 
washed with running tap water for 3 minutes and rinsed with distilled water.
The sections were then stained in Mayer's haematoxylin for 10 minutes, and 
washed thoroughly in running tap water, followed by rinsing in distilled 
water. Blueing of the section was done in Scott's Tap Water Substitute. At 
this stage, the sections were examined under a light microscope to 
determine the extent of staining. Excess staining can be removed with 1%
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acid alcohol, followed by rinsing in running tap water and then, distilled 
water.
Counter-staining was done with 1% eosin for 5 minutes, followed by a brief 
wash in tap water. The sections were then dehydrated in ascending 
concentration of alcohol, starting with 90% and 3 changes of 100% alcohol 
for 5 minutes each. This was then followed by 3 changes of xylene at 5 
minutes each. Finally, the sections were mounted with DPX and left to dry 
overnight in an oven set at 45°C.
Slides were then observed under a microscope equipped with image-capture 
facility (Nikon). Five measurements were made on each section using the 
image capture software (Axiovision LE, Carl Zeiss, Welwyn Garden City, UK)
12.2.2.5 Statistical analysis
Statistical tests for non-parametric data were conducted using InStat 3 for 
Microsoft Windows (GraphPad Software, Inc.)
12.3 Results and discussion
12.3.1 Epidermal thickness -  OCT
Figure 12.5 to Figure 12.10 shows the representative scans obtained from the 
4 treatment group from Day 0 to Day 10. Initial measurement of all the mice 
yielded an average epidermal thickness of 26.92 ± 1.17 pm, with a p value of 
0.5286. A change in epidermal thickness was already apparent by the next 
scan, revealing a pattern which was maintained throughout the whole 
duration of the study, as shown in Figure 12.11. The fish oil treated group
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(BF) exhibited a sustained increase in thickness, with an average increase of 
105% from baseline values. Conversely, the BD treated group showed a 
significant reduction in thickness (average 38.8%). The combined BD-FO 
treatment appeared to also reduce epidermal thickness although not to the 
same extent as BD alone, while the control group did not show appreciable 
changes over 10 days.
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Epidermis
Dermis
BDO (28.41 ± 1.60 nm)
BF (25.58 ±2.63 |im)
BDF (26.6215.05 |am)
Figure 12.5 : Representative OCT scan, day 0. Epidermal thickness in each
treatment group was not statistically significant (p 0.5286) at this point
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BDO (26.63 ± 3.07 jim)
Control (28.14 ± 2.02 |im)
Figure 12.6 : Representative OCT scan, day 2. The group treated with BF had 
began to show an increase in epidermal thickness, and the opposite with BDO.
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BDO (26.65 ±5.09 |im)
BF (52.63 ± 1.45 jam)
Figure 12.7 : Representative OCT scan, day 4
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Figure 12.8 : Representative OCT scan, day 6
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Figure 12.9 : Representative OCT scan, day 8
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Figure 12.10 : Representative OCT scan, day 10
{ 216}
Chapter 12
i/ i
1/1
0 2 4 6 8 10
Time (Day) —*-BDO H ^B F
BDF )( Control
Figure 12.11 : Epidermal thickness over 10 days obtained with OCT (n=5, ±SD). 
Treatment with BF increased epidermal thickness as early as the 2nd day of 
treatment and sustained throughout the whole duration of the study. The 
opposite was seen with BDO treatment. Treatment with BDF did not cause any 
notable changes compared to control
Figure 12.12 depicts the average pre- and post-study measurements for the 4 
groups. BDO, BF and BDF treated group showed statistically significant values 
at the conclusion of the experiment (p 0.0001, 0.0001, and 0.0136 
respectively). As mentioned earlier, changes in the control group were not 
statistically significant [p 0.3755).
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BDO BF BDF Control
Treatment
Figure 12.12 : Average pre- and post- treatment epidermal thickness (n=5, +SD). * 
= p < 0.05
12.3.2 Epidermal thickness - H & E
Figure 12.13 are representative skin sections of the 4 groups stained with 
H&E. Visual observation confirmed the OCT finding reported earlier. The 
BDO treated sections were noticeably thinner and, inversely, treatment with 
BF caused a gross thickening of the epidermis. Again, the combined 
treatment did not differ from control. The cells of the basal layer were found 
to be enlarged and columnar in nature in the BF treated group.
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Control
Figure 12.13 : Representative images of the H&E stained sections obtained from 
the 4 treatment groups (n=5). Note the apparent change in thickness for BDO and 
BF, while BDF remained unchanged.
12.3.3 Epidermal thickness measurement - comparison between OCT
and H&E
The average epidermal thicknesses measured using the 2 techniques are 
shown in Figure 12.14. Mann-Whitney test revealed that the values obtained 
were comparable between the two. It must be noted that in order to achieve 
the measurement with H&E, sacrifice of the animals was required, compared 
to the non-invasive OCT which permits live measurement.
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Treatment
Figure 12.14 : Comparison of average epidermal thickness as measured by H&E vs 
OCT after 10 days (n=5, ± SD). No significant differences were observed between 
the 2 techniques (p> 0.05).
The reduction in epidermal thickness seen with BDO is a direct effect of the 
corticosteroid. This class of drug exerts an anti-mitotic and anti-inflammatory 
effect through its action on DNA synthesis (Valencia and Kerdel 2003). As 
described previously, the phenotypic changes observed in the skin of DfL 
compared to wild-type mouse can possibly be attributed to increased 
infiltration of immune cells. Therefore the reduction in thickness can either 
be due to direct anti-proliferative effects of BD towards keratinocyte growth 
or the inhibition of immune cells which contributed to the increased growth 
in the first place.
The inverse effect seen with FO treatment is more difficult to explain. It was 
initially hypothesised that the anti-inflammatory effect possessed by FO 
would result in a similar outcome to that of the corticosteroid. This would 
imply that the hyperproliferation in DfL is not immune driven, or due to an 
unknown effect of fish oil or its constituents on the epidermis. In an earlier
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study using a guinea pig model of epidermal hyperproliferation, a similar 
finding was reported in which both topical application and dietary 
supplementation with fish oil (or components of) resulted in acanthosis of 
the epidermis (Chapkin et al. 1987; Mani et al. 1999). This was attributed to 
the effects of DHA in reducing the epidermal level of 13- 
hydroxyoctadecadienoic acid (13-HODE) (Mani et al. 1999) derived from 
linoleic acid, an n-6 fatty acid found in abundance in normal skin (Miller and 
Ziboh 1990). In normal skin, the level of 13-HODE is high, and the reduction 
seen in the animal models, corresponding with the increased epidermal 
thickness, suggested an important role for 13-HODE in maintaining a normal 
epidermis. The exact mechanism, however, is still poorly understood. It is 
known that n-3 fatty acids, when present in sufficient amount, will displace n- 
6 FAs from cellular membranes, and perhaps the changes observed with DfL 
reflected the same condition seen with the guinea pig model.
From one of the studies, Chapkin et al.(1987) also came to the conclusion 
that although FO-derived fatty acids possess an inhibitive effect on the 
formation of pro-inflammatory cytokines, they are unable to reverse 
epidermal hyperproliferation in the animal model, as the FAs lack EFA 
functional properties in skin.
The relatively unchanged epidermal thickness seen in the combined BD+FO 
treatment group suggested an opposing effect of the 2 principal constituents. 
It was initially assumed that FO would enhance the activity and delivery of 
BD, thus would result in a greater reduction in epidermal thickness. The 
delivery enhancing property of fish oil towards other compounds has been 
documented previously (Thomas et al. 2007b), attributed to what has been 
termed the 'pull effect' (Heard et al. 2006). This only serves to strengthen the 
notion that in vitro results may not necessarily be translated well in vivo.
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12.4 Conclusion
This study marks the first time that the in vivo effects of commonly used 
topical formulations and fish oil have been studied on DfL mouse. Although 
the findings were not as predicted, and the fact that a lot remains unknown 
with this particular animal model, it only warrants further investigation into 
the mechanism by which the phenotypic changes occur. It will also be 
interesting to see the effects of other classes of topical anti-psoriatics on DfL 
to further establish its potential as an animal model for psoriasis. 
Observations in this study also brings into focus the implication of topical fish 
oil application in psoriasis and/or other dermatoses, as it appears to 
contradict the reported benefits in patients receiving oral supplementation of 
the oil and the associated fatty acids.
On another aspect of the study, which is to evaluate the use of OCT in 
dermatological studies, it is encouraging to observe that it was successful as a 
means of obtaining continuous measurement of epidermal thickness, without 
the need of sacrificing test animals, compared to methods such as 
conventional H&E staining coupled with microscopy. In the long run, it is 
hoped that this will reduce the number of animals used in laboratories in line 
with the 3Rs principle of biomedical research (reduction, replacement, 
refinement) and possibly establish the use of OCT in clinical settings, 
particularly for dermatological studies.
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13.1 Introduction
In the previous chapter, the effects of fish oil and anti psoriatic agents on 
epidermal thickness were investigated. It was found that topical treatment 
with the agents revealed significant changes in the thickness of the epidermis 
over the whole duration of the study. In this chapter the investigations 
focused on finding a link between the earlier findings with markers of cellular 
proliferation, and also the protein and cells of the immune system.
Ki67 is an antigen produced by the gene MKI67 which is found to be 
expressed in the active phases of the cell cycle, namely the Gi, G2 and S 
phase in all cells. It is totally absent during the resting (G0) phase (Jorn et al. 
2006). This strict association makes Ki67 a useful marker for cell growth and 
division (Mirko et al. 2002), and has been extremely useful in the detection of 
tumours and other forms of malignancies (Scholzen and Gerdes 2000). In 
normal epidermis, it is found to be weakly expressed in the basal and 
suprabasal layers, while in psoriatic epidermis distribution of Ki67 were 
spread throughout all the layers of the epidermis (Tao et al. 2008).
K17 is one the numerous epithelial-associated keratins, which are further 
classified as Type I and Type II keratins. K17, along with other Type I keratins 
are acidic in nature, while Type II keratins such as K1-K5 are basic to neutral 
(Moll et al. 2008). In normal conditions, K17 is only expressed in the nail bed, 
hair follicles, sebaceous glands, internal epithelia and developing 
interfollicular epidermis (Bonnekoh et al. 1995). However, in psoriatic lesions, 
there is an increase of suprabasal K17 expression concurrent with 
overexpression of K16 (Leigh et al. 1995). The increase in K17 is attributed to 
the rise seen in the levels of IFN-y in psoriatic skin, both of which are believed 
to be contributing factors to the development of psoriasis (Bonnekoh et al. 
1995).
224 \
Chapter 13
Macrophage-1 antigen (MAC-1, also known as CR3; integrin alphaMbeta2, 
ITGAM) is a complement receptor consisting of C D llb  and CD18. It has an 
affinity towards complements C3b and C4b. MAC-1 is expressed on the cells 
of the innate immune system, such as macrophages, monocytes, neutrophils 
and natural killer (NK) cells (Ross and Vetvicka 1993). Identification of C3b 
and C4b on foreign cells facilitates phagocytosis and the subsequent 
destruction of the foreign cells by the MAC-1 positive cells. As widely agreed, 
there is an accumulation of inflammatory/immune cells in both the dermal 
and epidermal layers of the psoriatic skin. These include lymphocytes and 
also cells of the innate immune system, such as neutrophils (Menter et al. 
2004).
With regards to the DfL mouse, it was found that acanthosis and 
hyperkeratosis of the epidermis can be detected as early as 1 week of age, 
and the associated increase in Ki67 expression. Other hyperproliferation 
markers, such as keratins 6, 16, and 17, which are normally expressed only in 
the hair follicle, were found to be induced in the epidermis. This indicates an 
altered state of differentiation typical with thickened epidermis (Porter et al. 
2002). Throughout all stages, from morphogenesis to the different stages of 
hair follicles destruction, an increase in macrophage infiltration has been 
confirmed in DfL mouse (Ruge and Porter Unpublished data).
13.2 Materials and methods
13.2.1 Materials
Tissue-Tek® O.C.T™ Compound (OCTC) was obtained from Sakura Finetek 
Europe B.V. Antibody towards Ki67 clone MM1 (lot 111849) was obtained 
from Novocastra Laboratories Ltd. (Newcastle, UK). Alexa Flour 488 goat anti­
mouse IgG (lot 412441) and 4',6-diamidino-2-phenylindole (DAPI) were from
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Invitrogen (Paisley, UK).Hydromount aqueous non-fluorescing mounting 
medium (lot 030805) was from National Diagnostics (Atlanta, US). 
Vectastain™ avidin-biotin complex (ABC) reagent (lot V0310) was from Vector 
Labs, Inc., California. Donkey (D9663) and goat serum (G9023) were from 
Sigma Aldrich. COX-2 and MAC-1 C D llb  Rat anti-mouse antibody (lot 98414) 
were from Cell Signalling and BD Bioscience Pharmingen, respectively. 
Biotinylated anti-rat (lot 345191) and anti-rabbit (lot 372217) antibody were 
both from GE Healthcare, Buckinghamshire and K17 antibody was produced 
in-house. All other reagents were of analytical grade or equivalent.
13.2.2 Methods
13.2.2.1 Immunofluorescence staining -  Ki67
Frozen OCTC embedded tissue sections (from Section 12.2.4) were cut to a 
thickness of 7 pm using a Shandon Cryotome and mounted on pre-cleaned 
microscope slides and left for 1 hour before being stored at -80°C until 
required. The slides, after being taken out of storage, were fixed with freshly 
thawed 4% paraformaldehyde for 15 minutes, followed by rinsing in PBS for 5 
minutes. The skin sections were then circled with wax pen and blocked with 
5% w/v BSA in PBS for 30 minutes. The slides were then placed in a 
humidified chamber and incubated with primary antibody for Ki67 (diluted 
1:50 in PBS with 5% w/v BSA) at 4 °C overnight.
The following day, the slides were washed 3x with PBS/0.1% v/v Triton X100. 
Subsequently, the slides were incubated with anti-mouse Alexa 488 IgG 
diluted 1:500 in PBS for 30 minutes. After washing with PBS/0.1% Triton 
X100, DAPI at a concentration of 1 in 5000 (in PBS) was applied to the 
sections, and immediately tapped off before mounting in Hydromount™ and 
covered with glass cover slips. The slides were then left to dry for at least 1
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hour under a silver foil covered lid to prevent fading. Imaging was done under 
a microscope (Nikon) set at 20x magnification aided by a UV lamp and image 
capture facilities (Carl Zeiss). The presence of Ki67 was identified by green 
nuclei, while negative cells were stained blue. The ratio of dividing cells was 
obtained by counting the number of positive nuclei over a distance of 700 
basal cells. A higher ratio indicates an increase in Ki67, i.e. an increase in 
cellular proliferation, and vice versa.
13.2.2.2 IHC staining -  COX-2, K17, and MAC-1
Frozen slides were allowed to equilibrate to room temperature after removal 
from -80°C freezer and then fixed in acetone for 15 minutes. The slides were 
then left to air-dry for 15 minutes, followed by washing with 3 changes of PBS 
for 5 minutes. Tissue sections were outlined with a wax ring using Dako wax 
pen and incubated for 20 minutes with 5% normal serum according to the 
species the secondary antibodies were made of. For COX-2 and K17, it was 
donkey serum and goat serum for MAC-1. From this point onwards, the slides 
were placed in a humidity chamber to avoid desiccation.
Excess serum was then tapped off and primary antibody for COX-2 (1 in 50 
dilution, K17 (1 in 500 dilution) and MAC-1 (1 in 100 dilution) applied onto 
the section. After 1 hour incubation at room temperature (overnight for COX- 
2), the slides were washed with 3 x 5  minutes PBS, followed by incubation 
with biotinylated 2° antibody (anti-rabbit for COX-2 and K17, anti-rat for 
MAC-1) at 1 :200 dilution (in PBS) for 30 minutes. Next, the slides were 
incubated with Vectastain ™ avidin-biotin complex (ABC) reagent, again for 
30 minutes. After washing with PBS, development of slides with DAB was 
done for 10 minutes, and the slides dehydrated and finally mounted with DPX 
and left to dry overnight.
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The slides were then observed under a microscope equipped with image 
capture facilities. The presence of COX-2, K17 and MAC-1 were determined 
by a reddish-brown stain.
13.3 Results and discussion
13.3.1 COX-2
IHC for COX-2 (Figure 13.1) revealed no appreciable difference in COX-2 
staining, taking into account the change in thickness observed with the 
different treatment. It is suggested that COX-2 does not play a significant role 
in the development of the phenotypic changes seen in DfL. Unpublished data 
indicates that levels of COX-2 and COX-2-mediated AA derivatives were 
insignificant (Thomas and Porter Unpublished data).
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Control
Figure 1 3 .1 : IHC staining for COX-2 at 20x magnification. Clockwise from  top le f t : 
BDO (BD only), BF (fish oil only), Control (blank ointm ent base), and BDF 
(combined BD and FO)
13.3.2 K17
The expression of K17, as indicated in Figure 13.2, mirrored the changes seen 
in the epidermal thickness with the different treatments. The staining was 
very intense in BF, corresponding to the gross increase in the thickness of the 
epidermis. On the other hand, the reduction in K17 staining with BDO 
(compared to control) supported the thinning seen earlier. As before, the 
relative levels of K17 for both BDF and control did not differ significantly.
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Figure 13.2 : IHC staining for K17 at 20x magnification. Clockwise from top left : 
BDO (BD only), BF (fish oil only), Control (blank ointm ent base), and BDF 
(combined BD and FO)
13.3.3 Ki67
Visual determination of positive nuclei from the images shown in Figure 13.3 
showed an increased presence of Ki67 in the sections treated with FO, again 
reflecting the increased thickness of the epidermis. The antigen was weakly 
expressed in the basal layers of the BDO treated sections, and in BDF the 
expression was comparable to that of the control. Quantitatively, the ratios 
of Ki67 positive cells over total basal cells were 0.156, 0.703, 0.2063 and 
0.226 for BDO, BFO, BDF and control (Figure 13.4). Both BDO and BFO ratios 
showed a statistically significant difference compared to control, with p
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0.0415 and 0.0001, respectively. The ratio for BDF was not significant 
compared to control, with p 0.5732.
BDO ■  BF
BDF ■  Control
Figure 13.3 : Immunofluorescent staining for Ki67 at 20x magnification. Clockwise 
from  top le f t : BDO (BD only), BF (fish oil only), Control (blank o intm ent base), and 
BDF (combined BD and FO). Nuclei positive for Ki67 are shown in bright green, 
while negative cells are in blue. In all cases Ki67 was only found to  be expressed at 
the basal layer of the epidermis.
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Figure 13.4 : Ratio of Ki67 positive cells per 100 epidermal basal cells. p < 0.05. 
The increase in Ki67 ratio w ith  BF treatm ent corresponded w ith increase in 
epidermal thicknesses of the mice w ithin the group. The opposite was seen w ith  
BDO treatm ent.
13.3 .4  MAC-1
The IHC staining for MAC-1 is shown in Figure 13.5. In the control sections, 
the MAC-1 positive immune cells were found to be localized throughout the 
dermis, though particularly concentrated close to the epidermis and at the 
bottom of the dermis. This support the findings by Porter et al. (2002) which 
reported increased infiltration of DfL dermis with immune cells. Treatment 
with BD, a potent corticosteroid resulted in decreased presence of MAC-1 
positive cells, especially near to the epidermis. A small amount of MAC-1 
remained, though confined to the lower parts of the dermis.
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Figure 13.5 : IHC staining for MAC-1 antigen at lOx magnification. Clockwise from 
top le f t : BDO (BD only), BF (fish oil only), Control (blank ointment base), and BDF 
(combined BD and FO). The presence of MAC-1 was confirmed with the brown 
staining seen in the sections. Note the intense staining seen with BF and Control, 
and the opposite with the BD-containing treatment group (BDO and BDF)
The same was also observed with BDF, the other formulation which 
contained BD. The treatment with FO, however, did not reduce MAC-1 as 
expected. In fact, it was arguably increased compared to control. This was in 
contrast to the anti-inflammatory activity seen in previous chapters, although 
it might explain the increased epidermal growth seen with FO application. 
The anti-inflammatory activity of the principal components of the fish oil, the 
n-3 fatty acids, has been long supported and extensively documented. Thus, 
the result from this study was puzzling, to say the least. One possible 
explanation is the immune cells were reacting to other components of the oil,
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or perhaps an allergic response to the fish oil. Sensitivity towards topical 
application of fish oil has been reported in clinical trials with psoriatic 
patients (Escobar et al. 1992), therefore this possibility cannot be discounted.
1 3 .4  Conclusion
Evidence gathered from immunostaining of the different proteins and 
markers drew several conclusions. First, the relatively unchanged levels of 
COX-2 expression in all treatment groups suggest a non-involvement of COX- 
2 in the aetiology of the DfL phenotype. Though COX-2 is a major component 
in the inflammatory cascade, and there is evidence to suggest that the 
destruction of hair follicles and the epidermal changes are immune-driven, 
other mediators may play a larger role in this particular mutation. This will 
also explain why, in light of the inhibitory effect on COX-2 and its product by 
fish oil, it did not appear to reverse the epidermal thickening; in fact, the 
opposite was seen.
This leads to the second conclusion. Increased expression of Ki67 and K17, 
both markers associated with hyperproliferation, corresponded with the 
epidermal thickening seen with fish oil treatment. Although the exact cause is 
unknown, the increased presence of MAC-1 positive cells could explain, in 
part, why the epidermal changes were in great contrast to initial 
assumptions.
Furthermore, Porter et al. (1998), in their work with a mouse model for 
bullous congenital ichthyosiform erythroderma (BICE), which also exhibited 
epidermal thickening, acanthosis and focal keratosis much like DfL, concluded 
that hyperproliferation of keratinocytes was only partly responsible. Other 
mechanisms are likely to be involved, such as decreased desquamation.
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14.1 General discussion
There is an increasing body of evidence supporting the numerous therapeutic 
benefits of fish oil, encompassing a wide range of conditions, from skin 
diseases and cardiovascular diseases, to several types of malignancies. 
Although these benefits are well documented, little published work has 
involved the topical delivery of fish oil. Apart from several documented 
clinical trials and investigative work, the majority of the body of work has 
focused on orally and systemically delivered fish oil. Previous work has also 
established the skin penetration enhancing properties offish oil and its major 
constituent fatty acids, especially EPA on the delivery of topically applied 
therapeutic agents. The objective of this thesis was therefore to investigate 
both the activity and the topical delivery of fish oil, with a view towards 
incorporation in therapeutic regimens for psoriasis, or co-formulated with 
other active agents.
In the beginning of the study, the delivery of EPA from commercially available 
fish oil was investigated, along with several bioactive oils containing bioactive 
long chain fatty acids and metabolite products. It was found that the delivery 
of fatty acids were indeed possible from fish oil across in vitro models of skin 
permeation. While this generally supported earlier work involving fish oil, it 
was also contradictory to established topical drug delivery theory. The 
following chapters were then focused on the delivery of several commonly 
used anti-psoriatic medications, with a view to incorporating fish oil together 
with these agents in a single formulation, providing a multiple action 
formulation. In the first instance, the delivery of ASA from a fish oil vehicle 
was attempted. Owing to the anti-inflammatory action of ASA, the 
desmosomolytic capability of its metabolite SA and the benefits of fish oil, 
both in its intrinsic anti-inflammatory and delivery enhancing properties, it
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was hypothesised that this would lead to a multi-action preparation 
beneficial in the treatment of psoriasis.
The delivery of ASA, SA and EPA were indeed successful; however, contrary 
to the initial hypothesis, the delivery of EPA was retarded in the presence of 
ASA/SA, and the amount permeated was only half of that delivered from fish 
oil alone.
Nevertheless, subsequent work in Chapters 5 and 6, involving a combined BD 
and SA formulation (intended to replicate a commercially available 
preparation), with the addition of FO, was more successful. Increased 
deposition of BD was observed in the lower layers of the epidermis, a very 
important site of action for inflammatory skin diseases, in the presence of 
fish oil. This enhancement was observed in both non-viable and viable 
porcine skin membranes, and the skin of a potential new animal model for 
psoriasis, the DfL mouse. Reflective of the work in Chapter 2, the delivery of 
SA was not enhanced in all cases, suggesting that the enhancement of EPA 
depended on the chemical structure of the intended co-drug.
In Chapter 5, the impact of skin viability on drug permeation was also 
investigated. The findings indicated that it is an important factor to be 
considered in the design of experimental work in topical and transdermal 
studies, particularly with compounds that are metabolized in the skin. The 
amount of BD and SA recovered from viable skin sections using adhesive tape 
stripping were reduced by approximately 80% due to a more intact barrier 
and active metabolizing enzymes.
As the first part in the studies aimed at establishing the DfL mouse as a model 
for psoriasis, the delivery properties of the same agents were investigated 
with excised DfL skin sections in Chapter 6 . The overall reduced thickness and 
the barrier defects of the DfL skin led to a higher permeability compared to 
porcine skin, with a 10-fold increase in the amount of EPA permeating across
237
Chapter 14
the skin, while the permeation of BD was also increased, although to a lesser 
extent. The permeation of SA, yet again, was not affected by the presence of 
fish oil, with the fluxes obtained not statistically different between SA+FO, 
SA+BD+FO and SA alone. These two factors (thickness and impaired barrier) 
may have been a contributing factor in the outcome of the adhesive tape 
stripping work, with all three agents (BD, SA and EPA) not showing any 
statistically significant increase (p >0.05) in the deposition to the lower 
epidermis.
To summarise, the earlier chapters (2 to 6) reported on the delivery 
properties of the anti-psoriatic medication and the effects of fish oil on 
enhancing drug delivery. The following chapters (7-9) then focused on 
investigating the anti-inflammatory properties of fish oil. Utilizing IHC 
methods and WB assays with experimental model of skin inflammation, the 
effects of fish oil on the inflammatory enzymes COX-2 and 5-LOX were 
investigated. Both methods provided conclusive proof of the intrinsic anti­
inflammatory activity of fish oil, as shown by the inhibition of the expression 
of said enzymes even by fish oil alone. The combination of fish oil with the 
anti-psoriatic agents, however, did not translate to the anticipated increased 
activity, possibly attributable to saturation of inhibition pathways. In Chapter 
9, the inhibitory action of fish oil on the major product of COX-2 metabolism, 
PGE2, was demonstrated. Reflecting the IHC and WB results, the EIA analysis 
of PGE2 showed greater activity of BD and FO on their own, while the 
combined formulation failed to support the initial hypothesis of increased 
inhibition. The implication of these chapters is crucial, in view of the role 
played by products of the enzyme in the pathogenesis and progression of 
inflammatory skin diseases, such as psoriasis. The findings showed that 
topical delivery of fish oil was indeed feasible, and exhibited the anti­
inflammatory activity reported with other forms of administration.
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The response seen in whole skin may possibly be affected by the different 
types of cell that constitute the tissue. Therefore, in Chapters 9 and 10 the 
effects of FO and anti-psoriatic medications were studied in the primary cells 
of the skin, keratinocytes, in the form of the immortalised cell HaCaT cell line 
grown in culture. The addition of fish oil led to an approximately 30% 
increase in the anti-proliferative effect of BD. As there was no associated 
delivery issue (other than across the cell membrane), this enhancement was 
attributed directly to the properties of fish oil in arresting cellular growth. 
This fact has indeed been demonstrated by previous researchers, particularly 
in tumour cell lines and also keratinocytes. Perhaps as a contributing 
mechanism for growth arrest, the expression of the apoptotic marker cleaved 
caspase-3 was induced by fish oil in the culture, and it was more pronounced 
in combination with BD. The effect of fish oil on COX-2 expression was again 
demonstrated, this time at the cellular level. Inhibition of COX-2 expression 
was achieved by fish oil alone, comparable to the inhibition by BD.
In summary, the anti-inflammatory activity of fish oil was proven at both 
tissue and cellular level, with the activity encompassing several components 
of the inflammatory process. This was indicated by the inhibition of both 
inflammatory enzymes in the epidermis, COX-2 and 5-LOX, and one of the 
major products and an important pro-inflammatory eicosanoids, PGE2. The 
anti-psoriatic spectrum of fish oil activity also has been expanded to include 
its growth inhibition and induction of pro-apoptotic pathway in HaCaT cell 
line.
In the final part of the study, the main thrust was to attempt to replicate the 
above promising results in an in vivo situation. At the same time, the 
potential of the DfL mouse mutant presenting with skin defects, much akin to 
psoriasis, was investigated with a view to establishing a new murine model 
for the disease. Furthermore, the potential value of OCT technology in Veal 
time' skin modulation was assessed. These studies were successful on the
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basis that the animal model responded to treatment using a common anti­
psoriatic agent. At this stage, only two anti-psoriatic agents (BD and SA) were 
tested; therefore, the findings will hopefully support a larger role for the DfL 
mouse in the screening of new therapeutic compounds, and no less 
important, to better understand the pathogenesis and the mechanisms 
involved in the development of inflammatory skin diseases.
On the other hand, a major surprise was the observation that treatment with 
fish oil resulted in the opposite of the initial hypothesis of reversing the 
epidermal thickness seen in DfL owing to the anti-inflammatory properties 
showed by FO in the previous chapters. It was, however, no less interesting, 
as the findings only served to generate more interest in the role of fatty 
acids, particularly within the skin. It also served as proof that in vitro findings 
may not always be successfully replicated in vivo. Furthermore, there is still 
much to be understood about the animal model itself. As mentioned in the 
chapter, this represented the first time a study of anti-psoriatic medication 
was attempted on DfL; therefore, it is hoped that the findings will provide a 
basis for further work. Furthermore, OCT technology was successfully utilized 
in the study, providing a method to measure epidermal thickness which was 
less stressful compared to strenuous methods such as punch biopsy and 
more precise than the use of conventional measuring instruments, e.g. 
callipers. This would allow a reduction in the number of animals for further 
studies and allows refinement of previously used techniques, in line with the 
3Rs (reduction, replacement, refinement) principle of biomedical research 
(Goldberg et al. 1996)
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14.2 Future work
The potential value of the topical delivery of fish oil has been demonstrated 
in this study and, in tandem with anti-psoriatic medications, has been proven 
to potentiate their effects by possessing delivery enhancement and intrinsic 
anti-inflammatory activity of its own. A refinement in the formulation aspect 
of combining these agents is thus an important aspect that warrants further 
investigations. Other aspects that can be considered, including optimizing the 
amount of fish oil to be incorporated, is whether the same effects can be 
replicated or bettered with the use of the individual fatty acids. The exact 
mechanism of inhibition of inflammatory enzymes and their products, and 
other anti-psoriatic/anti-inflammatory properties of fish oil, can be 
elucidated further and perhaps investigated on a molecular level. An 
expansion to the animal study is also recommended, both to better 
understand the mutation itself, and in establishing DfL as a screen for 
therapeutic agents and understanding of inflammatory skin diseases. 
Investigation into the lipid content of DfL skin, particularly the different 
ceramides in the SC might shed light on the similarity in the barrier defect 
seen in DfL with human skin diseases. The successful use of OCT is also hoped 
to generate interest and for incorporation of this technology for future 
dermatological studies, and perhaps other fields of research as well.
14.3 Concluding remarks
The hypothesis of this study, which was to establish the potential and 
benefits of incorporating fish oil in the therapeutic regimen of psoriasis 
and/or other inflammatory skin disorders, has been achieved. Through the 
associated aims of the study, the delivery enhancing properties and the anti­
inflammatory/anti-psoriatic action of fish oil has been documented
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successfully. This study provides strong support for an expansion in the role 
of fish oil and other naturally occurring products in the treatment of disease.
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